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1. INTRODUCTION 
Although it is one the most common chronic conditions globally and the most common 
chronic disease in the pediatric population (up to 30% of children in the UK), the causes and 
pathophysiologic mecahnisms in asthma still remain poorly understood. Asthma is a major 
burden on healthcare systems worldwide and society in general, with significant financial 
costs both in terms of direct medical costs (such as those of medication, diagnostics and 
hospital admissions), as well as indirect costs (such as time lost from work or school and 
premature mortality). These costs are even more significant when accounted for under- or 
over- diagnosing and under- or over- medication of the disease in a large number of patients, 
with this effect being most prominent in people with uncontrolled or (more) severe asthma 
(GINA 2018, WHO, Masoli et al. 2004). 
Asthma is a syndrome of very complex and largely unknown etiology characterized by 
reversible airway obstruction, airway hyperresponsiveness to specific and non-specific 
stimuli, and a chronic inflammatory process of the airways in which mast cells, eosinophils, 
T lymphocytes, epithelial cells, and airway smooth muscle cells play a prominent role (Elias 
et al. 2003). 
Although asthma cannot be cured, with appropriate management adequate control and good 
quality of life can be achieved (GINA 2018, WHO 2013). Earlier common asthma 
classification by symptoms and lung function  measurements enables only treatment options 
and selection at the initial disease presentation, but not adequate disease control monitoring. 
Even the latest GINA guidelines and recommendations, involving symptom control (daily 
and nocturnal symptoms, rescue treatment requirements, especially need for 
bronchodilatators, effect on daily activity, mainly on physical activity) do not offer insight 
into disease aetiology and true level of asthma control. Also, there are no recommendations 
as to treatment failure identification and changes recommended towards the treatment of 
choice (different drug classes or their combinations) or only general choice recommendations 
are made (the physician can choose between several treatment options with the generally 
preferred option recommended).  
The lack of benefit to patients from this inadequate and ultimately arbitrary treatment 
selection process is probably due to the overgeneralized approach to asthma as a disease, 
disregarding very specific (individual) disease forms. Hence, in order to optimize medication 
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selection and maximize treatment response, further classification and characterization of 
specific asthma subtypes (phenotypes and endotypes) is more than necessary. Currently, a 
series of asthma subtypes have been reported and described, based on inflammation level and 
type (specific biomarkers), clinical features and natural course of disease, reversibility of 
airway obstruction, disease severity, response to treatment (resistance to inhaled 
corticosteroids, sensitivity to leukotriene receptor antagonists etc.), level of tissue remodeling 
and allergic sensitization (Bush and Menzies-Gow 2009).  
There is mounting evidence that despite the availability of several classes of asthma 
medications and their overall satisfactory effectiveness, a significant portion of patients fail to 
respond adequately to these therapeutic agents. Available data, according to numerous 
pharmacogenetic studies, suggest that genetics may contribute for as much as 60-80% to the 
interindividual variability in treatment response for all asthma medications (Duong-Thi-Ly et 
al. 2017). Although many studies are limited by small sample sizes and replication of the 
findings is needed, several candidate genes have consitently been identified. These include 
polymorphisms in the GLCCI1, CRHR1, TBX21 and FCER2 genes associated with the 
response to treatment with inhaled corticosteroids; polymorphisms in the ADRB2 gene 
associated with the response to treatment with-agonists and polymorphisms in the  ALOX5 
and MRP1 genes associated with the response to treatment with leukotriene modifiers 
(Vijverberg et al. 2018). Pharmacogenetic research, such as that presented in this doctoral 
thesis, is a step towards more personalized treatment of asthma, which will improve 
therapeutic outcomes, minimize side effects and lead to a more cost-effective care. 
The purpose of this translational research approach is to ultimately improve the health and 
wellbeing of asthmatic children. Today, asthma is diagnosed only after clinical symptoms 
arise, primarily because current technologies and guidelines do not enable earlier detection. 
Preventive measures and treatments are designed in a “one size fits all” approach, frequently 
leading to over- or under-medication and undesirable or possibly dangerous side effects. 
Gaining better insight into asthma pathophysiology and factors predisponing for asthma is 
important and in recent years advances in the pharmacogenetics of asthma have indicated that 
a number of genes associated with susceptibility to asthma or its intermediate phenotypes and 
disease characterization are also involved in an altered treatment response. The main focus of 
this doctoral research is to identify major factors underlying the huge interindividual 
variability in the response to common asthma medications, as well as genetic variants 
predisponing for the level of treatment success in children with asthma and specific disease 
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phenotypes. This might ensure more precise, individually tailored and personalized treatment 
options in this common chronic condition in the pediatric population, enabling them to be 
more effective, cause fewer side effects and be more cost-effective due to stratification of 
specific patient risk and even prediction of response to treatment. 
The main objectives in this doctoral thesis are: 
 To determine the differences in clinical presentation, genetic predisposition and 
response to treatment in children with asthma and specific disease subtypes 
(phenotypes); 
 More specifically, to determine the differences in response to treatment with common 
medication classes (inhaled corticosteroids, leukotriene receptor antagonists and -
agonists) in children with asthma (and certain disease phenotpyes) in regard with 
specific genetic polymorphisms in the GLCCI, TBX21, CRHR1, ADRB2 and MMP9 
genes. 
The main hypothesis is that there is marked variability in clinical parameters, the level of 
response to treatment and genetic predisposition in children with specific asthma phenotypes 
and that this variability is associated with certain genetic variants in the GLCCI, TBX21, 
CRHR1, ADRB2 and MMP9 genes. 
In order to address the issues in treatment success/failure in children with asthma, 365 
patients (aged 2-22 years) with physician diagnosed asthma of the outpatient clinic at 
Srebrnjak Children`s Hospital in Zagreb, Croatia were recruited to the study. At their first 
visit patients underwent physical examination, skin prick tests and other allergy assays, lung 
function tests and blood sampling for routine laboratory diagnostics and subsequent genetic 
analysis. After they were diagnosed with asthma, patients started treatment with inhaled 
corticosteroids (alone or in combination with -agonists) and/or leukotriene receptor 
antagonists, according to disease severity and previously assessed disease control (according 
to GINA guidelines, GINA 2018). Follow-up visits with lung function and other testing, 
physical examination as well as clinical assessment of treatment outcomes were made on 
average every 6 months over the period of 2.5 years. Patients were genotyped for the 
following genetic polymorphisms: rs37973 (GLCCI1), rs9910408 (TBX21), rs242941 and 
rs1876828 (CRHR1), rs1042713 (ADRB2) and rs17576 (MMP9). The level of response to 
treatment ("good", "moderate" and "bad") was analyzed in association with certain clinical 
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parameters and specific genotypes, and additionally, patients were stratified by cluster 
analysis (using the hierarchical clustering and Ward`s method)  into several subgroups based 
on specific biomarkers, clinical features, plausible pathophysiological mechanisms, response 
to treatment and genetic predisponing factors (analyzed genetic polymorphisms). 
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2. A LITERATURE OVERVIEW IN ASTHMA AND 
PHARMACOGENETICS 
Asthma is a heterogeneous disorder characterized by chronic airway inflammation. It is also 
associated with airway hyperresponsiveness and airway remodeling (to a more or less extent), 
and is classically considered to be a reversible airways disorder. Common symptoms of 
asthma include wheeze, shortness of  breath, chest tightness and/or cough, particularly at 
night or early in the morning. Patients with asthma can also experience exacerbations 
(commonly known as asthma attacks or flare-ups), which are triggered by a number of 
endgenous and exogenous factors such as exercise, exposure to allergens or irritants (eg. air 
pollutants), changes in weather (particularly cold weather) or viral respiratory infections 
(GINA 2018). 
Asthma is one of the most common chronic diseases in general, with up to 300 million people 
currently suffering from the disorder and up to 250 000 people estimated to now be dying 
from asthma annually. It is also the most common chronic disease in children (WHO 2013). 
Today, one child in three has some form of an allergic disorder (including asthma), and it is 
estimated that in 2015 half of the European population may have been suffering from one or 
more allergic disorders. One in four Europeans has some form of respiratory allergy and 
experts estimate that one in five infants develop asthma during childhood or later in life. 
Asthma symptoms vary from mild to life threatening and can have a devastating impact on 
patients` day to day life, their families and children’s school activity. According to the World 
Health Organization, asthma kills one person in Europe each hour.  
 
2.1. Global burden of asthma 
Asthma typically begins much earlier in life than other chronic disorders, and consequently 
imposes a significant lifetime burden on individuals, their caregivers and society in general. 
The financial costs of asthma in Europe are estimated to be up to 18 billion € per year. These 
only include direct costs of asthma management (diagnostics, medication, management of 
exacerbations) and, along with other indirect costs, including diminished quality of life and 
social impact (eg. reduced professional capacity), the total costs of asthma management range 
from €55 - €151 billion per annum (Zuberbier et al. 2014, ERS 2003), and can be avoided to 
a large extent. The WHO has estimated that 15 million disability-adjusted life years (DALYs) 
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are lost annually due to asthma, representing 1% of the total global disease burden (WHO). In 
the case of childhood asthma, the repercussions of the disease affect not only the asthmatic 
child, but also the parents and other members of the family. Parental fears of a serious attack 
create anxiety, and even with mild forms of the disease, family activities may be limited. 
Children miss days at school and abstain from sports and other recreational activities. 
Breathing problems and other accompanying conditions can also harm the self-image of 
young children, adults and especially teenagers. 
The European Commission (EC) is recognizing the growing health issue of asthma, 
particularly in children and is developing strategies to adequately address it. There is a strong 
link between poor health and environmental problems. A recent report from the European 
Environmental Agency (EEA) shows that as many as 60 000 deaths per year in large 
European cities are caused by long-term exposure to air pollution, including those caused by 
asthma (EEA 2009). Children are more sensitive to environmental risks than adults. In order 
to reverse this alarming trend the European Commission has launched a European 
Environment and Health Strategy. With this new strategy the Commission expects to achieve 
a better understanding of the complex relationship between environment and health and to 
identify and reduce diseases caused by environmental factors, including asthma. Also, this 
issue is of great importance for the Croatian Ministry of Health, as they included asthma as 
an important focus in the National Health Strategy (Croatian National Health Strategy 2012-
2020). 
 
2.2.   The prevalence of asthma 
Based on numerous epidemiological evidences it appears that there are marked variations in 
the prevalence of asthma in different countries. The prevalence, causes and clinical 
presentation of asthma all vary significantly with age. Many children first develop symptoms 
during infancy, but many cease wheezing in early childhood. Asthma can appear de novo 
throughout life, but it most commonly starts in early childhood.  
Like in other western (developed) countries of the world, there has been a three- to four-fold 
increase in the prevalence of childhood asthma in Europe in the last three to four decades. 
According to the ISAAC Phase I study, the highest prevalence of childhood asthma in Europe 
was found in the British Isles, with lifetime prevalence rates of asthma ranging from 1.6% in 
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Albania to 20.7% in the UK for 13-14-year-old children, and from 1.4% in Estonia to 22.9% 
in the UK among 6-7-year-olds, with markedly increasing rates across Europe from East to 
West (Figure 1). This East-to-West difference has changed over recent years with a relative 
increase in lifetime prevalence rates in eastern Europe compared with the western countries. 
This may be related to simultaneous changes in lifestyle in eastern Europe- a shift from 
traditional lifestyle to „westernized“ habits (sedentary lifestyle, changes in diet etc.). 
Currently, Croatia belongs to the countries with moderate prevalence of asthma in children 
with up to 10% of the paediatric population suffering from this (Figure 1), but further 
increase can be expected (GINA 2018). 
 
Figure 1. Lifetime asthma prevalence rates in European school children. a) Asthma prevalence rates in European 
countries in younger children (aged 6-7 years), b) asthma prevalence rates in European countries in older 
children (aged 13-14 years). Prevalence rates in Croatia (HR) range from 5 to 8 % (higher in older children). 
Source: ISAAC 1998 and Lai et al. 2009. 
 
2.3.   Pathophysiology of asthma 
Asthma is characterized by reversible airway obstruction, bronchial hyper-responsiveness to 
specific and non-specific stimuli (such as allergens, exercise or cold air), persistent 
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inflammation, mucus hyper-production, airway tissue remodeling (primarily airway 
narrowing), sub-epithelial fibrosis, smooth muscle tissue hypertrophy and hyperplasia, 
epithelial cell metaplasia, vasodilatation, angiogenesis and increased vascular permeability 
which lead to oedema and changes in the extracellular matrix, due to protein leakage to the 
extracellular space. The level of these structural changes correlates with disease severity and 
progressive lung function deterioration (Ribatti et al. 2009, Towns and van Asperen 2009, 
Lemanske and Busse 2010, Harkness et al. 2014). 
Characteristic pathophysiologic features of asthma are shown in Figure 2. Genetics, in 
combination with early life events as well as the environment, modulate the development of 
CD4+ (cluster of differentiation 4 or T) lymphocytes towards a type 2 helper (Th2) 
immunophenotype. These cells then produce cytokines, such as interleukin 3 (IL-3), 
interleukin 4 (IL-4), interleukin 5 (IL-5), interleukin 13 (IL-13), and granulocyte–
macrophage colony-stimulating factor (GM-CSF) and thereby promote the synthesis of 
immunoglobulin E (IgE), an important allergic effector molecule, creating an inflammatory 
airway milieu. Chemokines, such as eotaxin, Regulated on Activation, Normal T Cell 
Expressed and Secreted (RANTES)/Chemokine (C-C motif) ligand 5 (CCL5) and interleukin 
8 (IL-8) produced by epithelial and inflammatory cells, serve to amplify and perpetuate the 
inflammatory events. Several bronchoactive mediators, such as histamine, leukotrienes, and 
neuropeptides are released into the airways and precipitate an asthma attack by causing 
airway smooth muscle constriction, mucus secretion and oedema. In time, smooth muscle 
tissue proliferates and the deposition of subepithelial connective tissue occurs- a process that 
is commonly referred to as airway remodeling. As a result, patients with asthma have 
difficulty exhaling air because of an increase in airway resistance that is a consequence of 
smooth muscle contraction, inflammation and remodeling (Barnes 1996, Weiss et al. 2006). 
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Figure 2. A schematic representation of major contributors to asthma pathophysiology. Asthma is an 
inflammatory disorder of the airways induced by various environmental and endogeneous factors, including 
genetic predisposition. Chronic inflammation leads to a number of structural and functional changes in the 
airways which in turn lead to airway narrowing and the rise of characteristic asthma symptoms. TH17- type 17 T 
helper cells, TH0- naive T cells, TH1- type 1 T helper cells, TReg- regulatory T cells, IL-10- interleukin 10, IL-9- 
interleukin 9, IL-17- interleukin 17, IL-22- interleukin 22, TGF-- transforming growth factor beta, TNF- tumor 
necrosis factor, IFN- interferron gamma, FcR- FC fragment of IgE receptor. Modified from (Source): Holgate 
and Polosa (2008). 
2.3.1. Airway inflammation in asthma 
Chronic airway inflammation is a fundamental feature in asthma which involves different cell 
types: inflammatory cells such as mast cells, eosinophils and T lymphocytes, structural cells 
such as epithelial cells and numerous infammatory mediators (Holgate 2008, Olin and 
Wechsler 2014).  
Since allergic asthma is the most common asthma type in children, the inflammation is 
initiated by infiltration of allergens into the lower airway, which are taken up by dendritic 
cells (DCs). DCs process allergens to peptides and present the peptides to naive T (Th0) cells, 
and in a suitable environment the naive T cells develop into type 2 helper T (Th2) cells 
(Vijverberg et al. 2013, Brugha et al. 2015). Th2 cells produce cytokines such as IL-4 and IL-
13 which stimulates B lymphocytes to produce IgE as well as IL-3 and IL-5 which attracts 
eosinophils to the lungs; and IL-4 and interleukin 9I (IL-9), which stimulate mast cell 
hyperplasia. With repeated exposure to allergens that an individual is sensitized to, mast cells, 
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secondary to binding of allergens to IgE, release histamine and start to produce prostaglandin 
D2 (PGD2) and cysteinylleukotrienes (leukotriene C4- LTC4, leukotriene D4- LTD4, and 
leukotriene E4- LTE4), which attract inflammatory cells to the lungs. The early phase of 
asthma is a consequence of the effects of histamine and other mediators released from mast 
cells, while the delayed effect is a consequence of other inflammatory cells and the release of 
inflammatory mediators. The molecular mechanism of inflammation in asthma is 
characterized by increasing various inflammatory genes controlled by proinflammatory 
transcription factors, such as nuclear factor kappa beta (NF-kB) and activator protein-1 
(AP1). Both NF-kB and AP1 are activated by mediators, including cytokines, tumour 
necrosis factor alpha (TNF), IL-1 and other factors. A number of coactivators also 
participate in the activation and repression of inflammatory genes through acetylating core 
histones by recruiting histone acetyltransferases (HATs). As a result, inflammatory proteins 
or enzymes and other proteins are synthesized and their production perpetuates airway 
inflammation (Duong-Thi-Ly et al. 2017). Characteristic inflamamtory and molecular 
mechanisms involved in allergic asthma are shown in Figure 3. 
 
Figure 3. A schematic representation of mechanisms of airway inflammation in allergic asthma. GATA-3- 
GATA binding protein 3, CD154- cluster of differentiation 154; TBX21/Tbet- T-box 21, FcR1- Fc fragment of 
IgE receptor I, FcR2- Fc fragment of IgE receptor II. Source: Duong-Thi-Ly et al. 2017. 
An overview of the roles of inflammatory cells and molecules involved in asthma 
pathophysiology is presented in Tables 1 and 2. 
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Table 1. Different cell types (inflammatory and structural) involved in asthma pathogenesis (Barnes 2016, 
Cosmi et al. 2011, McDougall and Helms 2006, Peters-Golden 2004, Ngoc et al. 2005, Loxham et al. 2014). 
Cell type Role in the pathogenesis of asthma 
Mast cells Activated by various triggers (allergens, exercise, hyperventilation etc.) 
Involved in releasing pro-inflammatory mediators such as histamine, cytokines and 
chemokines, which leads to bronchoconstriction 
Involved in promoting chronic inflammatory responses 
Eosinophils Most prominent cell type involved in allergic inflammation in asthma 
Secrete cytokines and chemokines that promote inflammation via the Th2 cell-
mediated pathway 
Secrete lipid mediators (such as cysteinyl-leukotrienes) that cause airway epithelial  
damage and obstruct the airflow 
Associated with clinical responsiveness to glucocorticosteroids 
Neutrophils Predominatly found in the airways of patients with severe persistent disease, those 
with poor response to treatment with corticosteroids, smokers (with asthma) and 
during disease exacerbations 
Recruited by Th17 cell-mediated pathways and mediated by interleukin 8 (IL8) 
Exact mechanisms and roles in asthma not fully understood- corticosteroid 
medication supresses eosinophilia, which then in some patients results in 
neutrophilia 
Macrophages One of the most prominent and abundant immune cells in asthma pathophysiology 
Derived from monocytes 
Release inflammatory mediators and cytokines thet serve to amplify the 
inflammatory reponse in asthma 
Dendritic cells One of the major antigen-presenting cells (APC) in the airways 
Induce T-cell mediated immune responses 
Promote Th2 cell differentiation 
Lymphocytes B lymphocytes involved in the production of the major effector molecule- 
immunoglobulin E (IgE) 
T lymphocytes: role in coordinating the inflammatory response in asthma 
             Release specific cytokines (Th2 subpopulation) that                                 
             drive the inflammation 
                           Th1 cytokines also play a role in asthma inflammation (eg.   
                           IFNTNF) 
Structural cells 
(epithelial cells, 
fibroblasts, airway 
smooth muscle cells) 
Important sources of inflammatory mediators 
Epithelial cells are central to hostt tissue response to environmental factors 
Epithelial signaling is crucial for the recruitment and localisation of inflammatory 
cells and for informing APCs about the local environment 
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Table 2. Inflammatory mediators involved in asthma pathogenesis (Barnes 2016, Chung and Barnes 1999, 
Bisset and Schmid-Grendelmeier 2005, Prado et al. 2011). 
Inflammatory mediator Role in the pathogenesis of asthma 
Cytokines Orchestrate and perpetuate the chronic inflammatory response in asthma 
Th2 cytokines mediate allergic inflammation (interleukines IL4, IL5, IL9, IL13 
etc.) 
Pro-inflammatory cytokines (eg. IL-1 and TNF-) serve to amplify the 
inlammatory response 
GM-CSF prolongs eosinophil survival in asthmatic airways 
Chemokines Essential in directing the migration of various inflammatory cells into the 
affected (asthmatic) airways 
Contribute to allergic inflammatory response 
Interact with eosinophils and mast cells to maintain local balance in favour of 
Th2 cells 
Cysteinyl leukotrienes Potent bronchoconstrictors 
Successfully targeted by treatment with leukotriene receptor antagonists (LTRA) 
Markers of oxidative stress Activated inflammatory cells (eg. eosinophils) produce reactive oxygen species 
(ROS) 
Levels of oxidative stress correlate with disease severity 
Amplify the inflammatory response 
May contribute to reduced responsiveness to corticosteroid treatment 
Nitric oxide (NO) Produced mainly by inflammatory and epithelial cells 
Potent vasodilatator with a range of effects (neurotransmission, vascular and 
non-vascular smooth muscle relaxation) 
Levels of exhaled nitric oxide (eNO) are increased in asthma- concentrations of 
NO in exhaled breath (fractional nitric oxide, FENO) is a useful biomarker of 
airway inflammation (predominantly of eosinophilia) 
 
Inflammatory cells direct a complex network of mediators in the affected airways which 
results in a general inflammatory environment- the major contributor to the pathophysiology 
of asthma. Chronic inflammation then leads to other characteristic features of the disease: 
bronchoconstriction, mucus hypersecretion and other structural changes, including airway 
remodeling.  
2.3.2. Effects of airway inflammation in asthma 
Airway remodeling is defined as an increased thickness of the airway wall and increased 
airway narrowing, characterized by strucural changes such as subepithelial fibrosis, increased 
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smooth muscle mass, mucus gland and goblet cell hyperplasia, decreased cartilage integrity, 
angiogenesis, vascular proliferation and epithelial alterations- eg. subepithelial layer 
thickening and loss of epithelial integrity (Bergeron et al. 2009). The level of airway 
remodeling results from various factors, including genetic influences, early life exposure 
events, duration of the disease and long-term uncontrolled inflammation. These structural 
changes arise as a response to, for example, environmental exposure- to inhaled allergens, 
viral infections or air pollution, which can work synergistically to enhance them (eg. 
infections may exaggerate these changes in allergen-sensitized individuals). In most patients 
with asthma, airway obstruction and and remodeling (to a certain degree) is reversible and 
complete reversibility of long-standing impaired lung function parametres (such as forced 
expiratory volume in 1 second- FEV1) may be achieved with adequate treatment. However, in 
some patients these changes are more permanent and airway obstruction is not fully 
reversible leading to a progressive loss of lung function, despite substantial anti-inflammtory 
medication use (including inhaled and systemic corticosteroids and other). 
Airway epithelium can be damaged in asthma as a result of proteases released fro 
inflammatory cells and by inflammatory mediators. This contributes to airway 
hyperresponsiveness (another major feaure of asthma, AHR), defined as increased 
bronchoconstrictive reponse to various both specific (eg. allergens) and non-specific (cold 
air) stimuli. Several mechanisms can lead to AHR, such as loss of (epithelial) barrier function 
which enables the penetration of allergens, loss of enzymes that degrade inflammatory 
mediators and exposure of sensory nerves in the airway (Barnes 2016). The relationship 
between AHR and chronic inflammation remains unclear, but there is evidence that that anti-
inflammatory treatment is usually effective at reducing AHR and improving asthma control 
(Busse 2010, Janssen-Heininger et al. 2012).  
Subepithelial fibrosis in asthma leads to the thicknening of the basement membrane 
(Brewster et al. 1990). This is associated with eosinophil infiltration and presumably by the 
release of numerous cytokines, such as transforming growth factor beta (TGF-), platelet 
derived growth factor (PDGF) and certain Th2 cytokines (Bhakta and Woodruff 2011). This 
can lead to irreversible airway narrowing, especially in more severe asthma subtypes. 
Airway smooth muscle tissue plays a key role in asthma by releasing several cytokines, 
chemokines and lipid mediators that contribute to bronchoconstriction. The thickness of the 
airway smooth muscle layer (consisting of smooth muscle tissue, matrix, inflammatory cells, 
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mast cells and blood vessels) increases in asthma due to hypertrophy and hyperplasia. This is 
caused by the stimulation of airway smooth muscle cells by factors such as PDGF and 
endothelin-1 and is also associated with an increase in extracellular matrix. Smooth muscle 
hypertrophy occurs in the large airways in both non-fatal and fatal types of asthma, but 
hyperplasia is usually present in fatal (more severe) asthma only, and affects both the large 
and small airways (James et al. 2012, Berair et al. 2013). 
Inflammation in asthma also causes changes to blood vessels: vasodilatation, angiogenesis, 
vascular permeability etc. Vasodilatation leads to increased airway mucosal blood flow which 
then contributes to airway narrowing as well, but at the same time it also may be important 
for removing inflammatory mediators from the airways. Angiogenesis occurs in response to 
factors such as vascular endothelial growth factor (VEGF) as well as inflammatory mediators 
(IL-4, IL-5, IL-13 etc.) and is one of the key features of airway remodeling in asthma. 
Moreover, airway oedema is present in the airway mucosa of patients with asthma, resulting 
from increased microvascular permeability during the inflammatory process, which may then 
further increase airway wall thickening and lead to more severe airway obstruction (Zanini et 
al. 2010). Although oedema is a common asthma feature, it is very difficult to directly 
evaluate and quantify oedema in the airways of asthmatic patients. 
Chronic inflammation in asthma also leads to increased mucus secretion. This then 
contributes to the formation of viscid mucus plugs that obstruct or even plug the airways, 
especially in fatal asthma. Also, in asthma hyperplasia of submucosal glands in the large 
airways occurs and the number of epithelial goblet cells (that secrete gel-forming mucins, the 
major component of mucus) increases. Airway mucus hypersecretion may be indicative of 
poor disease control and it certainly contributes to the morbidity (and mortality) in asthma 
(Rogers 2004, Shale and Ionescu 2004, Evans et al. 2009). 
Remodeling in allergic diseases (including asthma) is not restricted solely to the airways, but 
it also affects the upper and lower airways and the skin. Moreover, the same profile of 
inflammation, mediators and adhesion molecules (eosinophil, mast cell and CD4+ T cell 
influx; histamine, cysteinyl-leukotrienes, cytokines etc.) is common for all allergic diseases, 
although long-term structural changes differ. As remodeling is observed in all atopic 
(allergic) diseases, this reinforces the hypothesis that it is a mainly inflammation- driven 
process (Bergeron et al. 2009). 
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2.4.   Diagnosis and assessment of asthma 
Establising and confirming a diagnosis of asthma can be difficult and challenging, as there is 
an absence of a gold standard for defining it (or diagnosing) and it is commonly defined 
simply as reversible airway obstruction. The initial diagnosis of asthma is often based on 
identifying the presence of symptoms such as (recurrent) wheezing, cough, shortness of 
breath (dyspnea), chest tightness and variable expiratory airflow limitation (Figure 4). 
However, these symptoms are not specific to asthma only (similar ones are characteristic to 
bronchitis, especially chronic bronchitis, pneumonia and a number of other respiratory 
diseases) and establishing a diagnosis requires rather extensive clinical experience and 
judgement. Moreover, signs and symptoms of asthma vary significantly between patients and 
may even fluctuate in the same patient at different times and under different circumstances 
(depending on, for example, exposure to allergens). Therefore, it is important to establish 
whether the symptoms are recurrent (and how often they occur) as well as to identify if the 
symptoms are provoked by specific triggers, such as exposure to allergens or exercise. 
Additionally, a detailed personal and family medical history, such as commencement and 
existence of respiratory symptomy in childhood and details on atopy (allergy) as well as any 
other clinically relevant data should be recorded- this significantly increases the certainty in 
diagnosis of asthma (GINA 2018). 
 
Figure 4. Diagnostic flow-chart for asthma in clinical practice. The diagnosis of asthma should be confirmed 
and evidence documented in the patient`s medical notes. Depending on clinical urgency and access to resources, 
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this should preferably be done before initiating controller treatment, as confirming a diagnosis of asthma is more 
difficult after treatment was started. * In case of clinical urgency (eg. current asthma attack), empiric treatment 
(eg. inhaled corticosteroids and bronchodilatator) should be administered and response to treatment assessed. 
Diagnostic tests should be performed again within 1 to 3 months after the event. Modified from (source): GINA 
2018. 
2.4.1. Objective measurements and tests for diagnosing and monitoring asthma 
Of course, besides obtaining the clinical history, objective measurements are required in 
order to make a confident diagnosis of asthma. This is done by measuring lung function 
parametres by spirometry or peak expiratory flow measurement. Spirometry measures airflow 
obstruction, which is usually defined as a ratio of forced expiratory volume in 1 s (the volume 
of air exhaled in the first second of a forced exhalation from a position of maximum 
inhalation, FEV1) to forced vital capacity (the total volume of air exhaled forcibly from 
maximum inhalation to maximum exhalation, FVC). Volumes (%) of FEV1 and FVC below 
80% of the predicted value for age, sex, height and ethnicity and FEV1/FVC ratios below 0.7 
(or 0.75) in adults and below 0.9 in children suggest airway obstruction. The lower the 
FEV1/FVC ratio is, the more severe the obstruction. Peak expiratory flow (PEF) measures the 
maximum flow of air achievable from forced expiration, starting from maximum lung 
inflation. To establish a diagnosis of asthma, average daily diurnal PEF variability (calculated 
from 2 or 3 daily measurements as: PEFmax minus PEFmin for that day, divided by the mean of 
PEFmax and PEFmin, averaged during 1-2 weeks) should be greater than 10% (in children 
greater than 13%), or diurnal variability should be greater that 20% for at least 3 days in a 
week for a period of two weeks. Measures of gas trapping (residual volume- RV and the ratio 
of residual volume to total lung capacity- RV/TLC) as well as specific airway resistance 
(Raw), the so-called body plethysmography, may be superior to measurements of expiratory 
flow in detecting airway obstruction, especially in asymptomatic individuals and children 
(GINA 2018, BTS 2014, Criee et al. 2011). 
When spirometry or PEF exhibit an obstructive pattern, in order to properly diagnose asthma, 
it is important to establish whether this obstruction is reversible. This is usually achieved by 
testing lung function with short-acting bronchodilatators and, when FEV1 is less than 60% of 
the predicted value (for age, sex, ethnicity etc.), also with corticosteroids (oral or inhaled). A 
significant increase in FEV1 (more than 12% from baseline value or more than 200 ml, in 
children more than 12% of the predicted value) after bronchodilatator indicates reversible 
airflow obstruction and supports the diagnosis of asthma. Increases in FEV1 by more than 
20 
 
12% and 200 ml from baseline value (in children, by more than 12% of predicted value) after 
(at  least) 4 weeks of anti-inflammatory treatment also strongly suggests a diagnosis of 
asthma. However, an absent response to bronchodilatators or corticosteroids does not exclude 
asthma. It is also worthy to note that response to bronchodilatators and corticosteroids is 
altered during and immediately after an exacerbation of the disease or viral infections, which 
is why it is recommended to perform diagnostic reversibility tests when the patient is 
clinically stable (BTS 2014). 
2.4.2. Peripheral airways in asthma and methods of assessing peripheral airway 
dysfunction 
The small, peripheral or distal airways, defined as airways with an internal diameter of less 
thna 2 mm, account for the majority of the luminal surface area within the airways, 
representing 98% of the total lung volume (James 2002). Due to a lack of accurate small 
airway dysfunction tests, direct evaluation of small airway tissue changes and obstruction has 
lead to the peripheral airways being termed the „lung`s quiet zone“ and to assessments in 
asthma being limited to the large central airways only. With the introduction of new 
techniques such as fiberoptic bronchoscopy, there has been a renewed interest in peripheral 
airways, which are now becoming increasingly appreciated for their significance to the 
clinical manifestations (expression) in asthma. 
Assessments of the peripheral airway have traditionally been challenging due to their small 
internal diameter and deep location in the thoracic cavity. New and more specialized methods 
and techniques have been developed to better assess peripheral airway dysfunctions in 
asthma, such as forced expiratory flow at 50% (FEF50%) and at 25-75% (FEF25-75%) of forced 
vital capacity, measuring airway resistance with impulse oscilometry (IOS), single/multiple 
breath nitrogen washout, alveloar nitric oxide, late-phase sputum induction, imaging 
techniques etc (van der Wiel et al. 2013, Usmani 2014, Downie et al. 2007). Other methods 
such as transbronchial biopsy and bronchoalveolar lavage (BAL) are available, but far more 
invasive and as such not recommended to be performed in children, except in specific 
indications. A list of most commonly used small airways assessment methods are 
summarized in Table 3. 
Table 3. Common methods of assessment of peripheral airways in asthma. FEF25-75% and  FEF50%- forced 
expiratory flow through 25-75% and at 50% of the forced vital capacity, R5- airway resistance at 5 HZ (IOS), 
R20- airway resistance at 20 Hz, R55-R20 – difference of R5 and R20, X5- reactance of the airways at 5 HZ, 
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AX- reactance area, Fres- resonant frequency of reactnace, FRC- functional residual capacity, CV- closing 
volume, CC- closing capacity, Sacin and Scond- ventilation heterogenetiy indices in the acinar and conductive lung 
zones, respectively, HRCT- high-resolution computed tomography, H3HeMRI- magnetic resonance imaging 
with inhaed hyperpolarized helium-3 gas. 
 
Method 
 
What it measures 
Parameter 
Peripheral airways Central airways 
Spirometry Airway obstruction FEF25-75%, FEF50%, 
FVC/SVC 
FEV1, FEV1/FVC, PEF 
Impulse oscilometry  Airway resistance R5-R20, X5, AX, Fres R20 
Body plethysmography Air trapping RV, RV/TLC, FRC  
Single breath nitrogen 
washout 
 
 
Ventilation heterogeneity 
CV, CC, Slope phase III  
Multiple breath nitrogen 
washout 
Sacin, Scond  
Exhaled nitric oxide (NO) Airway inflammation Alveolar NO Bronchial NO 
Induced sputum Airway inflammation Late-phase sputum Early-phase sputum 
HRCT/H3HeMRI Imaging techniques Lung attenuation  
 
Recognizing asthma as a disease of the entire respiratory tract is of great clinical significance 
and highlights the need to target the distal airways in therapeutic strategies for effective 
asthma management. 
2.4.3. Other tests and investigations used in asthma diagnosing 
Additionally, constrictor response tests can also be performed to assess the presence and 
severity of airway hyperresponsiveness. This is achieved by measuring the fall in FEV1 after 
bronchoconstrictor stimuli, such as certain pharmacological agents in metacholine or 
histamine challenge tests, exercise in spiroergometry tests or allergens in allergen challenge 
(provocation) tests. 
Above the age of 5 years, conventional lung function testing (measurements of airway 
obstruction, response to bronchodilatators and bronchoconstrictors and AHR) is usually 
possible in most children and most settings, although cooperation and compliance to the 
procedure is always an issue with children. In children between the age of 2 and 5 years, 
spirometry is commonly not performed, but most can perform other tests that do not rely so 
heavily on their ability to perform a forced expiratory manoeuvre. In general, these tests have 
not been evaluated as diagnostic tests for asthma specifically, as there is often substantial 
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overlap between the values measured in children with and without asthma. Of those tests, 
specific airways resistance (sRaw), impulse oscilometry (IOS) and measurements of residual 
volume (RV) appear most promising. In children under the age of 2 or even 3 years, lung 
function tests are almost impossible to perform and establishing a diagnosis of asthma is 
therefore extremely difficult, especially because episodic respiratory symptoms such as 
wheezing and cough are quite common in this population (associated with respiratory tract 
infections which occur 6-8 times per year in young children). This is why a confirmation of a 
diagnosis of asthma is often postponed for a certain period of time in which the child is 
carefully monitored (BTS 2014, GINA Pediatric 2015, Beydon et al. 2007, NHLBI 2007). 
Recently, novel objective respiratory function methods based on an impedance 
pneumography (IP) and flow-interruption (FI) technologies have been developed. These 
methods enable pulmonary function testing during tidal spontaneous breathing at home, even 
during sleep, which makes them suitable for use in very young children (Benoist et al. 1994, 
Lødrup et al. 1994, Dames et al. 2014., Gugten et al. 2013). 
Other non-invasive tests are often performed to assess certain features of asthma, such as 
tests of eosinophilic airway inflammation. These include induced sputum differential 
eosinophil count and exhaled nitric oxide concentrations (FENO). Higher sputum eosinophil 
counts are associated with a higher degree of airway obstruction and reversibility, greater 
disease severity and atopy in general. In children with newly diagnosed mild asthma forms, 
sputum eosinophilia is present and usually declines with anti-inflammatory treatment (eg. 
with inhaled corticosteroids). Although sputum induction is easily obtainable in school-aged 
children, it is technically demanding as well as time consuming and therefore at present it 
remains mostly a research rather than a routine diagnostic tool (Lex et al. 2005, Rytila et al. 
2004, Covar et al. 2004). Fractional exhaled nitric oxide (FENO) is feasible to measure in 
children from the age of 3 to 4 years. Increased levels of FENO are not a specfic marker of 
asthma and often ovelap with children who do not have asthma, because FENO is closely 
linked with atopy, age and height, but with underlying lung function. Still, measurement of 
FENO in exhaled breath is a quantitative, noninvasive, simple, and safe method of measuring 
the level of airway inflammation that provides a complementary tool to other ways of 
assessing asthma (Malmberg et al. 2005, Brussee et al 2005, Malmberg et al. 2006). 
Atopy status is also often assessed in individuals with suspected asthma, especially in 
children. Positive skin tests (skin-prick tests- SPT), blood eosinophilia (more than 4% of 
relative count) or increased levels of total and especially allergen-specific immunoglobulin E 
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in serum increase the probablity of asthma in children with wheeze (Castro-Rodriguez et al. 
2000, Chan et al. 2005, Simpson et al. 2005). 
 
2.5.   Asthma management and monitoring 
Asthma management is defined as: 
1. the control of symptoms such as wheeze, chest tightness, shortness of breath and 
cough, 
2. reduction  in the risk of severe and/or life-threatening exacerbations and long-term 
morbidity (including disease progression to more severe forms and other 
comorbidities) by therapeutic intervention (eg. with anti-inflammatory treatment), and 
3. reducing adverse events and side-effects of treatment. 
Recently, the main focus in the management of asthma has shifted from preventing (and 
sanation) of acute asthma attacks to achieving overall disease control, including 
improvements in symptoms score and overall quality of life (GINA 2018, BTS 2014). A list 
of tools commonly used to assess and monitor asthma and disease control are listed in Table 
4. 
Table 4. Summary of common tools in asthma management (monitoring and assessment of disease control), 
recommended to be clinically reviewed on at least an annual basis or more frequently, according to physician`s 
judgement (BTS 2014, Simon and Simon 2007, Hoffman et al. 2012). 
Measurement/tool Description/comment 
Spirometry Widely available, robust and enables clear demonstration of airflow obstruction. 
Adequate for children from the age of 5 years on. 
Peak expiratory flow 
(PEF) 
Widely available, simple (adequate for home use), results less reproducible than 
spirometry measurements. 
Changes in PEF are more meaningful that absolute values measured. 
Asthma Control Test 
(ACT), Supplement 1 
5 questions: 3 related to symptoms, 1 related to medication use and 1 to overall 
control. 
Score of  ≥25 indicates good asthma control, 20-24 indicates moderate control and 
≤19 indicates that asthma is poorly controlled. 
Validated in adults and children 4 years and older. 
Airway 
hyperresponsiveness 
Challenge tests (metacholine, indirect tests with inhaled mannitol, allergen challenge 
tests). 
Not applicable in patients with substantially impaired lung function (FEV1/FVC ≤0.7 
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and FEV1 ≤70% predicted). 
Exhaled nitric oxide 
(FENO) 
Normal range is <25 ppb at exhaled flow of 50 ml per second.  
Values >50 ppb in adults and >35 ppb in children highly predictive of eosinophilic 
airway inflammation and predicted positive response to corticosteroid treatment. 
Values <25 ppb highly predictive of absence of airway eosinophilia and of predicted 
poor response to corticosteroids or indicative for step down treatment with 
corticosteroids. 
Eosinophil differential 
count (blood or 
induced sputum) 
Feasible even in children, but time consuming and not available except in specialised 
centres. 
Normal range in sputum is <2% (or <3% in blood for adults and children older than 2 
weeks), and <300 or <350 cells per microliter of blood- absolute values. 
Increased sputum eosinophil count closely related to corticosteroid responsiveness in 
adults and together with FENO in children. 
 
Asthma management is adjusted in a continuous cycle to assess disease control, adjust 
treatment and review response (Figure 5). 
 
Figure 5. The control-based asthma management cycle and its main components. In children, especially those 
under the age of 5 years, parents or caregivers have a very important role in asthma management, which is why 
their preferences and satisfaction is cruicial in the management proccess. Modified from (source): GINA 2018, 
GINA Pediatric 2015. 
A list of currently available and most commonly used treatment options for asthma is 
presented in Table 5. 
Table 5. Most commonly used pharmacological treatment options for asthma today (Bonini and Usmani 2016). 
Table 4. continued 
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Reliever medication (bronchodilatators) Controller medication (anti-inflammatory 
treatment) 
2-agonists: Short-acting (SABA) 
                     Long-acting (LABA) 
Corticosteroids: inhaled corticosteroids (ICS) 
                           oral corticosteroids (OCS) 
                           parenteral corticosteroids 
Anticholinergics Anti-leukotrienes (leukotriene receptor antagonists, 
LTRA) 
 
Theophyline 
Theophyline (slow-releasing) 
Cromones 
Macrolides 
Monoclonal anti-IgE antibody (omalizumab) 
 
For the effective managament of asthma, experts recommend employing a stepwise approach. 
This stepwise approach is aimed at achieving early and adequate disease control by 
eliminating symptoms as soon as possible and to optimise lung function (eliminate airflow 
obstruction) by initiating treatment at the level most likely to achieve this. Based on this 
approach, asthma management in adults and children can be divided into five steps, as shown 
in Figure 6 (GINA 2018, GINA Pediatric 2015, BTS 2014).  
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Figure 6. A schematic representation of the stepwise approach in asthma management. *For children aged 4 to 
11 years, the use of theophyline is not recommended as controller treatment and the preferred option in Step 3 is 
medium dose ICS. In step 5, some patients may benefit from low dose OCS, but long-term systemic side-effects 
may occur. For children under the age of 5 years, step 1 treatment is as needed SABA, step 2 is daily or 
intermittent low dose ICS or LTRA, step 3 is „double low dose ICS“ and add-on option is LTRA, while step 4 is 
increasing the dose of ICS and add-on regular LTRA, with further expert advice, investigation and reconsidering 
diagnosis highly recommended. Source: GINA 2018, GINA Pediatric 2015. 
Patients should be carefully monitored every 1 to 3 months after treatment initiation, and 
every 3 to 12 months after that, if adeqate control is achieved or 1 week after an exacerbation 
for response review. Since asthma is often a variable condition, periodic adjustment of 
controller treatment may be needed. If adequate control is not reached, treatment step-up is 
recommended in a: 
1. sustained step-up manner for at least 2 to 3 months and if symptoms/exacerbations 
persist, other common causes such as incorrect inhaler technique and poor adherence 
(especially in young children), modifiable risk factors (like smoking) or comorbidities 
need to be assessed, 
2. short-term step-up manner for 1-2 weeks due to viral infection or allergen exposure, 
or 
3. day-to-day adjustment manner for patients on treatment steps 3-5.  
If asthma control has been reached and maintained for at least 3 months, treatment step-down 
should be considered by reducing ICS dose by 25-50% at 2 to 3-month-long intervals, during 
which the patient should be carefully monitored and disease control reassessed. A summary 
of the current guidelines in the management and treatment of asthma is presented in 
Supplement 2. 
 
2.6.   Heterogeneity in asthma 
Asthma and its key mechanisms remain poorly understood despite the fact that much 
progress has been made in understanding the underlying pathogenesis in recent years. This 
has largely been due to the failure in successfully identifying the distinct disease subtypes in 
asthma. 
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While asthma is generally considered an inflammatory disorder of the conducting airways, it 
is evident that the disease is extremely heterogeneous with respect to immunopathology, 
clinically observed phenotypes, response to treatment, and natural history. Although it was 
once considered purely an allergic disease dominated by Th2-type lymphocytes, IgE, mast 
cells, eosinophils, macrophages, and cytokines, it is becoming increasingly apparent that the 
pathogenesis of asthma also involves local epithelial, mesenchymal, vascular and neurologic 
events that are involved in directing the Th2 phenotype to the lung and through aberrant 
injury-repair mechanisms to remodeling of the airway wall (Holgate 2008). This 
demonstrates the urgent need for identifying additional immunologic and inflammatory 
pathways involved in asthma, in order to reveal new ways of intervening in the prevention 
and treatment of the disease. 
The most common asthma form is allergic asthma (especially in children), induced by 
allergic sensitization (usually by inhaled allergens) and immunoglobulin E (IgE) as well as 
Th2-mediated immune response play a crucial role in the pathogenesis of allergic asthma. A 
common form of asthma is non-specific asthma, caused by respiratory infections (viral), air 
pollutants (smoke, ash and other large particles), probably due to physical (mechanical) 
damage to the airways, physical activity and emotional stress. Asthma is often accompanied 
by comorbidity- allergic rhinitis/rhino-conjunctivitis (AR), atopic dermatitis (AD), gastro-
oesophageal reflux disease (GERD), obstructive sleep apnoea syndrome (OSAS), obesity etc. 
This, along with the variability in disease aetiology, level of inflammation, bronchial damage 
and lung function impairment, specific clinical features and natural course of the disease 
(persisting to adulthood or remission in adolescence), reflect the vast heterogeneity and 
complexity of asthma. Current knowledge of asthma pathophysiological mechanisms as a 
Th2 cell mediated allergic reaction does not suffice in explaining and dealing with a large 
portion of this heterogeneity, which is why in the past few years asthma has been revised and 
considered as a complex syndrome of several different subtypes (phenotypes) defined by 
newly conceived immuno-pathophysiological mechanisms called endotypes (Gagro 2011). 
This is also reflected in the multiplicity of asthma risk factors, both endogenous (sex, 
hormonal status, genetic predisposition and epigenetic status) as well as environmental 
factors (allergens, viral infections, air pollution etc.). 
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2.6.1. Phenotypes in asthma 
Phenotypes are described as the observable characteristic of an organism produced by 
interactions of the genotype and the environment (Henderson 2014). The presence of distinct 
asthma phenotypes has been described for a number of years: in the mid 20
th
 century there 
were two clinically distinct phenotypes of asthma defined- extrinsic (allergic) or early-onset 
asthma and intrisic (non-allergic) or late-onset asthma, with the age of onset emerging as one 
of the main clinical characteristics to define disease heterogeneity (Rackermann 1947). 
Subsequently, asthma phenotypes which identified the presence of eosinophilic inflammation 
and its link to corticosteroid responsiveness emerged (Brown 1961, Berry et al. 2002). 
Further studies confirmed the heterogeneity in asthma leading to the conclusion that not all 
patients respond to anti-inflammatory (corticosteroid) treatment and that treatment reponse is 
largely dependent on the presence and type of airway inflammation (Pavord et al. 1999, 
Gibson et al. 2001, Wenzel et al. 1999, Green et al. 2002), as well as that patients with poor 
response to treatment tend to develop severe, uncontrolled disease. The group of patients with 
non-eosinophilic type of inflammation were then further stratified into neutrophilic asthma, 
mixed granulocytic asthma with increased eosinophils and neutrophils and paucigranulocytic 
asthma with normal levels of both eosinophils and neutrophils (Simpson et al. 2006). 
Recently, there have been several attempts to use novel computing and machine learning 
techniques (eg. cluster analysis) to identify additional phenotypes in asthma (Haldar et al. 
2008, Siroux et al. 2011, Wu et al. 2014). Although these studies have performed unbiased 
statistically based analyses on large cohorts of patients involving a wide range of clinical 
variables, they have been limited in the terms of clinical characteristics they have used to 
identify different phenotypes in asthma and still do not provide much insight into the 
underlying disease mechanisms (Gauthier et al. 2015, Ray et al 2015).   
2.6.2. Endotypes in asthma 
Although different phenotypic clusters of asthma have emerged, these have been primarily 
clinically oriented and while they are useful for classifying patients, they provide little 
reference to the underlying pathophysiological processes. This has been one of the major 
hindrances in the development of targeted therapies in asthma so far (Chung and Adcock 
2015). Therefore, in order to capture disease mechanisms, molecular phenotypes or 
„endotypes“ are now being defined by integrating and correlating molecular markers with 
clinical phenotypes to describe a specific disease subtype based on distinct 
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pathophysiological mechanisms. For example, a clinical phenotype of asthma may be 
underpinned by several discrete endotypes, each of which leads to a final common pathway 
of disease manifestations that are characteristic to that particular phenotype. Conversely, a 
discrete endotype (for example, a particular inflammatory pathway such as eosinophilic 
airway inflammation) could be exant in a number of different clinical phenotypes, as shown 
in Figures 7A and 7B (Henderson 2014, Lötval et al. 2011, Wenzel 2012, Ray et al. 2015, 
Anderson 2008). 
 
Figure 7. A schematic representation of asthma subtypes: phenotypes and endotypes. A hiearchy of asthma 
phenotypes and endotypes. B Schematic representation of potential asthma phenotypes. For example, Th2-
associated asthma and non-Th2-associated asthma may share key features of symptoms, lung function and 
exacerbations but can be further subdivided according to other characteristics (Phenotypes A, B, C or D), 
including some molecular mechanisms. Source: Lötvall et al. 2011, Wenzel 2012. 
Most recent studies utilizing genetic, epigenetic and transcriptomic data together with 
extensive clinical data have been even more successful in characterizing the underlying 
predisponing genetic, epigenetic and gene expression patterns associated with specific asthma 
endotypes. Such approaches further advance the possibility of stratifying asthma at the 
molecular level in order to achieve personalized treatments and individually tailored 
management strategies (Chung and Adcock 2015, Wesolowska-Andersen and Seibold 2015). 
2.6.3. Asthma and obesity 
Obesity, that is, overweightness is one the most common asthma comorbidities. 
Approximately 38% of current adult asthmatics are also obese in the US, and obesity has 
been shown to be an indepedent risk factor for developing asthma. Obese asthmatics have an 
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increased risk for asthma exacerbations, more frequent and worse respiratory symptoms as 
well as poor disease control and poor quality of life, despite often using high-dose inhaled 
corticosteroids (Baffi et al. 2015). A meta-analysis of  7 longitudinal cohort studies involving 
over 300,000 adults indicated a dose response effect between increasing BMI and the odds 
ratio (OR) of incident asthma (Beuther and Sutherland 2007). Since obesity is a risk factor for 
asthma and a potential culprit for the rise in prevalence of asthma  in both children and adults 
and due to the fact that asthma and obesity have common pathophysiological mechanisms, it 
is now  thought that being obese and having asthma constitutes a unique clinical phenotype; 
in other words, the interaction of obesity (as an environmental risk factor) with underlying 
genetic traits (or other host susceptibility factors) leads to a set of defined observable traits- 
one or, more likely, multiple specific phenotypes. Although the clinical manifestations have 
been well documented, the aetiologies of obese asthma still remain unclear (Scott et al. 
2017). 
The mechanisms by which obesity exacerbates asthma are both mechanistic and 
physiological. Increased adiposity around the chest wall and abdomen may lead to lung 
restriction, resulting in reduced total lung capacity and most notably, low expiratory reserve 
volume, from upward diaphragmatic displacement due to increased abdominal fat. 
Consequently, airway closure occurs at or above functional residual capacity in the dependent 
lung zones, which can lead to significant ventilation/perfusion mismatching (Salome et al. 
2010). Although obesity is not associated with more airway obstruction, studies indicate that 
it is a risk factor for increased bronchial hyperresponsiveness (Dixon et al. 2010). Moreover, 
obesity promotes systemic inflammation, potentially exerting effects in the airways. 
Sputum samples of patients with asthma reveal that the obese have the largest proportion of 
non-eosinophilic airway inflammation. This is probably not due to an absolute reduction of 
airway eosinophils in obese patients, but rather, due to reduced migration into the airway 
lumen. A study of severe asthmatics demonstrates that obesity is associated with increased 
sub-mucosal eosinophils (but not in the airway lumen) and with greater IL-5 sputum levels 
(Desai et al. 2013). In contrast, obesity has been associated with increased airway 
neutrophilia (Telenga et al. 2012). All this suggests appear that the obesity-mediated changes 
in airway inflammation are more consistent with a non-predominant Th-2 phenotype, and 
potentially a more Th-1 polarized immune response (Rastogi et al. 2012). IL-17 producing 
innate immune cells detected in human BAL may constitute an additional non-Th2 pathway 
in obese asthma (Celedon and Kolls 2014). Increase in adipose tissue correlates with an 
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increase in the levels of leptin as well as a reduction in the levels of adiponectin and both of 
these changes have been implicated in the obese asthma pathogenesis (Dixon 2009). The 
levels of leptin are higher among asthmatics, and increase in relation to plasma leptin levels 
and BMI (Holguin et al. 2011,  Lugogo et al. 2012). The magnitude of leptin receptor 
expression in visceral fat has been related to BHR (Sideleva et al. 2012) and moreover, leptin 
has been shown to increase the oxidative and inflammatory response of alveolar macrophages 
derived from overweight and obese asthmatics ex vivo (Lugogo et al. 2012). Adiponectin, on 
the other hand, probably has protective effects. In females, higher plasma adiponectin levels 
are associated with decreased asthma risk (Sood et al. 2008), but whether it has anti-
inflammatory or immunomodulatory effects in the human airway is not clear. Both asthma 
and obesity are characterized by greater oxidative stress and may act synergistically to further 
increase it, especially in the NO metabolism. Exhaled NO (eNO) and BMI are inversely 
correlated in late-onset compared to early onset (childhood) asthma. This may be due to an 
imbalance between L-arginine, the precursor of NO and substrate for inducible nitric oxide 
synthase (iNOS), and asymmetric di-methyl arginine (ADMA), which is an endogenous 
inhibitor of all NOS synthases (Holguin et al. 2013). Lower L-arginine might result from 
increased arginase activity, which is associated with asthma severity, and increased ADMA 
has been related to obesity and metabolic syndrome (Morris et al. 2004, Palomo et al. 2011). 
Having lower airway NO bioavailability at baseline may impair the degree of physiological 
bronchial dilation, leading to increased respiratory symptoms, poorer disese control and 
imparied lung function (Ricciardolo et al. 2004). Compared to those with normal BMI obese 
asthmatics have poorer response to treatment with ICS according to changes in lung function 
parametres and disease control. This reduced steroid response in obese asthmatics could be 
due to increased steroid resistance. Studies have shown that obesity was associated with an in 
vitro blunted response to dexamethasone-induced mitogen-activated protein (MAP) kinase 
phosphatase-1 (MKP-1) and baseline tumor necrosis factor (TNF)-alpha in peripheral blood 
mononuclear cells (PBMCs) and BAL cells (Peters-Golden 2006, Sutherland et al. 2010). 
Obesity in asthma also increases the risk for other chronic diseases (such as OSA, GERD and 
metabolic syndrome), which are associated with worsened respiratory symptoms and poorer 
disease control (Teodorescu et al. 2013, Samson and Garber 2014). A summary of 
pathophysiological mechanisms involved in obese asthma are shown in Figure 8. 
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Figure 8. Pathophysiological mechanisms of obese asthma. A variety of mechanisms have been proposed as 
drivers of the physiologic and clinical observations in obese asthmatics, including changes in adipokines; Th-1 
skewed airway inflammation, lower ADMA to L-arginine ratio resulting in increased oxidative stress and 
decreased physiologic NO- a mediator in smooth muscle dilatation, reduced FRC and ERV due to excess 
abdominal adiposity, IL-17 associated airway inflammation, steroid resistance and dampened response to MKP-
1. Th-1- T-helper 1 cells, ADMA- asymmetric dimethylarginine, NO- nitric oxide, FRC- functional residual 
capacity, ERV- expiratory reserved volume, IL-17- interleukin 17, MKP-1- mitogen-activated protein (MAP) 
kinase phosphatase-1. Source: Baffi et al. 2015. 
Because the origins of obesity and asthma are multifactorial, it is now believed there are 
multiple obese-asthma phenotypes, with varied aetiologies and clinical consequences, and 
with childhood or early-onset obese asthma being an independent one (Baffi et al. 2015). 
 
2.7.  Genetics of asthma 
Genetic predisposition, that is, heritability, undoubtely plays a crucial role in the onset and 
development of asthma, as this disorder, as well as other allergic disorders, is more common 
in individuals with a positive atopic (allergic) and asthmatic family background. Twin studies 
have indicated that certain parameters, such as bronchial hyperresponsivness (BHR), are 
inherited independently (Los et al. 2001). Numerous genetic loci (SNPs, Single Nucleotide 
Polymorphisms) have been associated with the onset, progression and clinical features of 
asthma through genome-wide association studies (GWAS), and have recently been re-
assessed through a large meta-analysis involving more than 10,000 asthma patients (Moffatt 
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et al. 2010). These studies indicated that certain chromosome regions are associated with 
susceptibility to asthma, such as: 6p- containing genes encoding the major histocompatibility 
complex (MHC), 11q- containing genes encoding the high-affinity IgE receptor and 
glutathione S-transferase, 20p- containing the gene encoding ADAM33, which plays an 
important role in cellular fusion, adhesion, signalling and proteolysis processes and certain 
regions on chromosome 17- containing the gene ORMDL3 encoding an epithelial protein 
strongly associated with asthma development (Ober and Yao 2011). A GWAS meta-analysis 
has been recently conducted across different ethnicities highlighting the role of genes at the 
the 17q21 region (including genes encoding for interleukin 1 receptor-like 1- IL1RL1, thymic 
stromal lymphopoietin- TSLP, interleukin 33- IL33 etc.) across different ethnic groups 
(Torgerson et al 2011). Genetic risk of childhood-onset asthma has been reviewed recently 
emphasizing the role of the 17q21 region and more specifically, the GSDMB-ORMDL3 
(encoding for gasdermin B- GSDMB and oromucosoid 1 like-3- ORMDL3) locus in 
childhood asthma (Cookson et al. 2011). Novel technologies such as whole exome 
sequencing are only beginning to be utilized in the field. Recently variants in the CBLB (an 
E3 ubiquitin-protein ligase), KALRN (Kalirin RhoGEF kinase) and PDE4DIP 
(Phosphodiesterase 4D interacting protein) genes were foun d to segregate with patients in a 
family affected by asthma (DeWan et al. 2012). Certain cytokine and chemokine encoding 
genes, involved in the Th2 mediated immunological response, genes encoding proteins 
involved in oxidative stress processes and the keratin-binding protein filaggrin (FLG) have 
also been associated with asthma and other allergic diseases (Michel et al. 2010). 
Genes implicated by genome-wide association studies (GWAS), genome-wide linkage 
studies, and candidate gene studies can broadly be divided into 4 groups (according to their 
function and role in the development of asthma and allergic diseases):  
1. genes involved in epithelial barrier function, 
2. genes involved in environmental sensing and immune detection, 
3. genes ivolved in tissue response to allergic inflammation, and  
4. genes involved in TH2 cell polarization and response (presented in Figure 9). 
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Figure 9. Susceptibility genes for asthma and allergic diseases. Source: Holloway et al. 2010. 
2.7.1. Genes involved in epithelial barrier function 
A high proportion of the novel genes identified for susceptibility to allergic disease through 
genome-wide linkage and association approaches have been shown to be expressed in the 
epithelium. The RAD50 homolog is important for DNA double-strand break repair, cell-cycle 
checkpoint activation, telomere maintenance, and meiotic recombination. This gene is also 
adjacent to the interleukin 4/13 (IL4/IL13) locus and asoociated with increased total IgE 
levels, eczema, and atopic dermatitis. The FLG (filaggrin) gene, as well as RAD50 and IL-13 
have already been associated with allergic diseases (atopic dermatitis) and recent studies have 
implicated an overlap of certain loci within these genes with asthma and allergic rhinitis 
pathogenesis. Genes encoding filaggrin (a protein involved in keratin aggregation), defensin 
beta-1 and the RAD50/IL-13/IL4 loci may be also associated with asthma susceptibility and 
level of response to treatment in patients with loss-of-function FLG variants or defensin and 
RAD50/IL-13, which may be due to allergen sensitisation that occurs after the breakdown of 
the epithelial barrier (Weidinger et al. 2013). Other susceptibility genes, such as 
ORMDL3/GSDML (gasdermin-like or gasdermin B), PCDH1 (encoding protcadherin 1), and 
C11orf30 (or EMSY, BRCA2 Interacting Transcriptional Repressor) are also expressed in the 
airway epithelium and might have a role in regulating epithelial barrier function (Koppleman 
et al. 2009, Moffat et al. 2007, Holloway et al. 2010). 
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2.7.2. Genes involved in environmental sensing and immune detection 
Genes involved in sensing of environmental influences and immune detection include genes 
of the MHC class, genes encoding Toll-like receptors (TLR1, TLR6 and TLR10) an others. 
This group of genes encodes molecules that directly modulate the effect of environmental 
risk factors for allergic disease. For example, genes such as TLR2, TLR4, and CD14, 
encoding components of the innate immune system, interact with levels of microbial 
exposure to alter the risk of allergic immune responses (Yang et al. 2007).  Additionally, 
polymorphisms in genes encoding glutathione-S-transferase (GSTM1, GSTM2, GSTM3, 
GSTM5, GSTT1, and GSTP1) have been shown to modulate the effect of environmental 
exposures involving oxidant stress, including tobacco smoke and air pollution, on 
susceptibility for asthma (Romieu et al 2009, Breton et al. 2009). 
2.7.3. Tissue response to allergic inflammation 
A variety of genes involved in mediating the response to allergic inflammation and oxidative 
stress on tissue level appear to be important contributors to asthma and allergy susceptibility 
as well as disease progression and treatment effectiveness. Examples include genes encoding 
ADAM33, a disintegrin and metalloprotease expressed in lung fibroblasts and smooth muscle 
cells, the alpha-1 chain of type 29 collagen (COL29A1), phosphodiesterase 4D (PDE4D), 
leukotriene C4 synthase (LTC4S), glutathione-S-transferase (GSTP1, GSTM1), arachidonate 
5-lipoxygenase (ALOX-5), nitric oxide synthase 1 (NOS1), metallopeptidase 9 (MMP9), 
which are expressed in lung fibroblasts and smooth muscle cells, as well as the 2 adrenergic 
receptor (ADRB2) etc. (Lotvall et al. 2011, Himes et al. 2009).  The latter two genes (MMP9 
and ADRB2) have also been significantly associated with remodeling events that occur in 
asthma and related conditions (such as chronic obstructive pulmonary disease, COPD) as 
well as with response to certain classses of common asthma treatment, with MMP9 being 
pivotal in remodeling in asthma for its role in extracellular matrix degradation and ADRB2 
being crucial for bronchodilatation (Ohbayashi and Shimokata 2005, Litonjua et al. 2010). 
Polymorphisms in the VEGFA gene (vascular endothelial growth factor A, involved in tissue 
remodeling processes, mainly angiogenesis) have been associated with asthma, especially 
with phenotypes involving extensive airway tissue remodeling. The TBXA2R gene encodes 
the thromboxane receptor (TP), also known as the prostanoid TP receptor. Variations in this 
gene have been associated with asthma and level of response to therapy. TBX21 encodes the 
T-box transcription factor TBX21, a member of a phylogenetically conserved family of genes 
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that share a common DNA-binding domain, the T-box. TBX21 protein is a Th1 cell-specific 
transcription factor that controls the expression of the hallmark Th1 cytokine, interferon-
gamma (IFN). Variations in this gene have also been assoicated with asthma as well a to 
response to treatment (Van Eerdewegh al. 2002, Söderhall et al. 2007). 
2.7.4. Th2 cell polarization and response 
Th2 cell-mediated adaptive immune responses have been widely recognized as a crucial 
component of allergic disease. Genes involved in Th2 cell differentiation and function have 
been extensively studied in asthma candidate-gene association studies, and as one might 
expect, SNPs in many of these genes have been associated with asthma and other allergic 
phenotypes. Genes important for Th1 versus Th2 T cell polarization, such as those encoding 
transcription factors and certain cytokines (GATA3, TBX21, IL4, IL4RA, STAT6, and IL12B), 
have been implicated with asthma and specific disease phenotypes, as well as with response 
to treatment (Agache et al. 2012). The genes encoding IL-13 and the beta-chain of the IgE 
receptor FcεR1 are well replicated contributors to asthma susceptibility. This group includes 
genes that regulate Th1/Th2 differentiation and effector function (eg. IL13, IL4RA, STAT6, 
TBX21 and GATA3), as well as genes such as IRAKM, PHF11 and UPAR, that potentially 
regulate both allergic sensitisation and the level of inflammation that occurs at the end-organ 
location for allergic disease. This group also includes genes shown to regulate the level of 
blood eosinophilia: IL1RL1, IL33, MYB, and WDR36 (Kabesch et al. 2006, Suttner et al. 
2009, Pykäläinen et al. 2005, Barton et al. 2009). 
2.7.5. Corticosteroid transport and signaling genes 
Genes involved in corticosteroid transport have been associated with specific asthma 
endotype pathogenesis and response to treatment (ICS) in patients with different asthma 
phenotypes. These include: the gene encoding the corticosteroid-binding globulin SERPIN1, 
a major glucocorticoid transporter, that has already been associated with certain asthma 
subtypes and with the level of response to inhaled corticosteroids (Dijkstra et al. 2011), the 
gene encoding the solute carrier family 22, member 2 (SLC22A2), also known as organic 
cation transporter 2 (OCT2), which is predominantly expressed in the luminal membrane of 
airway epithelial cells and is involved in the release of acetylcholine from bronchial 
epithelium, and has previously been associated with certain asthma endotypes and response 
to medication (Park et al. 2011, Lips 2005) and other. Corticosteroid-induced genes, that is, 
corticosteroid-responsive genes, namely the gene GLCCI1, encoding the glucocorticoid 
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induced 1 protein of unknown function (although it may be an early marker for 
glucocorticoid-induced apoptosis), has already been associated with asthma pathogenesis and 
the level of response to asthma treatment, along with CRHR1, encoding the corticotropin 
releasing hormone receptor 1, essential for the activation of signal transduction pathways that 
regulate diverse physiological processes including stress, reproduction, immune response and 
obesity (Tantisira et al. 2011, McGeachie et al. 2013). 
As all of these genes were identified in screens for asthma susceptibility genes, most of them 
are listed as risk factors. Protective factors for asthma are less well characterized, and are 
often more descriptive of general genetic or lifestyle factors, such as a negative family 
history, history of breastfeeding, and exposure to pets and/or livestock and farm animals 
(Sandini et al. 2011). Exposure to endotoxin at young ages has been shown to be protective 
against the development of asthma. There is also a correlation between higher levels of the 
endotoxin binding molecule CD14 (soluble form) and lower asthma prevalence, and in 
animal models this is dependent on the Toll-like receptor 4 (TLR4). The proteins encoded by 
the TBX21 and IL12B genes promote the development of Th1 cells, which contribute to 
inflammation and generally suppress atopic phenotypes. It is likely that future studies of the 
genes identified as susceptibility loci will show that some have roles more consistent with 
protection from rather than susceptibility to asthma, at which point those genes would be 
recategorized. 
 
2.8.  Response to asthma treatment  
As there is still no real cure to asthma (due to the overwhelming complexity of this disease), 
today, common asthma treatment is actually symptomatic treatment, with short-term 
medications that are mostly used to relieve current symptoms (reliever medication) and long-
term medication used in case of persistent symptoms to control the underlying inflammation 
and prevent exacerbations (controller medication). These short term treatment options 
involve:  
1. bronchodilators, such as short acting β-adrenoreceptor agonists (SABA), used for 
example in case of asthma attacks or shortness of breath, 
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2.  both oral and parenteral corticosteroids, such as medrol (methylprednisolone), 
prednisone, pronisone, dexamethasone and solu-medrol (methylprednisolone sodium 
succinate), 
3.  and other drugs, such as theophylline, which are mostly used in the management of 
asthma exacerbations.  
Long-term medication involves:  
1. inhaled glucocorticoids (inhaled corticosteroids, ICS), the most commonly used 
treatment option in asthma, 
2. leukotriene receptor modifiers (LTM)- most commonly leukotriene receptor 
antagonists (LTRA) and, less frequentely, leukotriene inhibitors (LTI), and  
3. long acting β-adrenoreceptor agonists (LABA), which are commonly used in 
combination with ICS by millions of patients with asthma, mostly those with greater 
disease/symptom severity as maintenance treatment. 
Corticosteroids are synthesized and secreted by the cortex of the adrenal gland as a result of 
stimulation by the hypothalamus-pituitar-adrenal (HPA) axis. The HPA axis is responsible 
for the adaptation to stress and inflammatory stimuli. This response is characterized by a 
hypothalamic release of corticotropin-releasing hormone (CRH), which acts by combining 
with the CRH receptor (CRHR), predominantly CRH receptor 1 (CRHR1). Both endogenous 
and exogenous corticosteroids act by binding intracellularly to glucocorticoid receptors (GR). 
A protein complex including heat shock proteins HSP70 and HSP90 binds the inactive GR. 
While HSP70 inactivates GR through partial unfolding, HSP90 reverses this inactivation, and 
is required for activation of GR. GR homodimers bind to glucocorticoid response elements 
(GREs) in the promoter region of steroid-sensitive genes, by which the anti-inflammatory 
genes such as annexin-1, secretary leukocyte protease inhibitor (SLPI), MAPK phosphatase-1 
(MKP-1/DUSP1/MAPK1), NF-kB, inhibitor of NF-kB alpha (NFKBIA), IL-10 and 
glucocorticoid-induced leucine zipper (GILZ) are activated. Certain transcription factors (NF-
kB and AP1) activate coactivator molecules, like CBP (cAMP-response-element-binding-
protein (CREB) binding protein) which bind to nuclear GRs, which inactivates  a number of 
pro-inflamamtory genes, such as IL-8 (Barnes 2006, Duong-Thi-Ly et al. 2017). Molecular 
mechanisms involved in the anti-inflammatory action of corticosteroids are shown in Figure 
10. Corticosteroids also exert their anti-inflammatory action by inducing histone acetylation 
(and subsequent activation) of anti-inflammatory genes (eg. MKP-1), and by recruiting 
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histone deacetylases (HDAC2) and inducing deacetylation (and subsequent silencing) of 
proinflammatory genes, for example IL-8, NF-κB, AP-1 (Barnes 2009). 
 
Figure 10. A schematic representation of anti-inflammatory mechanism of corticosteroids. ACTH- 
adrenocorticotropic hormone, MC2R- melanocortin 2 receptors, STIP1- stress induced phosphoprotein 1, 
NR3C1- nuclear receptor subfamily 3 group C member 1, DUSP1- dual specificity phosphatase 1, ORMDL3, 
ORMDL sphingolipid biosynthesis regulator 3, pCAF- p300/CBP-associated factor, SRC- steroid receptor co-
activator, POMC- proopiomelanocortin, CRF- corticotrophin releasing factor. Source: Duong-Thi-Ly et al. 
2017. 
The leukotriene pathway begins with the conversion of arachidonic acid to leukotriene A4 
(LTA4), a reaction catalyzed by the enzyme 5-lipoxygenase (5-LO). LTA4 is subsequently 
converted to LTC4 under the influence of leukotriene C4 synthase (LTC4S), which is 
transported extracellularly. Sequential cleavage of glutamate and glycine residues results in 
the formation of leukotriene E4 and D4. Leukotrienes bind to receptors present on leukocytes 
and lung smooth muscle cells, such as cysteinyl leukotriene receptor 1 (CysLTR1), to cause 
smooth muscle contraction and mucus secretion. Current antileukotriene treatment (LTM) 
include CysLTR blockers or LTRA and inhibitors of 5-LO or LTI (Tse et al. 2011). The 
leukotriene pathway and mechanisms of LTM action are shown in Figure 11. 
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Figure 11. A schematic representation of the leukotriene pathway, with sites of action of antileukotriene 
treatment indicated in red x. Zileuton- an LTI, a 5-LO inhibitor montelukast, zafirlukast and pranlukast- LTRA, 
blockers of CysLTRs. CysLTR1- cysteinyl leukotriene receptor 1, CysLTR2- cysteinyl leukotriene receptor 2. 
Source: Tse et al. 2011. 
Combination treatment (ICS+LABA) is frequently used in the control of asthma and it is now 
recognized that there are important molecular interactions between these two classes of drug. 
Corticosteroids increase β2-receptor gene transcription, resulting in increased expression of 
cell surface receptors, thus protecting against the down-regulation of β2-receptors after long-
term administration. This is important for both bronchodilation and other 2-agonist effects, 
such as mast cell stabilization. Corticosteroids may also enhance the coupling of β2-receptors 
to G-proteins, which enhances β2-agonist effects and reverses the uncoupling of β2-receptors 
that may occur in response to inflammatory mediators, such as IL-1β through a stimulatory 
effect on a G-protein coupled receptor kinase (Figure 12). β2-agonists also act on 
glucocorticoid receptors to increase the anti-inflammatory effects of corticosteroids (Barnes 
2010). 
 
Figure 12. Biological actions of combination treatment (ICS+LABA). Corticosteroids have anti-inflammatory 
effects but also increase the number of β2-receptors, whereas β2-agonists, act on glucocorticoid receptors (GRs) 
to increase the anti-inflammatory effects of corticosteroids. Source: Barnes 2010. 
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Addtionally, low concentrations of theophylline, another drug commonly used for asthma 
treatment (usually in case of management of exacerbations), have been shown to reverse the 
effects of corticosteroid resistance by restoring HDAC2 activity, possibly via selective 
inhibition of phosphoinositide-3-kinase (PI3K)-δ and the phosphorylation of downstream 
kinases (Barnes, P. 2009). 
When it comes to asthma controller treatment options, there is marked patient-to-patient 
variability in the therapeutic response. For example, about one in three patients with asthma 
who use inhaled glucocorticoids may not benefit adequately from this treatment (Szefler 
2005). As asthma seems to be a complex genetic syndrome, the response to asthma treatment 
is also genetically complex and is characterized by high intra-individual repeatability and 
high inter-individual variability, with up to 50% of asthmatic patients having poor or even no 
response to treatment (Drazen et al. 2000, Szefler et al. 2002). Inhaled glucocorticoids are the 
most widely prescribed medications for controlling asthma. Levels of endogenous 
glucocorticoids are heritable and vary significantly, both at baseline and in response to 
environmental perturbation (Inglis et al. 1999, Ober et al. 2002, Steptoe et al. 2009). 
Moreover, studies in families with conditions other than asthma have shown both familial 
segregation and heritability in responses to glucocorticoid medications (Armaly 1967, 
Schwartz et al. 1972). 
 
2.9.  Pharmacogenetics of asthma 
Given the heritability within response to therapeutic classes of common asthma as well as the 
high degrees of between-patient variability and within-patient repeatability in the response to 
treatment of asthma, it is likely that this response has a strong genetic basis. Previous studies 
have suggested that up to 80% of asthma patients have different responses due to genetic 
factors (Baye et al. 2011). In fact, a number of single nucleotide polymorphisms in candidate 
genes have been identified by genome-wide association studies (GWAS), linkage and 
candidate gene studies that might influence the clinical response to treatment in patients with 
asthma. Different genetic variants associate with the response to commonly used asthma drug 
classes (bronchodilators, inhaled corticosteroids and leukotriene modifiers) and their direct or 
indirect effects depend on their role in the inflammatory immune response in asthma or the 
anti-inflammatory action of the medication, respectively (Duong-Thi-Ly et al. 2017). Certain 
genetic loci associated with the response to asthma treatment are shown in Table 7. 
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Table 6. Genetic variants (loci) associated with the response to different classes of asthma medication (ICS, 
LABA, SABA, LTM, theophylline) identified by GWAS and candidate gene studies. Bronchodilatator response 
(BDR)- reversibility after bronchodilatator, change in FEV1 after administration of SABA (Duong-Thi-Ly et al. 
2017, Vijverberg et al. 2018, Morrow 2007, Lima et al. 2009, Fal and Rosiek-Biegus 2012, Tse et al. 2011). 
Gene/genetic locus Relevant medication Outcome (assessed in study) 
FGF14, ASB3, SOCS, PRKCQ, 
IL15RA, IL2RA, COL22A1, 
CLOCK, SPATA13-AS1, 
SLC22A15, SPATS2L; ADRB2 
Gly16Arg, ADRB2 Gln271Glu 
SABA Bronchodilatator response (BDR) 
CMTR1, ALLC, FBXL7, T gene, 
GLCCI1, CRHR1, FCER2, 
GR/NR3C1, TBX21, STIP1, 
DUSP1, HDAC, ORMDL3, VEGF 
ICS Lung function changes, Symptom 
frequency and severity, 
Exacerbation frequency and 
severity, AHR 
CYP1A2, HNMT T314 allele Theophylline Drug metabolism and clearance, 
Toxicity 
ADRB2 Gly16Arg, CRHR1, ARG1 LABA Risk of exacerbations 
LTC4S, ALOX5, LTA4H, CysLTR1, 
CYPBA4, CYP2C9, SLCO2B1, 
MRP1/ABCC1, MLLT3, GLT1D1, 
MRPP3 
LTM Lung function changes, Symptom 
and exacerbation frequency and 
severity 
 
For example, certain loci  in the gene encoding T-box 21 (TBX21) and Fc fragment of IgE 
receptor II (FCER2) contribute indirectly to the variability in the response to ICS by altering 
the inflammatory mechanisms involved  in asthma pathogenesis, while other genetic loci 
such as those in the gene encoding corticotropin releasing hormone receptor 1 (CRHR1), 
nuclear receptor subfamily 3 group C member 1 (NR3C1), stress induced phosphoprotein 1 
(STIP1), dual specificity phosphatase 1 (DUSP1), glucocorticoid induced 1 (GLCCI1), 
histone deacetylase 1 (HDAC), ORMDL sphingolipid biosynthesis regulator 3 (ORMDL3), 
and vascular endothelial growth factors (VEGF) directly affect treatment response variability 
through the anti-inflammatory mechanisms of ICS (Vijverberg et al. 2018). 
TBX21 (T bet or T-box 21) is a transcription factor that acts as a regulator of Th1 cell 
development by inducing IFN- production and by inhibiting Th2 cytokines, such as 
interleukin IL-4, IL-5 and IL-13 (Lopert et al. 2013). Gene knockout mice lacking TBX21 
spontaneously develop histological and physiological features of asthma, including bronchial 
hyperresponsiveness (BHR), peribronchial inflammation and collagen deposit in the lung 
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basement membrane. Among others, ICS also affect BHR in asthma patients, so it is more 
than likely that treatment efficacy may be altered by variants in the TBX21 gene. Certain 
genetic polymorphisms, such as rs9910408 (c.-7947) and rs2240017 (H33Q C>G) have been 
associated with a decrease in BHR in both children and adults (Lopert et al. 2013, Raby et al. 
2006, Tantisira et al. 2004). 
CRHR1 is the key CRH (corticotropin releasing hormone) receptor in the pituitary gland, 
mediating the release of adrenocorticotropic hormone (ACTH, Figure 10) and the 
catecholaminergic response to CRH (Duong-Thi-Ly et al. 2017, Tantisira et al. 2004). 
Peripherally, CRH may bind to mast cells via CRHR1 (Theoharides et al. 1998). Alterations 
of any of these CRH effects, mediated by the CRHR1 gene, have the potential to influence the 
pathogenesis of asthma. For example, the absence of CRHR1 leads to enhanced airway 
inflammation and dysfunction (Maitland-van der Zee and Daly 2012). Moreover, decreased 
expression or function of CRHR1, due to genetic variations, could diminish the capacity to 
secrete cortisol in response to inflammation, as a consequence of decreased ACTH release. 
Therefore, asthmatic patients with certain CRHR1 variations would probably respond better 
following the administration of an exogenous corticosteroid. Certain genetic polymorphisms, 
such as rs242941 and  rs1876828 have been associated with a positive treatment response in 
both children and adults with asthma (Tantisira et al. 2004, McGeachie et al. 2013). 
The GLCCI1 gene encodes encodes the glucocorticoid induced element 1, a protein of a still 
unknown function. The expression of GLCCI1 is induced by glucocorticoids and may be an 
early marker for glucocorticoid-induced apoptosis. Certain genetic polymorphisms, such as 
rs37972 and rs37973, which are in complete linkage disequilibrium (i.e., perfectly 
correlated), are associated with decreases in GLCCI1 expression and poorer response to 
treatment with ICS in asthmatic patients, that is with reduced lung function in response to 
ICS (Tantisira et al. 2011). 
The non-intronic ADRB2 gene encodes the beta-2 adrenergic receptor (β2 adrenoreceptor) 
that binds epinephrine (adrenaline) whose signaling, via a downstream L-type calcium 
channel interaction, mediates physiologic responses such as smooth muscle relaxation and 
bronchodilation. This receptor-channel complex also contains a G protein, a cAMP-
dependent kinase, and the counterbalancing phosphatase, PP2A. Different polymorphic 
forms, point mutations, and/or changes in the expression of ADRB2 have been associated 
with asthma (especially severe asthma and exacerbations), obesity and type 2 diabetes 
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(Szczepankiewicz et al. 2009, Jocken et al. 2007, Puranik et al. 2017). For example, certain 
genetic polymorphisms such as rs1042713 (Arg→Gly16, 46A→G) and rs1042714 
(Gln→Glu27, 79C→G) are associated with higher agonist promoted receptor down-
regulation, rs1042714 with stronger desensitization of the 2 receptor and an additonal 
polymorphism rs1800888 (Thr→Ile164, 491C→T) with diminished affinity of 2-agonist to 
the receptor, decreased adenylate cyclase binding and 50% shorter lasting SABA. 
Consequently, patients with these polymorphisms had poorer response to SABA and LABA 
as well as more frequent and more severe asthma exacerbations (Fal and Rosiek-Biegus 2012, 
Green et al. 2001). 
The MMP9 gene encodes a matrix metalloproteinase (family of Zn
2+
-dependent 
endoproteinases) or gelatinase B produced mainly by macrophages and neutrophils (but also 
epithelial cells, mast cells, fibroblasts nad smooth muscle cells). MMP9 has several functions, 
displaying  gelatinolytic, elastolytic and collagenolytic activity, which is why it plays a key 
role in physiologic extracellular matrix turnover as well as tissue remodeling in certain 
diseases, such as asthma and chronic obstructive pulmonary disease (COPD). Additionally, 
MMP9 may also modulate the activity of various biological factors, including other 
proteinases (MMP13), their inhibitors (1-antitrypsin) and cytokines such as IL-1 (Grzela et 
al. 2016). Moreover, MMP9 seems to have a regulatory role in neutrophil migration across 
the basement membrane (Delclaux et al. 1996). Certain genetic polymorphisms such as 
rs17576 (Gln279Arg) are associated with non-atopic asthma in children, obesity and 
increased levels of systemic inflammation in children (Grzela et al. 2016, Belo et al. 2012) 
and may be involved in the pathophysiology of non-eosinophilic asthma and moreover, 
response to treatment in certain asthma phenotypes (Goleva et al. 2007, Grzela et al. 2016, 
Naik et al. 2017). 
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3. MATERIALS AND METHODS 
In order to study treatment success in asthmatic children, 365 pediatric patients (355 children 
aged 2-17 years and 10 adolescents aged 18-22 years) with atopic and non-atopic, intermitent 
to severe persistent asthma (according to GINA guidelines; GINA 2018, GINA Pediatric 
2015), patients of the outpatient clinic at the Srebrnjak Children`s Hospital, were recruited in 
a prospective, non-interventional type of clinical study. Informed consent was obtained from 
the childrens` parents/legal guardians following a presentation of the study by the physician 
and distribution of written material regarding the study. Parents/guardians were also asked to 
provide clinically relevant information about the child (personal and family medical history).  
This study protocol was compliant with all national, EU and international ethics related rules 
and professional codes of conduct. The study was approved by the Ethics Committees of the 
Srebrnjak Children`s Hospital and School of Medicine at the University of Zagreb, and 
written parental consent was obtained. 
 
3.1.  Establishing a diagnosis of asthma 
At their first visit patients underwent physical examination, anthropometric measurements 
(height and weight), along with a standard battery of diagnostic procedures and 
measurements to establish a diagnosis of asthma. These included skin prick tests for common 
allergens, lung function tests and blood sampling for routine laboratory tests (hematology, 
biochemistry and allergy assays) to establish a diagnosis of asthma. Peripheral whole blood 
samples were collected by venepuncture into EDTA coated vacutainers (for hematology 
analyses) and into vacutainers with clot activator and gel for serum separation (for 
biochemistry and certain allergy assays). Serum was separated by centrifugation at 3000 g for 
10 min (Eppendorf centrifuge 5702R, Eppendorf AG, Germany). During this study a total of 
10,5 ml peripheral blood samples per participant maximum was collected at the baseline visit 
(recruitment point). The remainder of blood samples (in EDTA coated vacutainers) and sera 
left over after diagnostic tests was stored at -20°C for subsequent analyses, including 
genotyping. 
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3.1.1. Assessment of allergy  
To assess their atopy status, all participants underwent skin prick testing (SPT) to a standard 
battery of inhaled allergens (Alyostal, Stallergenes Greer, France), including house dust mite, 
grass pollen, animal dander, weed pollen, tree pollen and molds, as well as additional inhaled 
(eg. Mediterranean species) and food allergens, if indicated. A full list of allergens tested is 
presented in Supplement 3 (Table 30). SPT was performed on the volar surface of the non-
dominant forearm with the listed allergen extracts, using plastic lancets and 0.9% phenolated 
glycero-saline solution as the negative and 10 mg/mL histamine hydrochloride solution as the 
positive control (Stallergenes Greer, France). The size of each urtica reaction wheal (in 
millimeters) was documented as the mean of the longest diameter and the diameter 
perpendicular to it at its mid-point, according to the International Study of Asthma and 
Allergies in Childhood (ISAAC) skin prick test (SPT) protocol (Asher et al. 1995). 
In addition to SPT, other standard assays of allergy status assessment was performed. More 
specifically, concentrations of total immunoglobulin E (IgE) and allergen-specific IgE (sIgE) 
in serum was determined in all participants, using a standardized sandwich fluorescent 
enzyme immunoassay- ImmunoCAP
®
 (Phadia AB, Sweden) on a Phadia 100 Laboratory 
system (Phadia AB, Sweden). In house established age dependent cut-off values were used to 
determinate elevated serum total IgE level (Dodig et al. 2006). 
3.1.2. Lung function assessment 
In order to evaluate the level of airflow obstruction, all participants underwent routine lung 
function measurements, according to age and indication (where applicable according to 
relevant clinical judgement). These included: 
1. spirometry (FEV1, FVC, PEF, MEF50% and other relevant parameters), SpiroScout, 
Ganshorn Medizin Electronic, Germany 
2. FEV1 reversibility (changes in FEV1 % predicted) 20 minutes after inhalation of 100-
400 g bronchodilatator (salbutamol), depending on body weight, SpiroScout, 
Ganshorn Medizin Electronic, Germany 
3. impulse oscillometry (in younger children, as indicated),  MasterScreen-IOS, Erich 
JÄEGER GmbH & CoKG, Germany 
4. body plethysmography, Q-box, COSMED, Italy, and  
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5. bronichial/airway challenge tests to assess airway hyperresponsiveness (metacholine 
challenge test- APS Pro System, Erich JÄEGER GmbH & CoKG, Germany and 
spiroergometry- MTM-1500 med ergometer, Schiller AG, Switzerland). 
Forced expiratory volume in one second (FEV1) was measured with SpiroScout, Ganshorn 
Medizin Electronic, Germany. The predicted value (% of predicted) was calculated for each 
subject, according to Stanojevic et al. 2008. 
As for the metacholine challenge test the decline in FEV1 was calculated from the control 
value, i.e. the value of FEV1 at baseline and after several inhalations of 3.2% metacholine 
solution (with the initial inhalation being with normal saline) using an automatic inhalation-
synchronized dosimeter jet nebulizer. Methacholine chloride was nebulized automatically by 
the measuring device in cumulative doses of  22.5 g, 45 g, 90 g, 180 g, 360 g, 720 g, 
1440 g and 2000 g. FEV1 was measured, before the challenge and 2 minutes after 
inhalation of saline and each dose of methacholine (APS Pro System, Erich JÄEGER GmbH 
& CoKG, Germany). Changes in post-metacholine FEV1 of 20% were considered a positive 
reaction (with a grading scale of: severe bronchial hyperresponsiveness- positive reaction to 
metacholine doses <24.5 g, intermediate bronchial hyperresponsiveness- positive reaction to 
doses 24.5-389.3 g and mild bronchial hyperresponsiveness- positive reaction to doses 
389.3-1291.3 g). The test was not performed if the post-saline FEV1 was reduced by more 
than 10% compared with the pre-saline FEV1. Methacholine challenges were terminated after 
a fall of FEV1 greater than 20% from the control value or after the last dose inhaled (Brannan 
and Lougheed 2012). 
Spiroergometry testing was performed according to the Bruce treadmill protocol for children 
(Van Der Cammen-van Zijp et al. 2009) on a MTM-1500 med ergometer, Schiller AG, 
Switzerland. Briefly, the participants had their heart rate, ECG and lung function monitored 
(oxygen uptake- VO2), as well as carbon dioxide production- VCO2, minute ventilation- VE, 
and respiratory exchange ratio at 10-second intervals). The treadmill protocol consisted of a 
60-second warm-up period (pacing at 2.74 km/h on a flat treadmill) followed by the initiation 
of the test at 2.74 km/h and a 10% gradient for 3 minutes then by incremental increases in 
speed and incline every 2 minutes until volountary exhaustion. After the test, participants 
were monitored for 2 min to ensure a normal recovery of heart rate (2 km/h with a flat 
treadmill). The test was terminated if at any point the participants felt diziness, exhaustion, 
shortness of breath etc. 
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Impulse oscillometry (IOS) was performed  in younger children (preschool, under the age of 
5 years) using sound waves to detect airway changes, requiring only normal tidal breathing 
from the patient. Pulmonary mechanics are determined by superimposing small external 
pressure signals on the spontaneous breaths of the participants. When analyzed, these 
pressure signals separately quantify the degree of obstruction in the central and peripheral 
airways. Briefly, in IOS a loudspeaker generates harmonic sound waves of single or multiple 
frequencies (2 and 4 Hz to between 30 and 35 Hz) that flow through a conduit tube and 
mouthpiece into the participant`s respiratory tract. The sound impulses travel superimposed 
on normal tidal breathing through the large and small airways, with higher frequencies 
reflecting back from the large airways to the mouth and lower frequencies traveling deeper 
into the lung before returning. A pressure and flow transducer measures inspiratory and 
expiratory flow and pressure. Respiratory impedance is the sum of all the forces (resistance 
and reactance) opposing the pressure impulses (oscillations) and is calculated from the ratio 
of pressure and flow at each frequency (Bickel et al. 2014). 
Body plethysmography provides measures of the lung that reflect a multitude of functional 
and structural aspects (such as lung residual volume- RV, total lung capacity- TLC etc.) that 
cannot be assessed with other tecniques (eg. spirometry). Briefly, it was performed in certain 
participants by detecting changes in pressure in combination with either changes of mouth 
pressure or with flow rate under defined breathing conditions in a sealed box with rigid walls 
(chamber), according to the law of Boyle-Mariotte (for a fixed amount of gas in a closed 
compartment, such as the sealed box used, the relative changes in the compartment’s volume 
are always equal in magnitude but opposite in sign to the relative changes in pressure, 
inferring relative volume changes from pressure changes). These signals are evaluated in 
order to determine static lung volumes and airflow resistance (Criee et al. 2011). 
3.1.3. Assessment of levels of inflammation 
In order to assess the levels and type of both systemic and local inflammation, certain 
inflammatory biomarkers were measured at baseline in all participants, including fractional 
exhaled nitric oxide (FENO), high-sensitive C-reactive protein (hsCRP) as well as certain 
inflammatory cell counts, such as eosinophils and neutrophils. 
FENO is used to detect the level of airway inflammation as well as likeliness to respond to 
treatment with inhaled corticosteroids. It can also help to predict the onset of asthma 
symptoms or loss of asthma control, and to monitor compliance with corticosteroid therapy 
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and the effectiveness of such treatment. Briefly, the FENO small and portable device 
(Medisoft, Belgium) was used to determine exhaled nitric oxide concentration in the 
participant`s breath sample, requiring 10-second exhalation of breath at a pressure of 10–20 
cm H2O to maintain a fixed flow rate of 50 ± 5 ml/s. The last 3 seconds of the 10-second 
exhalation were analyzed by a calibrated electrochemical sensor to give a definitive result in 
parts per billion (ppb). Clinical cut-off values can be applied to the exhaled nitric oxide 
values to categorise readings as low, intermediate or high according to the reference ranges 
for children and adults (Dweik et al. 2011). 
Serum C-reactive protein levels measured by high-sensitivity assays (hs-CRP) are known to 
be a marker of low-grade systemic inflammation, present in many chronic conditions, 
including cardiovascular diseases and asthma. It may also be associated with airflow 
obstruction and even serve as a surrogate marker of airway inflammation in asthma and 
moreover, it may indicate the level of disease control (Takemura et al. 2006, Navratil et al. 
2009). Brielfy, a highly sensitive CRP assay was performed with an Olympus AU680 
automated system (Beckman Coulter Inc., USA) using the latex agglutination method to 
quantitate CRP in serum samples of all participants at baseline (Rifai et al. 1999).  
In order to assess both the type and level of inflammation, total eosinophil and neutrophil 
counts were measured at baseline in peripheral blood samples of all participants, absolute 
and/or relative (to total white blood cell- WBC count) counts, using a Sysmex cell counter 
(Sysmex XT-1800i Automated Hematology Analyzer, Sysmex Canada Inc., Canada). 
3.1.4. Other assessments and diagnostic tests 
In order to assess their health status, other diagnostic measurements and tests were performed 
in all participants at baseline, including complete blood count (absolute and/or relative)- 
white blood cells (basophils, monocytes, lymphocytes etc.) and total number of platelets 
using the same cell counter (Sysmex XT-1800i Automated Hematology Analyzer, Sysmex 
Canada Inc., Canada), as well as other relevant biochemistry assays, such as immunoglobulin 
levels (immunoglobulin A- IgA, immunoglobulin G- IgG and immunoglobulin M- IgM), 
using a commercial turbidimetry assay and an Olympus AU680 automated system (Beckman 
Coulter Inc., USA). 
In order to identify additional conditions that might affect and aggravate the underlying 
disease (and asthma control), the participants were tested for common asthma comorbidities, 
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such as gastroesophageal reflux disease (GERD), obstructive sleep apnoea syndrome 
(OSAS), allergic rhinitis and atopic dermatitis. 
All participants (and/or their parents/legal guardians) were asked about the child`s medical 
history on allergic rhinitis/rhinoconjuctivitis (AR) and atopic dermatitis (AD). Additionally, 
participants who were suspected to have AR, underwent measurements of nasal fractional 
exhaled nitric oxide (nasal FENO) for diagnostic purposes (to assess the degree of local upper 
airway allergic inflammation as well as subjective symptoms), using the same FENO 
analyzer as with bronchial FENO with a nose adaptor (Medisoft, Belgium). 
Participants with unresolved persistent cough etiology or otherwise suspected reflux disease 
underwent 24-hour pH monitoring with a esophageal probe positioned approximately 5 cm 
above the lower esophageal sphincter barrier using a Ohmega pH and impedance monitoring 
system (Medical Measurement Systems B.V., The Netherlands), recording the number, type 
and duration of acidic, weakly acidic and non-acidic reflux episodes (Streets and DeMeester 
2003). This data was then used to calculate certain indices (such as the Boix-Ochoa and 
Johnson-DeMeester score) and association to reflux symptoms in order to diagnose or 
exclude GERD. 
Obstructive sleep apnoea syndrome (OSAS), characterized by episodes of complete or partial 
upper airway obstruction during sleep, is a common comorbidity in asthma and moreover, 
has been associated with disease severity (Salles et al. 2013). In order to diagnose or exclude 
any obstructive sleep disorder (including OSAS), certain participants (those with adequate 
indication- nocturnal symptoms, AR, extensive fatigue or affected cognitive and learning 
abilities due to sleep deprivation etc.) were subjected to all-night polysomnography (a multi-
parametric sleep study). Briefly, the participants spent one night sleeping in the Sleep lab at 
the Srebrnjak Children`s Hospital, at least 8 hours in duration. They were put to bed at their 
usual bedtimes, without the use of any hypnotic agents. During this procedure, the particpants 
had multiple body functions monitored using Nihon Kohden (Japan) digital system and PolyT 
software as well as standardized proceudre (Gjergja Juraški et al. 2013). These included 
monitoring of brain functions (electroencephalography, EEG), eye movements 
(electrooculography, EOG), chin and leg muscle activity (electromyography, EMG) and heart 
rhythm (electrocardiography, ECG), along with breathing functions such as nasal pressure, 
nasal airflow, respiratory effort (thoracic and abdominal plethysmography), pulse oxymetry, 
snore detection, body position sensoring etc. These recorded sleep onset latency, sleep 
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efficiency, stages of sleep (1, 2, 3 and REM- Rapid eye movement), breathing irregularities, 
arousals, cardiac rhythm abnormalities, leg movements and body positions during sleep and 
oxygen saturation, required for the assessment of sleep disorders, according to standard 
criteria of Rechtschaffen and Kales, including the apnoea-hypopnoea index, AHI (Lerman et 
al. 2012, Gjergja Juraški et al. 2013).  
3.1.5. Asthma severity assessment 
After the participants were diagnosed with asthma, the level of disease control and disease 
severity (grade) was assessed according to GINA guidelines (GINA 2018, GINA Pediatric 
2015), taking into account symptom severity and occurance (including nocturnal symptoms), 
need for reliever medications (namely SABA), number of asthma exacerbations, lung 
function and scoring based on certain health and quality-of-life questionnaires such as the 
Asthma Control Test (ACT). According to these severity criteria, participants were classified 
as either having: intermittent or persistent asthma, with persistent asthma being mild, 
moderate or severe. A summary of the GINA classification of asthma severity is presented in 
Tables 7 and 8. 
Table 7. Classification (grading system) of asthma severity in adults and children older than 5 years of age, 
according to GINA guidelines, involving daytime and nocturnal symptom severity and frequency, as well as 
certain lung function parameters. *The presence of one of the features of severity is sufficient to place a patient 
in that category (grade). May be applicable to children 5 years of age and younger. Source: GINA 2018, GINA 
Pediatric 2015. 
 Symptoms (daytime) Symptoms 
(nocturnal) 
PEF or 
FEV1 (% of 
predicted) 
PEF 
variability 
STEP/GRADE 1 
(Intermittent asthma) 
< 1 time a week; 
Asymptomatic and normal 
PEF between attacks 
≤ 2 times a month ≥ 80% < 20%  
STEP/GRADE 2 (Mild 
persistent asthma) 
> 1 time a week but  < 1 
time a day; Attacks may 
affect daily functioning 
>2 times a month ≥ 80% 20-30% 
STEP/GRADE 3 
(Moderate persistent 
asthma) 
Daily; Attacks affect 
activity and daily 
functioning 
>1 time a week 60-80% >30% 
STEP/GRADE 4 (Severe 
persistent asthma) 
Continuous; Limited 
physical activity 
Frequent ≤ 60% >30% 
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Table 8. Classification (grading system) of asthma severity in children under 5 years of age, according to GINA 
guidelines. Source: GINA Pediatric 2015. For persistent asthma, consider severity and interval since last 
exacerbation. Frequency and severity may fluctuate over time.* Exacerbations of any severity may occur in 
patients in any severity category (grade). 
 
Components of severity 
(criteria) 
Classification of asthma severity (children aged 0-4 yrs) 
Intermittent 
asthma 
(grade 1) 
Persistent asthma 
Mild (grade 2) Moderate 
(grade 3) 
Severe (grade 4) 
Im
p
a
ir
m
e
n
t 
   Im
p
a
ir
m
e
n
t 
Symptoms ≤ 2 days per 
week 
>2 days per week, but 
not daily 
Daily Daily, throughout 
the day 
Night-time 
awakenings 
0 1-2 times per month 3-4 times per 
month 
>1 times per week 
Use of reliever 
medication (SABA) 
≤ 2 days per 
week 
>2 days per week, but 
not daily 
Daily Severeal times per 
day 
Intereference with 
normal activity 
None Minor limitation Some 
limitation 
Extremely limited 
R
is
k
 
 
Exacerbations 
requiring OCS 
0-1 per annum ≥ 2 exacerbations in the last 6 months requiring OCS use, or ≥ 
4 episodes per year lasting for > 1 day AND risk factors for 
persistent asthma 
 
3.1.6. Assessment of treatment response 
After they were diagnosed with asthma, patients started treatment with inhaled 
corticosteroids, ICS  (alone or in combination with LABA) and/or LTRA, according to 
disease severity and previously assessed disease control. Follow-up visits with lung function 
and airway inflammation testing as well as physical examination were made on average every 
6 months over the period of  2 years. Additionally, treatment success (response) and the level 
of disease control (according to GINA guidelines) was assessed at each visit. A summary of 
GINA recommendations for asthma control monitoring is presented in Table 9. 
Table 9. Grading system for the assessment of asthma control between clinical visits, according to GINA 
guidelines. Source: GINA 2018, GINA Pediatric 2015. 
 Controlled Partly controlled Uncontrolled 
Characteristic Controlled if all of 
the following 
Any of the features 
present in one week 
 
 
 
 
Daytime symptoms (wheezing, cough, 
difficulty in breathing) 
None (≤ 2 times per 
week) 
>2 times per week 
short periods- 
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minutes)  
 
Three or more 
features of partly 
controlled present 
in one week 
Limitation of activities (cough, 
wheezing or difficulty in breathing 
during exercise, playing or laughing) 
 
None 
 
Any 
Nocturnal symptoms/awakenings 
(cough, wheezing or difficulty in 
breathing) 
 
None 
 
Any 
Need for reliever/rescue treatment None (≤ 2 times per 
week) 
>2 times per week 
Lung function (PEF or FEV1) Normal <80% predicted or 
personal best 
Exacerbations None One or more per year One or more per 
week 
 
Acute exacerbation severity and frequency was assessed at each follow-up visit as: none, 
mild, moderate and severe. 
 
3.2. Genetic analysis 
3.2.1. DNA isolation 
Genomic DNA was extracted from EDTA-containing peripheral whole blood samples, 
previously stored at -20°C, using QIAamp DNA Blood Mini Kit (Qiagen GmbH, Germany) 
according to the manufacturer’s instructions, by an automated (Qiacube, Qiagen GmbH, 
Germany) or manual spin protocol. DNA was eluted in a total volume of 100 l. The quality 
and concentration (A260/A280 ratio, concentration in ng/l, A260/A230 ratio) of each DNA 
isolate was checked using a NanoDrop
™
 2000 spectrophotometer (ThermoFisher Scientific 
Inc., USA).  
3.2.2. Genotyping 
The genotypes of the SNPs analyzed were determined using a 5`-nuclease allelic 
discrimination assay in a 96-well format and Taqman technology. Primers and probes were 
purchased from Applied Biosystems (Life Technologies, USA) for SNP genotyping assays 
rs37973 in GLCCI1, rs9910408 in TBX21 and rs242941 and rs1876828 in CRHR1, as well as 
rs1042713 in ADRB2. Allelic discrimination assays were performed in 5 L reaction 
Table 9. continued 
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volumes, using approximately 5 ng of DNA as a template, 2x TaqMan Fast Advanced Master 
Mix, and predesigned SNP genotyping assays provided by Applied Biosystems for rs37973, 
rs9910408, rs242941 and rs1876828. Temperature conditions for qPCR were set at 50°C for 
2 minutes and 95°C for 20 seconds, followed by 40 cycles at 95°C for 3 seconds and at 60°C 
for 30 seconds.  
For rs17576 SNP (MMP9) genotyping a primer and probe set were designed using a free 
online software qPCR primer & probe design tool and design service (Eurofins Genomics, 
Germany). The forward and reverse primer as well as probe sequences are presented in Table 
10. 
Table 10. Primers (forward and reverse) and probes (allele 1 and allele 2) design for the rs17576 genotyping 
assay (MMP9 Gln279Arg, A/G transition detection). FWD- forward primer, REV- reverse primer, Allele 1 PR- 
probe for SNP allele 1, Allele 2 PR- probe for SNP allele 2, bp- base pairs (length of sequence in base paris), 
reporter- fluorescent dye, quencher- fluorescent dye quencher pair. For probe sequences nucleotides highlighted 
in red denote the ambiguity position (transition). 
Oligonucleotide type Length (bp) Sequence  Reporter/quencher 
MMP9 Gln279Arg FWD primer 19 TCCCCCTTTCCCACATCCT  
MMP9 Gln279Arg REV primer 21 CAGGGTTTCCCATCAGCATTG  
MMP9 Gln279Arg Allele 1 PR 17 CTCTACACCCAGGACGG VIC-BHQ1 
MMP9 Gln279Arg Allele 2 PR 17 TCTACACCCGGGACGG FAM-BHQ1 
 
Allelic discrimination assays for rs1042713 and rs17576 was performed in 12.5 l reaction 
volume, using approximately 5 ng of DNA template, 100 M of primer set (forward and 
reverse) and 10 M of probes, with qPCR conditions as follows: 50°C for 2 minutes and 
95°C for 10 minutes, followed by 40 cycles at 95°C for 15 seconds and at 60°C for 1 minute.   
Genotyping of the amplified PCR products was determined by differences in VIC and FAM 
fluorescent levels, using the ABI Prism 7500 Fast Real-Time PCR system (system instrument 
equipped with SDS v2.0.5 software, Applied Biosystems, ThermoFisher Scientific Inc., 
USA) for rs37973, rs9910408, rs242941 and rs1876828 and using the Agilent AriaMX Real-
Time PCR system (system instrument equipped with AriaMx software v1.0, Agilent 
Technologies, USA) for rs1042713 and rs17576. 
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3.3. Statistical analysis 
The Hardy-Weinberg equilibrium was tested using the chi-squared () test for the goodness-
of-fit (one degree of freedom) model and Michael H. Court's (2005-2008) online calculator 
(Court 2012). Data distribution was evaluated by the Kolmogorov-Smirnov test and the 
Shapiro-Wilk’s W test. Parametric statistics (one-way ANOVA) were used on normally 
distributed data, and non-parametric statistics (the Kruskal-Wallis test) was used if the 
distribution deviated from normal. Genotypic distribution and allelic frequencies in „good’’, 
„moderate“ and „bad’’ responders (with regard to change from baseline in FEV1, MEF50, 
FENO and level of asthma control after 6 months, 12 months, 18 months and 2 years of  
treatment) were compared using the 2 test calculated on contingency tables. A Spearman's 
rank-order correlation was run to determine the relationship between the response to 
treatment (according to the above mentioned changes in lung function parameters- FEV1 and 
MEF50, changes in exhaled nitric oxide and level of asthma control) and other baseline 
parameters (demographic and clinical parameters, including cell count, inflammation 
biomarkers, comorbidity etc.). A multivariate general linear model (or a multi-way 
ANCOVA) was conducted to determine a statistically significant association between the 
level of response to treatment (according to changes in FEV1, MEF50, FENO and asthma 
control) and specific genotypes for rs37973, rs9910408, rs242941, rs1876828, rs1042713 and 
rs17576 controlling for certain confouding variables. IBM
®
 SPSS
®
 Statistics software was 
used for these analyses (version 21, release 21.0.0.0 for Windows; International Business 
Machines Corp., USA). A p-value of  less than 0.05 was accepted as statistically significant. 
 
3.4. Cluster analysis 
Following the 2-year clinical assessment period, all participants were stratified into specific 
subgroups (asthma phenotypes/endotypes) by a cluster analysis, according to specific 
biomarkers- clinical features, treatment success, possible pathophysiological mechanisms and 
genetic predisposition by hierachical clustering analysis (HCA). HCA is considered an 
unsupervised machine learning method. It is used to reveal structures within data based on 
certain distance or similarity between objects and/or variables. All operations on data were 
performed either in R (https://www.r-project.org/) or Python (https://www.python.org/). Data 
taken for hierarchical clustering were the data gathered at baseline (demographic and clinical 
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parameters, including cell count, lung function, inflammation biomarkers, comorbidity etc.), 
follow up visits (lung function, airway inflammation- FENO and level of disease control 
according to GINA guidelines) and response to treatment data.  
Hierachical clustering analysis was performed using the Ward method (Moore et al 2010, 
Kim et al. 2013, Qiu et al. 2018) with the use of Pythons’ SciPy library. Ward's method 
minimizes the total within-cluster variance. This method is implemented in a way that each 
step finds the pair of clusters that leads to minimum increase in total within-cluster variance 
after merging. The clusters were subsequently tested on stability using bootstrapping, i.e. the 
data was reshuffled and separated on train-test splits. Jaccard similarity (Irani et al. 2016) was 
used to calculate similarities between the patients` association to the same cluster, i.e. the 
clusters are more stable the higher the Jaccard similarity. To increase cluster stability the 
entry data for HCA was performed on PCA (principal component analysis) transformed data 
(Deliu et al. 2018). PCA is a dimensionality reduction technique based on orthogonal 
transformation. The reduced data was represented as principal components which are 
mutually uncorrelated, each being a linear combination of original variables, and ordered by 
the amount of variance they cary. 
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4. RESULTS 
Basic participant demographic and clinical data at baseline (age, gender and BMI 
distribution, common comorbidities, and disease severity assessment according to GINA 
guidelines, GINA 2018 as well as disease duration) are shown in Table 11. 
Table 11. Basic participant data (clinical and demographic) at baseline (recruitment point). M- male, F- female 
participants; AR- allergic rhinitis; AD ever- atopic dermatitis ever; AD curr- atopic dermatitis in the last 12 
months; GERD- gastroesophageal reflux disease; RI score- reflux index; OSA- obstructive sleep apnea, AHI- 
apnea/hipopnea index; Y- yes, N- no, SD- standard deviation, y- years. Underweight- ≤5 centile, normal- 5-85 
centile, overweight- 85-95 centile, obese- ≥95 centile. 
Age (years)- 
Mean (SD) 
Gender 
(male/female, 
M/F)- N (%) 
Percentile of 
height and 
weight- N (%) 
Disease 
severity 
(GINA)- N 
(%) 
Duration of 
disease (y)- 
mean (SD) 
Comorbidity- N 
(%), mean (SD) 
 9.97 (3.97) 
 
M 9.68 (3.93) 
 
F 10.44 (4.01) 
M 223 (61.10)  
 
F 142 (38.90) 
Underweight- 
11 (3.01) 
Normal- 253 
(69.32) 
Overweight- 50 
(13.70) 
Obese- 51 
(13.97) 
Grade 1- 221 
(60.55) 
Grade 2- 119 
(32.60) 
Grade 3- 19 
(5.21) 
Grade 4- 6 
(1.64) 
3.27 (2.83) 
(N=302) 
AR 312 (85.48) 
AD ever 101 
(27.82) 
AD curr 23 (6.33) 
GERD 101 
(27.67) 
RI score 9.10 ± 
11.19 
OSA 14 (3.84), 
AHI 0.57 ± 2.84 
 
Participant atopy status as well as key allergy and inflammation features (total serum IgE,  
peripheral blood eosinophil count, peripheral blood neutrophil count, hsCRP, lung FENO) at 
baseline (recruitment point) are shown in Table 12. 
Table 12. Participant atopy status and certain allergy and inflammation features. IgE- immunoglobulin, hsCRP- 
high-sensitive C-reactive protein, FENO- fraction of exhaled nitric oxide, WBC- white blood cells (leukocytes). 
Atopy 
(Y/N)- 
N(%) 
Total IgE 
(kIU/l)- 
mean (SD) 
Eosinophil count (Dunger)- 
median (SD) 
Neutrophil 
count (% of 
total WBC)- 
mean (SD) 
hsCRP 
(mg/l)- 
mean (SD) 
Lung FENO 
(ppb)- mean 
(SD) 
Y 319 
(87.40) 
614.54 
(1145.62) 
416.35 (341.27) (N=355) 49.76 (12.86) 
(N=364) 
2.23 (9.30) 
(N=311) 
20.49 (20.07) 
(N=350) 
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N 46 
(12.60) 
(N=351) 
 
Participant lung function data (% of FEV1 and MEF50 predicted for age, gender and posture) 
at baseline is shown in Table 13. 
Table 13. Participant lung function parameters at recruitment point (baseline). FEV1- forced expiratory volume 
in 1 second, MEF50- maximum expiratory flow at 50%, N=365. 
% of FEV1 predicted (at baseline)- mean (SD) % of MEF50 predicted (at baseline)- mean (SD) 
87 (17.14) 88 (23.11) 
 
Genotype distribution (frequency) for each genetic polymorphism is shown in Figure 13. All 
participants were successfully genotyped for rs37973, rs9910408, rs242941 and rs1876828. 
For rs1042713 and rs17576 genotype data was missing for 1 and 19 participants, 
respectively, due to insufficient DNA extract material or degraded DNA samples in 
subsequent/repeated analysis. 
 
Figure 13. Genotype frequency (%) for respective genetic polymorphisms: rs37973, rs9910408, rs242941, 
rs1876828, rs1042713 and rs17576. GLCCI1- glucocorticoid induced 1; TBX21- T-box 21, T-bet; CRHR1- 
corticotropin releasing hormone receptor 1, ADRB2- beta-2-adrenergic receptor; MMP9- matrix 
metallopeptidase 9. For rs37973, rs9910408, rs242941 and rs1876828 N=365, for rs1042713 N=364 and for 
rs17576 N=346.
Table 12. continued 
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Consistency with the Hardy- Weinberg equilibrium (HWE) for each genetic polymorphism, along with global and population-specific minor 
allele frequency (MAF) is presented in Table 14. 
Table 14. HWE consistency for genotype frequencies for rs37973, rs9910408, rs242941, rs1876828, rs1042713 and rs17576. chi-squared value, p < 0.05 consistent with 
HWE. Global and population specific (Central European) MAF according to NCBI dbSNP (https://www.ncbi.nlm.nih.gov/SNP/). HWE- Hardy-Weinberg equilibrium, MAF- 
minor allele frequency, CEU- Central European, reference population. Calculated using Michael H. Court's (2005-2008) online calculator (Court 2012). 
 
Genotype 
rs37973 rs9910408 rs242941 rs1876828 rs1042713 rs17576 
Observed Expected Observed Expected Observed Expected Observed Expected Observed Expected Observed Expected 
Homozygote 
reference 
130 130.2 103 106.9 150 155.2 270 270.1 113 88.0 50 83.0 
Heterozygote 176 175.6 189 181.3 176 165.6 88 87.7 132 182.0 239 172.9 
Homozygote 
variant 
59 59.2 73 76.9 39 44.2 7 7.1 119 94.0 57 90.0 
Variant allele 
frequency 
0.40 0.46 0.35 0.14 0.51 0.51 
 0.002 0.664 1.433 0.003 27.433 50.508 
p (1 degree of 
freedom) 
0.965 0.415 0.231 0.956 0.000 0.000 
Global MAF 0.396 0.384 0.323 0.086 0.476 0.456 
CEU MAF 0.442 0.456 0.282 0.240 0.358 0.381 
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4.1.  Definition of response  
According to their response to specific classes of treatment (ICS alone, LTRA alone, 
combination treatment- ICS+LABA/LTRA), patients were divided into ‘‘poor’’ or 
„inadequate“ („moderate“ and „bad“) and ‘‘good’’ responders in accordance with the 
American Thoracic Society (ATS) and European Respiratory Society (ERS) task forces` 
interpretation of changes in lung function (FEV1 and MEF50) as well as data from other 
studies evaluating treatment response in asthma- by taking into account changes in the level 
of disease control (according to GINA), as well as changes in the level of airway 
inflammation, i.e. FENO values (GINA 2018, Pellegrino et al. 2005, Reddel et al. 2009, Oei 
et al. 2011, Dweik et al. 2011, Buchvald et al. 2003, Smith et al. 2005, de Jongste 2005, 
Smith et al. 2005).  
4.1.1.     Definition of response according to changes in lung function 
Bad response to treatment according to changes in FEV1 was defined as a decrease in FEV1 
predicted (for children of certain age, gender and posture- height, weight) by 10% or more 
between clinical visits/follow-ups (≤10%). Moderate response to treatment according to 
changes in FEV1 was defined as a relative change in FEV1 predicted by ±10% and good 
response to treatment was defined as an increase in FEV1 predicted by 10% or more (≥10%) 
between clinical assessments/follow-ups.  
Bad response to treatment according to changes in MEF50 was defined as a decrease in 
MEF50 predicted (for children of certain age, gender and posture) by 15% or more (≤15%); 
moderate response was defined as a relative change in MEF50 predicted by ±15% and good 
response to treatment was defined as an increase in MEF50 predicted by 15% or more (≥15%) 
between clinical visits/follow-ups (Telenga et al. 2013, Boskabady et al. 2008).  
4.1.2.     Airway inflammation 
According to ATS recommendations, cut points rather than reference values were used when 
interpreting FENO levels (Dweik et al. 2011): low FENO (25 ppb in adults; 20 ppb in 
children), high FENO (50 ppb in adults, 35 ppb in children), intermediate FENO (between 25 
ppb and 50 ppb in adults; 20- 35 ppb in children). Bad response to treatment was defined as 
an increase in FENO greater than 20% for values over 35 (50 for patients older than 18 years) 
ppb or more than 10 ppb for values lower than 35 (50) ppb between clinical visits. A 
reduction of at least 20% in FENO for values over 35 (50) ppb or more than 10 ppb for 
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values lower than 35 (50) ppb was defined as the cut point to indicate a significant (good) 
response to anti-inflammatory treatment. Moderate response to treatment was defined as 
changes in FENO values ranging from a reduction of ≤20% and increase ≤20% for FENO 
values over 35 (50) ppb and ±10 ppb for values lower than 35 (50) ppb from one visit to the 
next. 
4.1.3.    Asthma control 
The level of asthma control between clinical visits was assessed according to GINA 
guidelines (GINA 2018): symptom occurance (including nocturnal symptoms), need for 
reliever medications (namely SABA), number and severity of asthma exacerbations, lung 
function and Asthma Control Test (ACT), where applicable. The level of control was defined 
as either controlled, partly controlled or uncontrolled, whereas bad response to treatment was 
defined as a deterrioration in asthma control between visits (controlled to uncontrolled or 
partly controlled), good response was defined as an improvement in asthma control (partly- 
or uncontrolled to controlled) and moderate response was defined as no changes in partial 
asthma control between clinical visits, with the exception of the patient having uncontrolled 
asthma from visit to visit, which was considered a bad response or good response to 
treatment, when the patient had controlled asthma symptoms between visits. 
 
4.2.  Association of response to treatment with genetic and other 
parameters 
Significant correlations in response to treatment (in general, including all 3 major classes of 
treatment- ICS, LTRA and combination treatment- ICS+LABA/LTRA) according to relative 
changes in lung function parameters (FEV1 and MEF50), changes in markers of local (airway) 
inflammation (FENO) and changes in the level of asthma control according to GINA 
guidelines, between respective visits over the period of (on average) 2 years with specific 
genetic polymorphisms (rs37973, rs9910408, rs242941, rs1876828, rs1042713 and rs 17576) 
are presented in Table 15. 
Table 15. Correlation of response to treatment after 6, 12, 18 and 24 months (on average), according to changes 
in FEV1, MEF50, FENO and asthma control, with the analyzed genetic polymorphisms: rs37973 (GLCCI1), 
rs9910408 (TBX21), rs242941 (CRHR1), rs1876828 (CRHR1), rs1042713 (ADRB2) and rs17576 (MMP9). 
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Spearman`s correlation test, p< 0.05. Abbreviations for respective responses to treatment are defined in 
Supplement 4. R- Spearman`s Rho (correlation coefficient). 
 rs37973 rs9910408 rs242941 rs1876828 rs1042713 rs17576 
Resp_MEF50_diagn_1
st
 
control 
   R= -0.116 
p= 0.027 
N= 365 
  
Resp_FENO_1
st
_2
nd
 
control 
 R= -0.141 
p= 0.008 
N= 350 
    
Resp_FENO_3
rd
_4
th 
control 
     R= -0.175 
p= 0.009 
N= 223 
Resp_MEF50_3
rd
_4
th
 
control 
R= 0.180 
p= 0.006 
N= 234 
     
Resp_FEV1_diagn_4
th
 
control 
  R= 0.158 
p= 0.016 
N= 231 
   
Resp_CRTL_diagn_4
th
 
control 
    R= 0.147 
p= 0.024 
N= 234 
 
 
Significant correlations in response to treatment (in general, including all 3 major classes of 
treatment- ICS, LTRA and combination treatment- ICS+LABA/LTRA) according to relative 
changes in lung function parameters (FEV1 and MEF50), changes in markers of local (airway) 
inflammation (FENO) and changes in the level of asthma control according to GINA 
guidelines, between respective visits over the period of (on average) 2 years with other 
clinical and physiological parameters are presented in Table 16. 
Table 16. Correlation of response to treatment after 6, 12, 18 and 24 months (on average), according to changes 
in FEV1, MEF50, FENO and asthma control, with all other physiological and clinical variables (medical 
history, biochemical, lung function, demographic and other parameters). Spearman`s correlation test, p< 0.05. 
Abbreviations for respective responses to treatment are defined in Supplement 4. R- Spearman`s Rho 
(correlation coefficient). Diagnosis- recruitment point; AD- atopic dermatitis, AR- allergic rhinitis, OSA- 
obstructive sleep apnea. 
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Response to treatment Association with physiologic and clinical parameters 
Resp_FEV1_diagn_1
st
 control 
(N=365) 
MEF50 at diagnosis (R= 0.236, p= 0.000), total IgE (R= 0.108, p= 0.040), FVC at 1
st
 control (R= -0.364, p=0.000), PEF at 1
st
 control (R= 
-0.303, p= 0.000), MEF50 at 1
st
 control (R= -0.376, p= 0.000), Atopy (R=0.120, p= 0.021), Asthma severity (R= 0.114, p= 0.029), 
Exacerbation severity at 1
st
 control (R= 0.111, p= 0.034), FVC at 2
nd
 control (R= -0.175, p= 0.001), PEF at 2
nd
 control (R= -0.112, p= 
0.033), MEF50 at 2
nd
 control (R= -0.180, p=0.001), FVC at 3
rd
 control (R= -0.184, p= 0.000),  PEF at 3
rd
 control (R= -0.190, p= 0.000), 
MEF50 at 3
rd
 control (R= -0.159, p= 0.002), FENO at 4
th
 control (R= 0.134, p= 0.010), Asthma control at 4
th
 control (R= 0.109, p= 0.038) 
Resp_FENO_diagn_1
st
 control 
(N= 352) 
Asthma control at diagnosis (R= -0.121, p=0.023), Age (R= 0.199, p= 0.000), Disease duration (R= 0.166, p= 0.002), total IgE (R= 
0.113, p= 0.034), Eosinophil count (R= 0.114, p= 0.033), AD (R= -0.105, p= 0.049), Night symptoms at 3
rd
 control (R= -0.110, p= 0.039) 
Resp_CTRL_diagn_1
st
 control 
(N= 365) 
MEF50 at diagnosis (R= -0.118, p= 0.024), Age (R= 0.153, p= 0.003), total IgE (R= 0.204, p= 0.000), Basophil count (R= 0.125, p= 
0.017), FEV1 at 1
st
 control (R= -0.109, p= 0.037), MEF50 at 1
st
 control (R= -0.142, p= 0.007), FENO at 1
st
 control (R= 0.149, p= 0.004), 
AR (R= 0.121, p= 0.021), AD (R= 0.147, p= 0.005), Atopy (R= 0.134, p= 0.010), FEV1 at 2
nd
 control (R= -0.137, p= 0.009), FVC at 2
nd
 
control (R= -0.115, p= 0.028), FENO at 2
nd
 control (R= 0.174, p= 0.001), FENO at 3
rd
 control (R= 0.169, p= 0.001) 
Resp_MEF50_diagn_1
st
 control 
(N= 365) 
FEV1 at diagnosis (R= 0.236, p= 0.000), Eosinophil count (R= -0.112, p= 0.033), FEV1 at 1
st
 control (R= -0.375, p= 0.000), FVC at 1
st
 
control (R= -0.168, p= 0.001), PEF at 1
st
 control (R= -0.294, p= 0.000), FEV1 at 2
nd
 control (R= -0.227, p= 0.000), FVC at 2
nd
 control 
(R= -0.132, p= 0.012), PEF at 2
nd
 control (R= -0.156, p= 0.003), FEV1 at 3
rd
 control (R= -0.141, p= 0.007), PEF at 3
rd
 control (R= -0.194, 
p= 0.000) 
Resp_FEV1_1
st
_2
nd
 control (N= 
365) 
Disease duration (R= 0.130, p= 0.013), OSA (R= 0.122, p= 0.019), total IgE (R= -0.118, p= 0.024), Neutrophil count (R= -0.107, p= 
0.040), Basophil count (R= 0.107, p= 0.041), FVC at 1
st
 control (R= 0.284, p= 0.000), PEF at 1
st
 control (R= 0.256, p= 0.000), MEF50 at 
1
st
 control (R= 0.306, p= 0.000), Atopy (R= -0.111, p= 0.034), FVC at 2
nd
 control (R= -0.194, p= 0.000), PEF at 2
nd
 control (R= -0.221, 
p= 0.000), MEF50 at 2
nd
 control (R= -0.119, p= 0.023), FVC at 4
th
 control (R= -0.105, p= 0.046), Asthma control at 4
th
 control (R= -
0.127, p= 0.015) 
Resp_FENO_1
st
_2
nd
 control 
(N= 350) 
BMI percentile (R= -0.113, p= 0.035), Neutrophil count (R= -0.133, p= 0.013), PEF at at 2
nd
 control (R= -0.145, p= 0.007), FEV1 at 4
th
 
control (R= -0.151, p= 0.005), FVC at 4
th
 control (R= -0.182, p= 0.001), PEF at 4
th
 control (R= -0.188, p= 0.000), MEF50 at 4
th
 control 
(R= -0.135, p= 0.01), Asthma control at 4
th
 control (R= -0.154, p= 0.004) 
Resp_CTRL_1
st
_2
nd
 control 
(N=365) 
Neutrophil count (R= 0.125, p= 0.016), AD (R= 0.116, p= 0.027), FEV1 at 2
nd
 control (R= -0.231, p= 0.000), FVC at 2
nd
 control (R= -
0.116, p= 0.027), MEF50 at 2
nd
 control (R= -0.212, p= 0.000), FEV1 at 3
rd
 control (R= -0.131, p= 0.012), MEF50 at 3
rd
 control (R= -0.119, 
64 
 
p= 0.023) 
Resp_MEF50_1
st
_2
nd
 control 
(N=365) 
Disease duration (R= 0.198, p= 0.000), Eosinophil count (R= 0.121, p= 0.020), Neutrophil count (R= -0.117, p= 0.025), Basophil count 
(R= 0.119, p= 0.024), FEV1 at 1
st
 control (R= 0.354, p= 0.000), FVC at 1
st
 control (R= 0.243, p= 0.000), PEF at 1
st
 control (R= 0.337, p= 
0.000), Exacerbation severity at 1
st
 control (R= -0.110, p= 0.035), FEV1 at 2
nd
 control (R= -0.190, p= 0.000), FENO at 2
nd
 control (R= 
0.110, p= 0.035), Asthma control at 4
th
 control (R= -0.123, p= 0.019) 
Resp_FEV1_2
nd
_3
rd
 control (N= 
365) 
Age (R= 0.109, p= 0.037), BMI percentile (R= 0.112, p= 0.032), FVC at 2
nd
 control (R= 0.166, p= 0.001), PEF at 2
nd
 control (R= 0.175, 
p= 0.001), MEF50 at 2
nd
 control (0.229, p= 0.000), Asthma control at 2
nd
 control (R= -0.109, p= 0.037), FVC at 3
rd
 control (R= -0.112, p= 
0.032), PEF at 3
rd
 control (R= -0.136, p= 0.009), MEF
50
 at 3
rd
 control (R= -0.167, p=0.001) 
Resp_FENO_2
nd
_3
rd
 control 
(N= 350) 
Atopy (R= 0.167, p= 0.002), PEF at 2
nd
 control (R= 0.164, p= 0.002), FEV1 at 4
th
 control (R= 0.214, p= 0.000), FVC at 4
th
 control (R= 
0.254, p= 0.000), PEF at 4
th
 control (R= 0.243, p= 0.000), MEF50 at 4
th
 control (R= 0.198, p= 0.000), Asthma control at 4
th
 control (R= 
0.228, p= 0.000), Exacerbation severity at 4
th
 control (R= 0.106, p= 0.049) 
Resp_CTRL_2
nd
_3
rd
 control 
(N= 365) 
MEF50 at diagnosis (R= -0.152, p= 0.004), Age (R= -0.187, p= 0.000), Monocyte count (R= -0.112, p= 0,032), FEV1 at 1
st
 control (R= -
0.172, p= 0.001), FVC at 1
st
 control (R= -0.155, p= 0.003), PEF at 1
st
 control (R= -0.142, p= 0.006), MEF50 at 1st control (R= -0.127, p= 
0.015), FENO at 1
st
 control (R= -0.225, p= 0.000), AD (R= 0.140, p= 0.007), FVC at 2
nd
 control (R= -0.105, p= 0.046), PEF at 2
nd
 control 
(R= -0.151, p= 0.004), MEF50 (R= -0.141, p= 0.007), FENO at 2
nd
 control (R= -0.132, p= 0.012), FEV1 at 3
rd
 control (R= -0.314, p= 
0.000), FVC at 3
rd
 control (R= -0.162, p= 0.002), PEF at 3
rd
 control (R= -0.230, p= 0.000), MEF50 at 3
rd
 control (R= -0.299, p= 0.000), 
FEV1 at 4
th
 control (R= -0.139, p= 0.008), FVC at 4
th
 control (R= -0.134, p= 0.010) 
Resp_MEF50_2
nd
_3
rd
 control 
(N= 365) 
OSA (R= -0.115, p= 0.028), Platelet count (R= 0.122, p= 0.020), FEV1 at 2
nd
 control (R= 0.137, p= 0.009), FVC at 2
nd
 control (R= 0.108, 
p= 0.039), PEF at 2
nd
 control (R= 0.120, p= 0.022), FEV1 at 3
rd
 control (R= -0.201, p= 0.000), Asthma control at 3
rd
 control (R= 0.240, 
p= 0.000), Exacerbation severity (R= 0.222, p= 0.000) 
Resp_FEV1_3
rd
_4
th
 control 
(N=234) 
Age (R= -0.149, p= 0.023), Disease duration (R= -0.129, p= 0.049), FVC at 2
nd
 control (R= -0.136, p= 0.038), MEF50 at 3
rd
 control (R= 
0.139, p= 0.034), FVC at 4
th
 control (R= -0.209, p= 0.001), PEF at 4
th
 control (R= -0.129, p= 0.049) 
Resp_FENO_3
rd
_4
th
 control 
(N= 223) 
Exacerbation severity at 1
st
 control (R= -0.141, p= 0.035) 
Resp_CTRL_3
rd
_4
th
 control hsCRP (R= 0.134, p= 0.040), Neutrophil count (R= 0.151, p= 0.021), MEF50 at 1
st
 control (R= -0.147, p= 0.023), PEF at 2
nd
 control (R= 
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(N= 236) 0.160, p= 0.014), PEF at 3
rd
 control (R= 0.216, p= 0.001) 
Resp_MEF50_3
rd
_4
th
 control 
(N= 234) 
FEV1 at 3
rd
 control (R= 0.132, p= 0.044), FEV1 at 4
th
 control (R= -0.181, p= 0.006), PEF at 4
th
 control (R= -0.143, p= 0.029) 
Resp_FEV1_diagn_2
nd
 control 
(N= 365) 
MEF50 at diagnosis (R= 0.387, p= 0.000), Asthma control (R= -0.104, p= 0.047), Disease duration (R= 0.108, p= 0.040), Neutrophil count 
(R= -0.135, p= 0.010), FVC at 2
nd
 control (R= -0.240, p= 0.000), PEF at 2
nd
 control (R= -0.191, p= 0.000), MEF50 at 2
nd
 control (R= -
0.306, p= 0.000), FVC at 3
rd
 control (R= -0.113, p= 0.032), PEF at 3
rd
 control (R= -0.114, p= 0.029), MEF50 at 3
rd
 control (R= -0.179, p= 
0.001) 
Resp_FENO_diagn_2
nd
 control 
(N= 349) 
Disease duration (R= 0.145, p= 0.007), GERD (0.155, p= 0.004), Asthma control at 3
rd 
control (R= -0.133, p= 0.013), Exacerbation 
severity at 3rd control (R= -0.111, p= 0.039) 
Resp_CTRL_diagn_2
nd
 control 
(N= 365) 
Disease duration (R= 0.117, p= 0.025), Neutrophil count (R= 0.109, p= 0.037), Monocyte count (R= -0.104, p= 0.046), AR (R= 0.120, p= 
0.022), FEV1 at 2
nd
 control (R= -0.256, p= 0.000), FVC at 2
nd
 control (R= -0.129, p= 0.013), MEF50 at 2
nd
 control (R= -0.200, p= 0.000), 
FEV1 at 3
rd 
control (R= -0.120, p= 0.022) 
Resp_MEF50_diagn_2
nd
 control 
(N= 365) 
FEV1 at diagnosis (R= 0.400, p= 0.000), Asthma control at diagnosis (R= -0.119, p= 0.023), MEF50 at 1
st
 control (R= -0.167, p= 0.001), 
FEV1 at 2
nd
 control (R= -0.332, p= 0.000), PEF at 2
nd
 control (R= -0.217, p= 0.000), FEV1 at 3
rd
 control (R= -0.170, p= 0.001), PEF at 3
rd
 
control (R= -0.149, p= 0.004) 
Resp_FEV1_diagn_3
rd
 control 
(N= 365) 
MEF50 at diagnosis (R= 0.457, p= 0.000), Asthma control at diagnosis (R= -0.122, p= 0.020), total IgE (R= 0.110, p= 0.036), Neutrophil 
count (R= -0.105, p= 0.044), AR (R= 0.104, p= 0.047), FVC at 2
nd
 control (R= -0.142, p= 0.007), PEF at 2
nd
 control (R= -0.124, p= 
0.018), MEF50 at 2
nd
 control (R= -0.108, p= 0.039), FVC at 3
rd
 control (R= -0.188, p= 0.000), PEF at 3
rd
 control (R= -0.261, p= 0.000), 
MEF50 at 3rd control (R= -0.290, p= 0.000), Asthma control at 3
rd
 control (R= 0.149, p= 0.004), Exacerbation severity at 3
rd
 control (R= 
0.173, p= 0.001) 
Resp_CTRL_diagn_3
rd
 control 
(N= 365) 
Age (R= -0.129, p= 0.014), Monocyte count (R= -0.162, p= 0.002), FEV1 at 1
st
 control (R= -0.162, p= 0.002), FVC at 1
st
 control (R= -
0.152, p= 0.004), PEF at 1
st
 control (R= -0.134, p= 0.010), MEF50 at 1
st
 control (R= -0.120, p= 0.022), FENO at 1
st
 control (R= -0.161, p= 
0.002), AD (R= 0.127, p= 0.015), FEV1 at 2
nd
 control (R= -0.166, p= 0.001), FVC at 2
nd
 control (R= -0.113, p= 0.032), PEF at 2
nd
 control 
(R= -0.120, p= 0.021), MEF50 at 2
nd
 control (R= -0.135, p= 0.010), FEV1 at 3
rd
 control (R= -0.313, p= 0.000), FVC at 3
rd
 control (R= -
0.181, p= 0.001), PEF at 3
rd
 control (R= -0.240, p= 0.000), MEF50 at 3rd control (R= -0.295, p= 0.000) 
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Resp_MEF50_diagn_3
rd
 control 
(N= 365) 
FEV1 at diagnosis (R= 0.435, p= 0.000), Asthma control at diagnosis (R= -0.123, p= 0.019), Age (R= 0.114, p= 0.029), FEV1 at 2
nd
 
control (R= -0.119, p= 0.023), PEF at 2
nd
 control (R= -0.124, p= 0.018), FEV1 at 3
rd
 control (R= -0.275, p= 0.000), PEF at 3
rd
 control (R= 
-0.189, p= 0.000), FENO at 3
rd
 control (R= 0.115, p= 0.028), Asthma control at 3
rd
 control (R= 0.142, p= 0.007), Exacerbation severity at 
3
rd
 control (R= 0.141, p= 0.007) 
Resp_FEV1_diagn_4
th
 control 
(N= 231) 
MEF50 at diagnosis (R= 0.413, p= 0.000), hsCRP (R= -0.147, p= 0.025), AR (R= 0.137, p= 0.037), FVC at 2
nd
 control (R= -0.143, p= 
0.030), MEF50 at 3rd control (R= -0.194, p= 0.003), FVC at 4
th
 control (R= -0.196, p= 0.003), PEF at 4
th
 control (R= -0.184, p= 0.005), 
MEF50 at 4
th
 control (R= -0.274,  p= 0.000) 
Resp_FENO_diagn_4
th
 control Disease duration (R= 0.152, p= 0.023), Basophil count (R= -0.144, p= 0.032), Atopy (R= 0.156, p= 0.020), FVC at 2
nd
 control (R= -
0.134, p= 0.046) 
Resp_CTRL_diagn_4
th
 control FEV1 at 3
rd 
control (R= -0.155, p= 0.017), FEV1 at 4
th
 control (R= -0.143, p= 0.028) 
Resp_MEF50_diagn_4
th
 control FEV1 at diagnosis (R= 0.417, p= 0.000), PEF at 2
nd
 control (R= -0.137, p= 0.037), PEF at 4
th
 control (R= -0.176, p= 0.007) 
 
 
4.3. Association of treatment response with genetic and other parameters in specific treatment class groups 
Significant associations in treatment response according to relative changes in FEV1, MEF50, FENO and level of asthma control between 
respective visits over the period of 2 years (recruitment to 4
th
 control visit) with specific genetic polymorphisms (rs37973, rs9910408, rs242941, 
rs1876828, rs1042713 and rs17576), as well as significant associations adjusted for certain confouding variables- covariates (demographic and 
clinical parameters, previously identified by a Spearman`s correlation test- see Table 16) in specific subgroups of participants on different 
classes of asthma treatment (ICS alone, LTRA alone and combination treatment- ICS+LABA/LTRA) are presented in Tables 17 (use of ICS 
alone), 18  (use of LTRA alone) and 19 (use of combination treatment). 
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Table 17. Association of response to treatment after 6, 12, 18  and 24 months (on average), according to changes in FEV1, MEF50, FENO and asthma control with the 
analyzed genetic polymorphisms: rs37973 (GLCCI1), rs9910408 (TBX21), rs242941 (CRHR1), rs1876828 (CRHR1) and rs17576 (MMP9) in patients using inhaled 
corticosteroids (ICS) alone. Kruskal-Wallis test, p< 0.05, 2- chi square, N= 158.     Adjusted model (F adjusted) corrected for possible confounding variables: age, disease 
duration, atopy status, total IgE level, eosinophil count, neutrophil count, basophil count, hsCRP level, monocyte count, platelet count,  BMI percentile category, comorbidity 
(AR, AD, OSA, GERD). General linear model test, p< 0.05, Partial 2- partial eta squared (effect size statistics), N= 158. BMI percentile category: underweight (0-3 
percentile), normal (5-85 percentile), overweight (86-95 percentile), obese (>95 percentile). Abbreviations for respective responses to treatment are defined in Supplement 4. 
rs37973 (GLCCI1) 
 Resp_CTRL_
diagn to 1
st 
control 
Resp_FEV1_ 1
st
 
to 2
nd
 control 
Resp_FENO_
1
st
 to 2
nd
 
control 
Resp_CTRL_
1
st 
to 2
nd
 
control 
Resp_MEF50_
1
st
 to 2
nd
 
control 
Resp_CTRL_3
rd
 
to 4
th 
control 
Resp_CTRL_diagn 
to 2
nd 
control 
Resp_MEF50
_diagn to 3
rd
 
control 
2 10.736 9.353 11.111 16.525 6.492 9.122 14.543 8.600 
p value (two-tailed) 0.005 0.009 0.004 0.000 0.039 0.010 0.001 0.014 
 Resp_FENO_1
st
 to 2
nd
 control Resp_FENO_2
nd
 to 3
rd
 control 
F (adjusted) 2.397 2.139 
p value 0.005 0.012 
Partial 2 0.519 0.491 
rs9910408 (TBX21) 
 Resp_MEF50_dia
gn to 1
st 
control 
Resp_FEV1_1
st
 
to 2
nd
 control 
Resp_FENO_1
st
 
to 2
nd
 control 
Resp_FEV1_ 2
nd
 
to 3
rd
 control 
Resp_FENO_
2
nd
 to 3
rd
 
control 
Resp_MEF50_
2
nd
 to 3
rd
 
control 
Resp_CTRL_
3
rd
 to 4
th
 
control 
Resp_MEF50
_diagn to 2
nd
 
control 
2 6.768 6.545 25.672 17.028 20.671 7.337 15.960 7.314 
p value (two-tailed) 0.034 0.038 0.000 0.000 0.000 0.026 0.000 0.026 
 Resp_FEV1_1
st
 to 2
nd
 control Resp_FENO_1
st
 to 2
nd
 control Resp_CTRL_3rd to 4th control 
F (adjusted) 1.769 2.685 2.143 
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p value 0.047 0.002 0.013 
Partial 2 0.428 0.532 0.476 
rs242941 (CRHR1) 
 Resp_FENO_ 1
st
 
to 2
nd
 control 
Resp_MEF50_
1
st
 to 2
nd
 
control 
Resp_FEV1_diagn 
to 2
nd
 control 
Resp_FENO_ 
diagn to 2
nd
 
control 
Resp_FEV1_diag
n to 3
rd
 control 
Resp_FEV1
_diagn to 
4
th
 control 
Resp_CTRL_
diagn to 4
th
 
control 
Resp_MEF50
_diagn to 4
th
 
control 
2 12.335 11.023 17.452 15.395 10.556 17.303 12.966 11.617 
p value (two-tailed)  0.002 0.004 0.000 0.000 0.005 0.000 0.002 0.003 
 Resp_FENO_ 1
st
 to 2
nd
 control Resp_FENO_ diagn to 2
nd
 control 
F (adjusted) 2.550 2.077 
p value 0.003 0.015 
Partial 2 0.535 0.484 
rs1876828 (CRHR1) 
 Resp_CTRL_
diagn to 1
st
 
control 
Resp_CTRL_ 
1st to 2nd 
control 
Resp_FENO_3
rd
 
to 4
th
 control 
RespFEV1_diagn 
to 2
nd
 control 
Resp_MEF50_diagn 
to 2
nd
 control 
Resp_FEV1_diagn 
to 3
rd 
control 
Resp_CTRL_diagn 
to 3
rd 
control 
2 7.017 6.542 6.980 13.423 6.891 6.511 11.313 
p value (two-tailed) 0.030 0.038 0.031 0.001 0.032 0.039 0.003 
rs17576 (MMP9) 
 Resp_CTRL_diagn to 1
st
 control Resp_FEV1_3
rd
  to 4
th
 control Resp_FENO_diagn to 2
nd
 control 
2 11.327 14.268 6.035 
p value (two-tailed) 0.003 0.001 0.049 
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Table 18. Association of response to treatment after 6, 12, 18 and 24 months (on average), according to changes in FEV1, MEF50, FENO and asthma control with the 
analyzed genetic polymorphism rs17576 (MMP9) in patients using leukotriene antagonists (LTRA) alone. Kruskal-Wallis test, p< 0.05, 2- chi square, N= 38.    Adjusted 
model (F adjusted) corrected for possible confounding variables: age, disease duration, atopy status, total IgE level, eosinophil count, neutrophil count, basophil count, 
hsCRP level, BMI percentile category, comorbidity (AR, AD, OSA, GERD). General linear model test, p< 0.05, Partial 2- partial eta squared (effect size statistics), N= 38. 
BMI percentile category: underweight (0-3 percentile), normal (5-85 percentile), overweight (86-95 percentile), obese (>95 percentile).Abbreviations for respective responses 
to treatment are defined in Supplement 4. 
rs17576 (MMP9) 
 Resp_FENO_3
rd
 to 4
th
 control 
2 7.119 
p value (two-tailed) 0.028 
 Resp_CTRL_1
st
 to 2
nd
 control 
F (adjusted) 8.488 
p value 0.026 
Partial 2 0.971 
 
Table 19. Association of response to treatment after 6, 12, 18 and 24 months (on average), according to changes in FEV1, MEF50, FENO and asthma control with the 
analyzed genetic polymorphisms: rs37973 (GLCCI1), rs9910408 (TBX21), rs242941 (CRHR1) and rs1042713 (ADRB2) in patients using combination treatment (ICS + 
LABA and/or LTRA). Kruskal-Wallis test, p< 0.05, 2- chi square, N= 106. Adjusted model (F adjusted) corrected for possible confounding variables: age, disease duration, 
atopy status, total IgE level, eosinophil count, neutrophil count, basophil count, monocyte count, platelet count, hsCRP level, BMI percentile category, comorbidity (AR, AD, 
OSA, GERD). General linear model test, p< 0.05, Partial 2- partial eta squared (effect size statistics), N= 106. BMI percentile category: underweight (0-3 percentile), 
normal (5-85 percentile), overweight (86-95 percentile), obese (>95 percentile). Abbreviations for respective responses to treatment are defined in Supplement 4. 
rs37973 (GLCCI1) 
 Resp_FENO_diagn to 1
st
 Resp_CTRL_1
st
 to 2
nd
 Resp_MEF50_3
rd
 to 4
th
 Resp_FENO_diagn to 2
nd
 Resp_CTRL_diagn to 
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control control control control 2
nd
 control 
2 9.076 13.275 11.903 13.822 14.722 
p value (two-tailed) 0.011 0.001 0.003 0.001 0.001 
rs9910408 (TBX21) 
 Resp_FENO_1
st
 to 2
nd
 control Resp_FEV1_2
nd
 to 3
rd
 control Resp_MEF50_3
rd
 to 4
th
 control Resp_FEV1_diagn to 3
rd
 control 
2 20.335 6.927 8.165 6.152 
p value (two-tailed) 0.000 0.031 0.017 0.046 
 Resp_FENO_1
st
 to 2
nd
 control 
F (adjusted) 2.060 
p value 0.031 
Partial 2 0.586 
rs242941 (CRHR1) 
 Resp_ME
F50_diagn 
to 1
st
 
control 
Resp_FEV1
_1
st
 to 2
nd 
control 
Resp_FEV1
_2
nd
 to 3
rd
 
control 
Resp_ME
F50_2
nd
 to 
3
rd
 control 
Resp_FEV1
_3
rd
 to 4
th
 
control 
Resp_FEN
O_3
rd
 to 4
th
 
control 
Resp_FEN
O_diagn to 
3
rd
 control 
Resp_FEN
O_diagn to 
4
th
 control 
Resp_CTR
L_diagn to 
4
th
 control 
Resp_ME
F50_diagn 
to 4
th
 
control 
2 8.844 14.822 23.482 18.020 8.162 6.342 10.527 11.913 6.150 7.273 
p value (two-tailed) 0.012 0.001 0.000 0.000 0.017 0.042 0.005 0.003 0.046 0.026 
 Resp_FENO_diagn to 4
th
 control 
F (adjusted) 2.463 
p value 0.010 
Partial 2 0.629 
rs1042713 (ADRB2) 
 Resp_FENO_diagn to 1
st 
control Resp_CTRL_2
nd
 to 3
rd
 control Resp_FENO_diagn to 2
nd
 control Resp_CTRL_diagn to 3
rd
 control 
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2 16.814 7.926 12.803 12.942 
p value (two-tailed) 0.000 0.019 0.002 0.002 
 Resp_FENO_diagn to 1
st 
control 
F (adjusted) 2.321 
p value 0.015 
Partial 2 0.615 
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Genotype distribution (frequencies) for respective genetic polymorphisms (rs37973, 
rs9910408, rs242941, rs1876828, rs1042713 and rs17576) in „good“, „moderate“ and „bad“ 
responders according to relative changes in FEV1, MEF50, FENO and level of asthma control 
between each visit over the period of 2 years (recruitment to 4
th
 control visit) in specific 
subgroups of participants on different classes of asthma treatment (ICS alone and 
combination treatment- ICS+LABA/LTRA) are presented in Tables 20 (use of ICS alone) 
and 21 (use of combination treatment). 
Table 20. Genotype distribution for analyzed genetic polymorphisms: rs37973 (GLCCI1), rs9910408 (TBX21) 
and rs242941 (CRHR1) in patients with „good“, „moderate“ and „bad“ response to treatment with ICS alone 
according to changes in FEV1, MEF50, FENO and asthma control after (on average) 6, 12, 18 and 24 months of 
medication use. Abbreviations for respective responses to treatment are defined in Supplement 4. Pearson`s 2 
test, p < 0.05. 2- chi square, N= 158. 
rs37973 (GLCCI1) 
 GG GA AA Total 2 p value  
Resp_FENO_
1
st
 to 2
nd
 
control 
Good response 10 64 38 112 13.980 0.007 
Moderate response 7 6 9 22 
Bad response 3 5 9 17 
Total 20 75 56 151 
Resp_FENO_
2
nd
 to 3
rd
 
control 
Good response 10 16 12 38 10.210 0.037 
Moderate response 6 47 38 91 
Bad response 4 11 6 21 
Total 20 74 56 150 
rs9910408 (TBX21) 
    AA AG GG Total 2 p value 
Resp_FEV1_1
st
 to 2
nd
 
control 
Good response 2 24 5 31 
19.340 0.000 
Moderate response 28 54 12 94 
Bad response 15 9 9 33 
Total 45 87 26 158 
Resp_FENO_1
st
  to 2
nd
 
control 
Good response 40 63 9 112 
27.663 0.000 
Moderate response 0 14 8 22 
Bad response 2 8 7 17 
Total 42 85 24 151 
Resp_CTRL_3
rd
  to 4
th
 
control 
Good response 7 26 9 42 
22.710 0.000 Moderate response 16 36 7 59 
Bad response 13 4 0 17 
73 
 
Total 36 66 16 118 
rs242941 (CRHR1) 
    AA AC CC Total 2 p value  
Resp_FENO_diagn to 
2
nd
 control 
Good response 7 6 4 17 
19.650 0.000 
Moderate response 11 38 48 97 
Bad response 0 18 19 37 
Total 18 62 71 151 
Resp_FENO_1
st
 to 2
nd
 
control 
Good response 8 45 59 112 
14.210 0.007 
Moderate response 4 11 7 22 
Bad response 6 6 5 17 
Total 18 62 71 151 
 
Table 21. Genotype distribution for analyzed genetic polymorphisms: rs9910408 (TBX21), rs242941 (CRHR1) 
and rs1042713 (ADRB2) in patients with „good“, „moderate“ and „bad“ response to treatment with combination 
therapy (ICS+LABA/LTRA) according to changes in FEV1, MEF50, FENO and asthma control after (on 
average) 6, 12, 18 and 24 months of medication use. Abbreviations for respective responses to treatment are 
defined in Supplement 4. Pearson`s 2 test, p < 0.05. 2- chi square, N= 106. 
rs9910408 (TBX21) 
    AA AG GG Total 2 p value (2) 
Resp_FENO_1
st
 to 2
nd
 
control 
Good response 29 37 2 68 
28.745 0.000 
Moderate response 8 6 11 25 
Bad response 1 7 3 11 
Total 38 50 16 104 
rs242941 (CRHR1) 
    AA AC CC Total 2 p value (2) 
Resp_FENO_diagn to 
4
th
 control 
Good response 0 7 8 15 
13.522 0.007 
Moderate response 4 23 21 48 
Bad response 7 7 4 18 
Total 11 37 33 81 
rs1042713 (ADRB2) 
    GG GA AA Total 2 p value (2) 
Resp_FENO_diagn to 
1
st
 control 
Good response 13 30 30 73 
17.460 0.001 
Moderate response 2 0 3 5 
Bad response 12 1 13 26 
Total 27 31 46 104 
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Significant allelic frequencies (distribution) for respective genetic polymorphisms (rs37973, 
rs9910408, rs242941, rs1876828, rs1042713 and rs17576) in „good“, „moderate“ and „bad“ 
responders according to relative changes in FEV1, MEF50, FENO and level of asthma control 
between each visit over the period of 2 years (recruitment to 4
th
 control visit) in specific 
subgroups of participants on different classes of asthma treatment (ICS alone, LTRA alone 
and combination treatment- ICS+LABA/LTRA) are presented in Tables 22 (use of ICS 
alone), 23 (use of LTRA alone) and 24 (use of combination treatment). 
Table 22. Allelic distribution for analyzed genetic polymorphisms: rs37973 (GLCCI1), rs9910408 (TBX21) and 
rs242941 (CRHR1) in patients with „good“, „moderate“ and „bad“ response to treatment with ICS alone 
according to changes in FEV1, MEF50, FENO and asthma control after (on average) 6, 12, 18 and 24 months of 
medication use. Abbreviations for respective responses to treatment are defined in Supplement 4. 2 test, p < 
0.05. 2- chi square, N= 158. 
rs37973 
Response GG GA+AA 
2
 p value 
 Good 10 102 
8.707 0.0129 Resp_FENO_1
st
 to 2
nd 
control Moderate 7 15 
Bad 3 14 
Good 10 28 
9.713 0.008 Resp_FENO_2
nd
 to 3
rd
 control Moderate 6 85 
Bad 4 17 
rs9910408 
Response AA AG+GG 
2
 p value  
Good 2 29 
12.130 0.0023 Resp_FEV1_1
st
 to 2
nd
 control Moderate 28 66 
Bad 15 18 
Good 7 35 
21.05 <0.0001 Resp_CTRL_3
rd
 to 4
th
 control Moderate 16 43 
Bad 13 4 
Good 40 72 
14.14 0.0009 Resp_FENO_1
st
  to 2
nd
 control Moderate 0 22 
Bad 2 15 
rs242941 
Response AA AC+CC 
2
 p value 
 Good 7 10 
18.90 <0.0001 Resp_FENO_diagn to 2
nd
 control 
Moderate 11 86 
75 
 
Bad 0 37 
Good 8 104 
12.10 0.0024 Resp_FENO_1
st
 to 2
nd
 control Moderate 4 18 
Bad 6 11 
 
Table 23. Allelic distribution for analyzed genetic polymorphisms: rs17576 (MMP9) in patients with „good“, 
„moderate“ and „bad“ response to treatment with LTRA alone according to changes in FEV1, MEF50, FENO 
and asthma control after (on average) 6, 12, 18 and 24 months of medication use. Abbreviations for respective 
responses to treatment are defined in Supplement 4. 2 test, p < 0.05. 2- chi square, N= 38. 
rs17576 
Response AA+AG GG 
2
 p value 
 Good 29 4 
6.221 0.0446 Resp_CTRL_1
st
 to 2
nd
 control Moderate 0 1 
Bad 2 1 
 
Table 24. Allelic distribution for analyzed genetic polymorphisms: rs9910408 (TBX21), rs242941 (CRHR1) and 
rs1042713 (ADRB2) in patients with „good“, „moderate“ and „bad“ response to treatment with combination 
therapy (ICS+LABA/LTRA) according to changes in FEV1, MEF50, FENO and asthma control after (on 
average) 6, 12, 18 and 24 months of medication use. Abbreviations for respective responses to treatment are 
defined in Supplement 4. 2 test, p < 0.05. 2- chi square, N= 106. 
rs9910408 
Response AA+AG GG 
2 p value 
 Good 66 2 
25.01 <0.0001 Resp_FENO_1
st
 to 2
nd
 control Moderate 14 11 
Bad 8 3 
rs242941 
Response AA AC+CC 
2
 p value 
 Good 0 15 
13.31 0.0013 Resp_FENO_diagn to 4
th
 control Moderate 4 44 
Bad 7 11 
rs1042713 
Response GG GA+AA 
2
 p value 
 Good 13 60 
8.552 0.0139 Resp_FENO_diagn to 1
st
 control Moderate 2 3 
Bad 12 14 
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4.4.  Clustering analysis 
Prior to cluster analysis, the data had to be preprocessed. The data consisted of 365 patients 
and 280 variables in total. The dataset did not include any incomplete cases up to the 3
rd
 
control visit, which corresponds to the roughly 1.5 year- follow-up period.  At the 4
th
 control 
visit, a significant proportion of the dataset had missing values due to the fact that not all 
patients were followed up to the 4
th
 control visit (ca. 2 years after recruitment) or simply 
dropped out of the study. Some features had missing values due to patients` lack of 
cooperation (eg. patient was too young to cooperate for lung function or FENO 
measurement), there was insufficient blood/serum sample to perform certain biochemical 
tests etc.  
The variables used in this study can be broadly separated into: 
 baseline demographics (such as gender, age); 
 subjective clinical data obtained from the parents/patient at the patient`s first research 
contact (personal and family medical history, such as atopy status, allergic rhinitis, 
atopic dermatitis); 
 objective clinical data collected at the patient`s first research contact and other follow-
up appointments. These include personal anamnesis in the period since the last visit, 
such as symptom control and frequency and severity of exacerbations, lung function 
and airway inflammation (FENO) measurement; 
 biologically (and clinically) relevant data collected at the patient`s first research 
contact (such as skin prick and total and specific IgE allergy test results, hematologic 
and biochemical blood test results, comorbidity status- pH probing and reflux 
episodes monitoring for diagnostics of GERD, polysomnography for diagnostics of 
OSAS, anthropometric measurements- height and weight and calculation of BMI and 
BMI percentiles); 
 genetic data- genotypes for rs37973 (GLCCI1), rs9910408 (TBX21), rs242941 
(CRHR1), rs1876828 (CRHR1), rs1042713 (ADRB2) and rs17576 (MMP9). 
The data was divided into treatment periods, i.e. diagnosis (baseline), first, second, third and 
fourth control visit. Feature selection in clustering was conducted through filtering based on 
the variance threshold, which was set to 5%, meaning variables with less than 5% variance 
were excluded from further analysis (Belgrave et al. 2018).  
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Features describing allergic sensitization were converted to binary or ordinal features, and 
grouped into 4 clinically relevant categories: seasonal allergens (i.e. grass, weed and tree 
pollen), perennial allergens (house dust mite and molds), insect venom (bee, wasp or hornet) 
and food allergens. Both SPT results and specific IgE results were into account for each 
respective sensitization category. Additionally, certain sensitization features were assigned 
separate variables, due to their possible clinical relevance- strong sensitization to house dust 
mite (D. pteronyssinus, D. farinae), cat dander and ragweed (Ambrosia). These sensitizations 
have previously been associated with disease severity and more severe outcomes (Sheehan 
and Phipatanakul 2016, Li et al. 2013, Lombardi et al. 2017). Strong sensitization was 
defined as sIgE class R4-R6 to the respective allergen. 
Features with string notation (e.g. “medication (treatment) prescribed”) were numerically 
coded and converted to categorical features. Features with a large portion of missing values 
(ca. 20%) were imputed by median for continuous variables and most frequent value for 
categorical variables. 
Data clustering was performed with data regarding treatment outcomes (level of response to 
treatment according to changes in lung function, airway inflammation and asthma control, as 
defined in Section 4.1) to identify patterns of response to treatment with common classes of 
asthma treatment ("response" clusters). These clusters were transformed to classes and 
relevant data (at recruitment point, baseline) was used to establish plausible underlying 
disease phenotypes (clusters) predisponing for certain treatment outcomes (classes). To 
understand feature importance for classification the decision tree algorhytm was used. For 
this, a Gini index (Gini coefficient) which represents a measure of statistical dispersion 
(Wittebole et al. 2009) was set to 0.2 as the lowest limit. A Gini coefficient of zero expresses 
perfect equality, but to avoid potential noise and overfitting the clustering data, an empirical 
cutoff of 0.2 was implemented. 
Response clusters are presented in Figure 14. Relevant features (main discriminants) 
distinguishing each cluster according to the decision tree algorhytm for the response clusters 
are shown in Figure 15. The relevant features corresponding to clinical, demographic and 
genetic data from recruitment point (baseline) characterizing each response cluster/class 
(main discriminants) are shown in Figure 16. Cluster statistics related to response to 
treatment patterns and data from recruitment point (baseline) are shown in Tables 25 and 26, 
respectively.  
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Figure 14. Heatmap of response clusters indicating patterns of response to treatment with common classes of asthma treatment (ICS alone, LTRA alone, ICS+LABA/LTRA). 
Ward`s Euclidean method, p< 0.05. 
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Figure 15. Main discriminants distinguishing between each response cluster (N= 4) according to the decision tree algorhytm. Ward`s Euclidean method, p< 0.05, Gini < 0.2. 
Disc- discrete variable, asthmalev- level of asthma control, fen0- FENO, th- treatment (therapy), init- 1
st
 control visit (after 6 months of treatment use), 1st- 2
nd
 control visit 
(after 12 months of medication use), 2nd- 3
rd
 control visit (after 1.5 years of treatment use), resp- response.  
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Table 25. Response to treatment- related cluster statistics. Ward`s Euclidean method, 2 test, p< 0.05. Abbreviations for respective responses to treatment are defined in 
Supplement 4. 
Feature Cluster 1 Cluster 2 Cluster 3 Cluster 4 Significa
nce 
No of patients N= 58 N= 87 N= 138 N= 64 p value 
 Good 
N (%) 
Moderate 
N (%) 
Bad N 
(%) 
Good 
N (%) 
Moderate 
N (%) 
Bad N 
(%) 
Good 
N (%) 
Moderate 
N (%) 
Bad N 
(%) 
Good 
N (%) 
Moderate 
N (%) 
Bad N 
(%) 
 
Resp_FEV1_diagn to 
1
st
 control 
17 
(29.31) 
27 (46.55) 14 
(24.14) 
8 (9.2) 45 (51.72) 34 
(39.08) 
75 
(54.35) 
49 (35.51) 14 
(10.14) 
19 
(29.69) 
24 (37.5) 21 
(32.81) 
< 0.001 
Resp_FENO_diagn to 
1
st
 control 
1 (1.72) 57 (98.28) 0 (0) 79 
(90.8) 
7 (8.05) 1 (1.15) 108 
(78.26) 
14 (10.14) 16 
(11.59) 
58 
(90.62) 
4 (6.25) 3 (3.12) < 0.001 
Resp_CTRL_diag to 
1
st
 control 
34 
(58.62) 
12 (20.69) 12 
(20.69) 
55 
(63.22) 
22 (25.29) 10 
(11.49) 
94 
(68.12) 
16 (11.59) 28 
(20.29) 
34 
(53.12) 
11 (17.19) 19 
(29.69) 
< 0.05 
Resp_MEF50_diag to 
1
st
 control 
18 
(31.03) 
22 (37.93) 18 
(31.03) 
5 (5.75) 43 (49.43) 39 
(44.83) 
75 
(54.35) 
43 (31.16) 20 
(14.49) 
20 
(31.25) 
22 (34.38) 22 
(34.38) 
< 0.001 
Resp_FEV1_1
st
 to 2
nd
 
control 
9 
(15.52) 
46 (79.31) 3 (5.17) 10 
(11.49) 
64 (73.56) 13 
(14.94) 
44 
(31.88) 
70 (50.72) 24 
(17.39) 
18 
(28.12) 
40 (62.5) 6 (9.38) < 0.001 
Resp_FENO_1
st
 to 
2
nd
 control 
48 
(82.76) 
10 (17.24) 0 (0) 55 
(63.22) 
21 (24.14) 11 
(12.64) 
84 
(60.87) 
30 (21.74) 24 
(17.39) 
39 
(60.94) 
14 (21.88) 11 
(17.19) 
< 0.05 
Resp_CTRL_1
st
 to 
2
nd
 control 
52 
(89.66) 
2 (3.45) 4 (6.9) 59 
(67.82) 
11 (12.64) 17 
(19.54) 
118 
(85.51) 
4 (2.9) 16 
(11.59) 
46 
(71.88) 
6 (9.38) 12 
(18.75) 
< 0.01 
Resp_FEV1_2
nd
 to 3
rd
 
control 
3 (5.17) 45 (77.59) 10 
(17.24) 
11 
(12.64) 
73 (83.91) 3 (3.45) 21 
(15.22) 
89 (64.49) 28 
(20.29) 
4 (6.25) 42 (65.62) 18 
(28.12) 
< 0.001 
Resp_FENO_2
nd
 to 
3
rd
 control 
16 
(27.59) 
26 (44.83) 16 
(27.59) 
29 
(33.33) 
48 (55.17) 10 
(11.49) 
54 
(39.13) 
75 (54.35) 9 (6.52) 23 
(35.94) 
29 (45.31) 12 
(18.75) 
< 0.01 
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Res_CTRL_2
nd
 to 3
rd
 
control 
53 
(91.38) 
3 (5.17) 2 (3.45) 82 
(94.25) 
5 (5.75) 0 (0) 128 
(92.75) 
6 (4.35) 4 (2.9) 2 (3.12) 9 (14.06) 53 
(82.81) 
< 0.001 
Resp_MEF50_2
nd
 to 
3
rd
 control 
3 (5.17) 41 (70.69) 14 
(24.14) 
20 
(22.99) 
57 (65.52) 10 
(11.49) 
38 
(27.54) 
76 (55.07) 24 
(17.39) 
4 (6.25) 36 (56.25) 24 
(37.5) 
< 0.001 
Resp_FEV1_diagn to 
2
nd
 control 
22 
(37.93) 
23 (39.66) 13 
(22.41) 
6 (6.9) 42 (48.28) 39 
(44.83) 
79 
(57.25) 
54 (39.13) 5 (3.62) 19 
(29.69) 
30 (46.88) 15 
(23.44) 
< 0.001 
Resp_FENO_diagn to 
2
nd
 control 
7 
(12.07) 
0 (0) 51 
(87.93) 
13 
(14.94) 
65 (74.71) 9 
(10.34) 
25 
(18.12) 
90 (65.22) 23 
(16.67) 
14 
(21.88) 
42 (65.62) 8 (12.5) < 0.001 
Resp_CTRL_diagn to 
2
nd
 control 
50 
(86.21) 
6 (10.34) 2 (3.45) 61 
(70.11) 
16 (18.39) 10 
(11.49) 
120 
(86.96) 
10 (7.25) 8 (5.8) 42 
(65.62) 
10 (15.62) 12 
(18.75) 
< 0.01 
Resp_MEF50_diagn 
to 2
nd
 control 
17 
(29.31) 
27 (46.55) 14 
(24.14) 
3 (3.45) 36 (41.38) 48 
(55.17) 
74 
(53.62) 
60 (43.48) 4 (2.9) 14 
(21.88) 
35 (54.69) 15 
(23.44) 
< 0.001 
Resp_FEV1_diagn to 
3
rd
 control 
19 
(32.76) 
20 (34.48) 19 
(32.76) 
8 (9.2) 49 (56.32) 30 
(34.48) 
71 
(51.45) 
62 (44.93) 5 (3.62) 8 (12.5) 39 (60.94) 17 
(26.56) 
< 0.001 
Resp_FENO_diagn to 
3
rd
 control 
12 
(20.69) 
25 (43.1) 21 
(36.21) 
15 
(17.24) 
56 (64.37) 16 
(18.39) 
34 
(24.64) 
86 (62.32) 18 
(13.04) 
10 
(15.62) 
37 (57.81) 17 
(26.56) 
< 0.01 
Resp_CTRL_diagn to 
3
rd
 control 
53 
(91.38) 
5 (8.62) 0 (0) 81 
(93.1) 
6 (6.9) 0 (0) 135 
(97.83) 
3 (2.17) 0 (0) 4 (6.25) 20 (31.25) 40 
(62.5) 
< 0.001 
Resp_MEF50_diagn 
to 3
rd
 control 
11 
(18.97) 
30 (51.72) 17 
(29.31) 
5 (5.75) 37 (42.53) 45 
(51.72) 
71 
(51.45) 
61 (44.2) 6 (4.35) 4 (6.25) 36 (56.25) 24 
(37.5) 
< 0.001 
 
 
 
 
Table 25. continued 
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Table 26. Cluster statistics related to relevant clinical, demographic and genetic data from recruitment point (diagnosis). Ward`s Euclidean method, Kruskal- Wallis and 2 
test, p< 0.05. Strong sensitization defined as sIgE to respective allergen of  >17.51 kU/L (classes 4-6), food allergy defined as any sIgE to food allergens > 0.35 kU/L (> class 
1). Abbreviations for respective responses to treatment are defined in Supplement 4.  
Feature Cluster 1 Cluster 2 Cluster 3 Cluster 4 Significa
nce 
No of patients N= 58 N= 87 N= 138 N= 64 p value 
 No Yes No Yes No Yes No Yes  
Strong sensitization 
to dust mite (sIgE d1) 
18 (31.03%) 40 (68.97%) 40 (45.98%) 47 (54.02%) 73 (52.90%) 65 (47.10%) 31 (48.44%) 33 (51.56%) < 0.05 
Food allergy 51 (87.93%) 7 (12.07%) 70 (80.46%) 17 (19.54%) 122 (88.41%) 16 (11.59%) 54 (84.38%) 10 (15.63%)  
AD comorbidity 44 (75.86%)  14 (24.14%) 60 (68.96%)  27 (31.03%) 94 (68.12%)  44 (31.88%)  34 (53.12%)  30 (46.88%) < 0.05 
Gene_rs37973 
 GG GA AA GG GA AA GG GA AA GG GA AA < 0.05 
13 
(22.41%) 
18 
(31.03%) 
27 
(46.55
%) 
13 
(14.94
%) 
48 
(55.17%) 
26 
(29.89%) 
15 
(10.87
%) 
70 
(50.72%) 
53 
(38.41%) 
12 
(18.75%) 
34 
(53.12%) 
18 
(28.12
%) 
 
Mean (STD) 
% FEV1 predicted at 
baseline 
0.89 (0.20) 0.96 (0.13) 0.82 (0.17) 0.88 (0.15) < 0.001 
% MEF50 predicted 
at baseline 
0.92 (0.22) 1.03 (0.19) 0.79 (0.22) 0.84 (0.24) < 0.001 
FENO at baseline 
(ppb)  
21.5 (23.61) 17.23 (16.15) 23.07 (23.14) 18.59 (13.38)  
Age (yrs) 
11.79 (3.39) 10.16 (3.82) 9.98 (3.84) 9.61 (3.64) < 0.01 
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Height (cm) 
153.05 (17.78) 143.9 (19.11) 143.86 (21.12) 142.23 (21.24) < 0.05 
Disease duration 
(yrs) 
5.72 (3.43) 5.08 (3.84) 4.12 (3.8) 3.45 (3.11) < 0.001 
Total IgE (kIU/L) 
686.34 (744.36) 421.95 (578.5) 653.9 (1164.19) 484.79 (516.04)  
Eosinophil absolute 
count (Dunger) 
419.99 (284.96) 418.71 (347.17) 380.16 (305.29) 377.22 (349.65)  
Neutrophil blood 
count (%) 
49.72 (11.26) 50.79 (13.18) 49.57 (12.82) 51.99 (12.96)  
hsCRP (mg/L) 
2.58 (6.31) 4.02 (14.45) 3.11 (7.52) 2.57 (3.72)  
Platelets (x 10
9
/L) 
291.09 (86.54) 278.68 (108.14) 283.72 (105.47) 257.7 (105.31)  
Asthma severity Grade 1-2 Grade 3-4 Grade 1-2 Grade 3-4 Grade 1-2 Grade 3-4 Grade 1-2 Grade 3-4  
55 (94.83%) 3 (5.17%) 84 (96.55%) 3 (3.45%) 131 (94.93%) 7 (5.07%) 55 (85.93%) 9 (14.06%) < 0.05 
 
BMI percentile 
0-5, 
N(%) 
5-85, 
N(%) 
>85, 
N(%) 
0-5, 
N(%) 
5-85, 
N(%) 
>85, 
N(%) 
0-5, 
N(%) 
5-85, 
N(%) 
>85, 
N(%) 
0-5, 
N(%) 
5-85, 
N(%) 
>85, 
N(%)  
0 (0) 
47 
(81.03) 
11 
(18.87) 3 (3.45) 
52 
(59.77) 
32 
(36.78) 4 (2.9) 
94 
(68.11) 
40 
(28.99) 3 (4.69) 
47 
(73.43) 
14 
(21.88) < 0.05 
Table 26. continued 
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5. DISSCUSSION 
A number of studies have demonstrated that there is a high degree of variability in the 
magnitude of response to common asthma medications and that this is largely due to genetic 
predisposition, i.e. specific genetic variants. Moreover, several genetic variants have 
reproducibly been identified by large genomic (GWAS) studies as well as candidate gene 
studies for each class of medications commonly used in asthma management (Vijverberg et 
al. 2018, Duong-Thi-Ly et al. 2017). These genetic variants (including those in the TBX21, 
GLCCI1, CRHR1 and ADRB2 genes) have been associated with the heterogeneity in 
bronchodilator reversibility and asthma worsening (exacerbations) in patients continuously 
using SABA and LABA (ADRB2 polymorphisms), as well as with the variability in response 
regarding lung function improvement, airway hyperresponsiveness, and exacerbations in 
patients on ICS- GLCCI1, CRHR1, TBX21 polymorphisms (Lima et al. 2009). Despite the 
urging need for standardization in reporting measures of clinical validity, there still no 
consensus in defining primary outcomes/endpoints in pharmacogenetic studies, although 
most of them focus on lung function parameters, BHR and exacerbation risk (Vijverberg et 
al. 2018). 
 
5.1.  Selection of outcomes (study endpoints) 
In clinical trials, including pharmacogenetic studies such as this one, the degree of resistance 
and physiological lung function impairment is quantitated most commonly by the forced vital 
capacity in 1 s, FEV1 (ATS 1987, Fal and Rosiek-Biegus 2012). FEV1 is a commonly used 
endpoint in respiratory disease trials, because the measurement is reproducible, standardized 
and easy to measure. On the other hand, there is no consensus as to what constitutes a 
clinically meaningful change. In general, FEV1 abnormalities tend to parallel clinical 
measures of respiratory health and the European Medicines Agency (EMA) definition of 
clinical endpoints and pulmonary exacerbations in lung disease list FEV1 as a primary 
endpoint (EMEA/CHMP/EWP/9147 2008). However, certain studies have shown relatively 
poor correlations of FEV1 with episodes of dyspnea or exercise tolerance in patients with 
stable forms of lung diseases (Niewoehner et al. 2000). Although EMA lists other lung 
function parameters (FVC, FEF25-75) as surrogate endpoints, they are rarely assessed as 
outcomes in clinical studies investigating treatment success. 
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Recently, there has been a renewed interest in the peripheral airways, which are now 
becoming increasingly appreciated for their significance to the clinical manifestations 
(expression) in asthma. The level of inflammation present in the peripheral airways of 
asthmatics may be more intense than the one observed in the large airways (Corren 2008). 
Moreover, peripheral airways resistance in patients with asthma contributed to up to 50% of 
the total airways resistance and the distal parts of the lung have been recognized as a 
predominant site of airflow obstruction in asthmatics (Hamid and Tulic 2007). Small airways 
dysfunction has been associated with nocturnal asthma, exercise-induced asthma and more 
severe and difficult-to-treat disease forms (Yanai et al. 1992, Kraft et al. 1999, Anderson 
2006, Veen et al. 2000).  Also, the small (peripheral) airways seem to contribute significantly 
to the severity of bronchial hyperresponsiveness (BHR), independently of the level of FEV1 
measured (Telenga et al. 2013). Although it is not commonly used as a clinical endpoint, the 
level of reponse to treatment according to parameters of the distal (small or peripheral) 
airway function (MEF50) was assessed as one of 4 primary study endpoints, due to the 
mounting evidence of the distal airway involvement being a crucial factor in asthma in 
children (Torrego Fernandez and Munoz Cano 2011). 
The level of response to treatment according to the measurement of fractional nitric oxide 
(FENO) in exhaled breath was also assessed, because it is a quantitative, noninvasive (which 
is imperative in pediatric asthma management), simple, and safe method of measuring airway 
inflammation that provides a complementary tool to other ways of assessing airways disease, 
including asthma (Dweik et al. 2011). The latest GINA guidelines even suggest that FENO-
guided treatment adjustment significantly reduces exacerbation rates compared with 
guideline-based treatment in children (GINA 2018). 
According to GINA gudielines, the long-term goals in asthma management are achieving 
adequate symptom control, maintaining normal activity levels as much as possible (minimum 
impairment of quality of life), minimizing future risk of exacerbations, fixed airflow 
limitation and medication side-effects (GINA 2018). Although asthma control assessment is a 
multifactorial parameter that involves symptom occurance (including nocturnal symptoms) 
and severity, need for reliever medications (namely SABA), number and severity of asthma 
exacerbations (especially those that require the use of oral corticosteroids and 
hospitalization), as well as patient self-assessment (ACT) and provides good insight into the 
current disease status, it is rarely used as an endpoint in clinical studies probably because it 
encompasses certain subjective variables and there is always the risk of patient-originated 
87 
 
bias. On the other hand, objective measurements (such as lung function parameters) are not 
always in concordance with symptom control nor predictive of exacerbation episodes, and 
patient self- assessment is an essential part of the "shared- care approach" in asthma 
management (implying a high level of patient involvement in tailoring their own treatment 
care) associated with improved outcomes (Wilson et al. 2010), which is why the parameter of 
asthma control was used in assessment of the level of response to treatment in this doctoral 
research. 
 
5.2.  Selection of genetic variants 
rs37973 is a polymorphism in the promoter region of the gene encoding the glucocorticoid 
induced transcript 1 (GLCCI1) located on chromosome 7. In patients with asthma, treatment 
with ICS increases the expression levels of the GLCCI1 protein in epithelial lung cells. This 
increase is suggested to be followed by inflammatory cell apoptosis and diminished airway 
inflammation levels. Studies report that the level of response to treatment with ICS as well as  
the amount of GLCCI1 protein induced by glucocorticoids in the bronchial epithelial cells of 
patients with the GG genotype is significantly lower/poorer as compared to wild type 
homozygotes- AA (Chiba et al. 2018, Tantisira et al. 2011, McGeachie et al. 2013), which is 
why it was chosen as a candidate genetic variant in this doctoral research. 
rs9910408 (c.-7947) is a polymorphism in the 3`UTR region of the gene encoding the Th1 
transcription factor T-bet (TBX21, T-box 21) located on chromosome 17. TBX21 influences 
naive T lymphocyte development and has been implicated in asthma pathogenesis by GWAS 
(Tantisira et al. 2004). It serves as a regulator of Th1 cell differentiation by inducing IFN- 
production and it may play a critical role in the supression of the Th2-mediated immune 
response by inhibiting interleukins IL-4, IL-5, and IL-13 (Lopert et al. 2013, Zhu et al. 2012) 
Moreover, TBX21 knockout mice spontaneously develop airway hyperresponsiveness and 
other asthma related features (Finotto et al. 2002). Studies have established the association of 
rs9910408 with BHR in both children and adults, as well the association of the AA genotype 
with good (adequate) levels of response to treatment with ICS in non-smoking and non-atopic 
adult patients with asthma  (Raby et al. 2006,  Lopert et al. 2013), which is why it was chosen 
as a candidate SNP in this doctoral research. 
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rs242941 and rs1876828 are polymorphisms in the intronic region of the gene encoding the 
corticotropin-releasing hormone receptor 1 (CRHR1) located on chromosome 17. CRHR1 is 
the key corticotropin releasing hormone receptor, mediating the release of 
adrenocorticotropic hormone and the catecholaminergic response to CRH (Duong-Thi-Ly et 
al. 2017). The absence of CRHR1 leads to enhanced airway inflammation and dysfunction 
(Maitland-van der Zee and Daly 2012). Certain genetic variants may cause decreased 
expression of CRHR1 and diminished cortisol secreting capacity in response to inflammation. 
Moreover, in both children and adult patients with asthma (and other respiratory conditions) 
certain CRHR1 genotypes (including rs242941 and rs1876828) have been shown to be 
associated with either better or poor response to treament in terms of lung function 
improvement (FEV1), bronchodilatator reponse and risk of exacerbations following the 
administration of an exogenous corticosteroid, such as ICS (Tantisira et al. 2004, McGeachie 
et al. 2013, Rogers et al. 2009, Kim et al. 2009), which is why they were chosen as candidate 
genetic variants in this study. 
rs1042713 is a non-synonymous variation in the intronless gene encoding the beta-2-
adrenergic receptor located on chromosome 5. ADRB2 is a member of the G protein-coupled 
receptor superfamily, mediating a plethora of physiologic responses such as smooth muscle 
relaxation, bronchodilation, glucose and lipid metabolism, inhibition of histamine release fom 
mast cells etc. Genetic variants (including rs1042713) and changes in the expression of this 
gene have been associated with a number of disorders, including asthma (nocturnal asthma, 
severe forms and exacerbations), obesity and type 2 diabetes mellitus (Saliba et al. 2014, 
Rebordosa et al. 2011, Thomsen et al. 2012). The G allele encodes the G (glycine) form at 
position 16 in ADRB2, while the A allele encodes the R (arginine) residue. A Scottish study 
involving pediatric patients with asthma showed that the rs1042713 A allele is associated 
with disease exacerbations, regardless of treatment regime. The risk of exacerbations in 
patients with the A allele was higher in patients using both short- and long-acting -agonists, 
odds ratio- OD ca 1.6 for AA homozygotes and 1.2 for hetergozygotes (Basu et al. 2009, 
Vijverberg et al. 2018), which is why it was chosen as a candidate genetic variant in this 
doctoral research, primarily regarding treatment success in patients using combination 
therapy. 
rs17576 is a non-synonymous variation in exon 6 of the gene encoding the matrix 
metelloproteinase 9 (MMP9) located on chromosome 20. MMP9 plays an essential role in 
remodeling in asthma (and other conditions such as COPD) including airway wall thickening 
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and inflammation due to its role in extracellular matrix degradation and genetic variants in 
the MMP9 gene (including rs17576) have been associated with different forms of childhood 
asthma (non-atopic phenotypes) as well as wheezing (Pinto et al. 2010). The rs17576 G allele 
encodes the R (arginine) residue at position 279 of MMP9 and has been associated with higer 
morbidity risk, while the A allele encodes the glutamine residue (Q). Additionally, rs17576 
has been associated with childhood obesity causing lower plasma MMP9 levels which may 
modify relevant pathogenetic mechanisms involved in the development of a number of 
conditions (including asthma) associated with obesity in childhood (Belo et al. 2012). 
Although rs17576 has not been reviewed in the context of treatment outcomes in asthma, a 
recent study involving 127 pediatric patients with asthma indicated that other genetic variants 
in the MMP9 gene are associated with better asthma control and with better response to 
treatment (Dragicevic et al. 2018). It is therefore highly likely that other poylmorphisms in 
this gene, including rs17576 are also involved in modulating treatment success in asthmatic 
patients, which is why it was chosen as a candidate genetic variant in this study. 
 
5.3.  Association of genetic variants with treatment outcomes 
Treatment outcomes were assessed at 4 timepoints (follow-up visits) over the period of 2 
years with folow-up appointments on average 6 months apart (6-8 months), according to 
relative changes in lung function parameters (FEV1 and MEF50 predicted for age, gender and 
posture), changes in FENO levels and changes in the level of disease (symptom) control as 
well as exacerbation rate and severity according to GINA guidelines (as discussed in section 
4.1). These were then associated with genotype and allele frequencies for polymorpisms in 
the GLCCI1 gene (rs37973), TBX21 gene (rs9910408), CRHR1 gene (rs242941 and 
rs1876828), ADRB2 gene (rs1042713) and MMP9 gene (rs17576) in patients using different 
classes of treatment (ICS alone, LTRA alone and combination treatment- 
ICS+LABA/LTRA). 
5.3.1. Association of genetic variants with treatment outcomes in patients using 
ICS only 
158 patients were treated with inhaled corticosteroids continuously over the period of 2 years. 
When success of treatment with ICS alone was assessed by changes in lung function 
parameters, the polymorphisms rs37973 in the GLCCI1 gene, rs9910408 in the TBX21 gene 
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as well as rs242941 and rs1876828 in the CRHR1 gene were associated with the level of 
response to treatment according to % change in FEV1 after 6 months (for rs37973 and 
rs9910408) as well as after 12 months and 1.5 years (for rs242941 and rs1876828) and 2 
years of medication use (rs242941)- see Table 17, which was in concordance with previous 
studies (Chiba et al. 2018, Lopert et al. 2013, McGeachie et al. 2013). Additionally, the 
polymorphism rs37973 was significantly associated with the level of response to treatment 
according to relative changes in MEF50 (see Table 17) after 6 months and 1.5 years of ICS 
use, which was previously reported in a small pediatric asthma cohort (Ding et al. 2017). The 
rs9910408 polymorphism in the TBX21 gene, rs242941 and rs1876828 in the CRHR1 gene 
were also associated with the level of response to treatment according to relative changes in 
MEF50 after 6 and 12 months (for rs9910408), after 6 months and 2 years for rs242941 and 
after 12 months of medication use for rs1876828 (see Table 17), which was not previously 
reported. Interestingly, the rs17576 SNP in the gene encoding MMP9 was significantly 
associated with the level of response to treatment assessed by % change in FEV1 after 6 
months of ICS use, which has not been reported so far.  
Moreover, when outcomes in treatment with ICS alone were assessed by relative changes in 
the level of airway inflammation (FENO level), the rs37973 polymorphism (GLCCI1 gene), 
rs9910408 in the TBX21 gene, rs242941 and rs1876828 in the CRHR1 gene as well as 
rs17576 (MMP9) were significantly associated with the level of reponse to treatment after 6 
months. The rs242941 and rs17576 polymorphisms were also associated associated with the 
level of reponse to treatment according to changes in FENO after 12 months of medication 
use (see Table 17). None of these associations (of these polymorphisms and changes in 
FENO) have been reported so far.   
When treatment outcomes were assess by changes in the level of disease control (symptom 
control and exacerbation frequency and severity, as discussed in section 4.1), the rs37973 
(GLCCI1), rs9910408 (TBX21), rs1876828 (CRHR1) and rs17576 (MMP9) polymorphisms 
were significantly associated with the level of response to treatment after 6 months of ICS 
use, while rs37973 was also associated with the level of response after 12 months. 
Additionally, the rs242941(CRHR1) polymorphism was associated with the level of response 
to treatment according to changes in disease control after 2 years of medication use (see 
Table 17). No such results have been reported previously. 
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In order to correct for potential confounding variables influencing these associations an 
adjusted model was applied according to parameters significantly correlating with response to 
treatment. The variables chosen as potential confounders (covariates) included: age, disease 
duration, atopy status, total IgE level, eosinophil count, neutrophil count, basophil count, 
hsCRP level, monocyte count, platelet count,  BMI percentile category, comorbidities- AR, 
AD, OSA, GERD (Table 16). Other lung function parameters (such as FVC, PEF or FEV1 for 
assessment of treatment response according to % change in MEF50 or FVC, PEF or MEF50 for 
assessment of treatment response according to relative changes in FEV1) were not taken into 
account for correction although they significantly correlated with the level of response to 
treatment since all these variables are functions of the same exhaled breath (lung air) volume 
and this correlation provides little information on biologically relevant associations (plausible 
underlying pathophysiologic mechanisms). Additionally, since the level of response to 
treatment according to changes in FENO and asthma control were also selected as outcomes 
(study endpoints), these correlations involving FENO and disease control variables were not 
taken into consideration for the adjusted model, especially because the level of disease 
control is a multifactorial parameters that partially encompasses measures of lung function 
and local (airway) inflammation. 
After the adjustment for potential confounders, the rs37973 polymorphism in the GLCCI1 
gene was significantly associated only with the level of response to treatment according to 
changes in FENO after 6 months (p= 0.005 and p= 0.012). Similarly, after correction for 
covariates, the rs242941 polymorphism in the CRHR1 gene was associated only with the 
level of response to treatment according to changes in FENO after 6 and 12 months of ICS 
use (p= 0.003 and p= 0.015, respectively). In the adjusted model, only rs9910408 in the 
TBX21 gene was associated with treatment outcomes assessed by changes in all parameters 
(lung function, airway inflammation level and asthma control): with the level of response 
according to % change in FEV1 after 6 months (p= 0.047), with the level of response to 
treatment according to changes in FENO after 6 months  (p= 0.002) as well as with the level 
of response to treatment with ICS according to changes in asthma control after 6 months (p= 
0.013), see Table 17. This is the first such association of the analyzed polymorphisms with 
response to treatment according to changes in FENO and asthma control reported. rs9910408 
in TBX21 has previously been associated with response to treatment with ICS assessed by % 
change in FEV1 in an adult asthma cohort (Lopert et al. 2013). 
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No significant associations of treatment outcomes assessed by changes in lung function (% 
change in FEV1 and MEF50), changes in FENO and asthma control were identified  in the 
adjusted model for rs1876828 (CRHR1) and rs17576 (MMP9). 
When treatment success was assessed by changes in FENO after 6 months, the frequency of 
the AA genotype in rs37973 (GLCCI1) was significantly higher in good responders (p= 
0.007), as well as moderate responders (p= 0.037) compared to the GG genotype (see Table 
20). Moreover, the frequency of the A allele was significantly higher in good responders (p= 
0.0129) and patients with moderate levels of response ot treatment (p= 0.008) compared to 
bad responders (see Table 22). Although this association of FENO related treatment success 
and the rs37973 polymorphism has not been previously reported, a large study involving 
more than 900 pediatric patients with asthma has demonstrated a similar genotype related 
effect on response to ICS according to % change in FEV1 predicted (Tantisira et al. 2011). 
For the rs9910408 polymorphism (TBX21 gene) the frequency of the G allele was 
significantly higher in good responders compared to moderate and bad responders, when 
treatment outcomes were assessed by changes in FEV1 and asthma control after 6 months of 
medication use (p= 0.0023 and p<0.0001, respectively). When treatment success was 
assessed by changes in FENO levels after 6 months, the frequency of the G allele was 
significantly higher in moderate responders compared to patients with bad and good response 
(p= 0.0009), see Table 22. Although these associations were not previously reported, a study 
involving patients from the Childhood Asthma Management Program (CAMP) observed a 
similar allelic effect on the level of response to treatment according to changes in airway 
hyperresponsiveness (Raby et al. 2006). Conversly, a study involving a Slovenian adult 
asthma cohort reported that the AA genotype was overrepresented in good responders 
according to changes in FEV1 and AHR (Lopert et al. 2013), but these were adult non-atopic 
participants, whereas our cohort involves children the majority of which had allergic asthma. 
For rs242941 in the CRHR1 gene the frequency of the C allele was significantly higher in 
good and moderate responders compared to patients with inadequate (bad) levels of response 
to treatment according to changes in FENO after 12  and 6 months of ICS use (p= 0.0024 and 
p< 0.0001, respectively), see Table 22. Although this association of response according to 
relative changes in FENO has not been reported so far, similar effects (association of the C 
allele) with positive treatment outcomes (improved lung function, % FEV1 change) was 
reported in a Korean adult COPD cohort (Kim et al. 2009). Interestingly, a study involving 
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CAMP participants demonstrated that the minor allele (A) was associated with poor reposnse 
to treatment with ICS assessed by % change in bronchodilatation reversibility- % FEV1 
change after administration of bronchodilatator (Rogers et al. 2009). 
There was no significant association of response to treatment with ICS alone with rs1042713 
(ADRB2), neither prior nor post adjustment for confounding variables, which was expected, 
since this polymorphism was previously associated with response to -agonists (Basu et al. 
2009). 
5.3.2. Association of genetic variants with treatment outcomes in patients using 
LTRA only 
38 patients were treated with leukotriene receptor antagonists continuously over the period of 
2 years. When success of treatment with LTRA alone was assessed by changes in FENO 
levels, only the rs17576 polymorphism (MMP9 gene) was significantly associated with the 
level of response to treatment after 6 months of medication use. This association, however, 
was not reproduced in the adjusted model (after correction for confounding variables). 
Instead, treatment outcome assessed by changes in asthma control after 6 months of LTRA 
use was significantly associated with rs17576 (p= 0.026), see Table 18. The frequency of the 
A allele was significantly higher in good responders compared to patients with moderate and 
bad response to treatment with LTRA assessed by changes in disease control after 6 months 
(p= 0.0446), see Table 23. This is the first such association of rs17576 with the level 
treatment response in asthma reported so far, but similar effects of disease control 
improvement after treatment were reported for other genetic variants in the MMP9 gene 
(Dragicevic et al. 2018). However, since the association with the level of response to 
treatment with LTRA accroding to changes in asthma control was rather weak and identified 
only post adjustment for confounders and, moreover, due to the small sample size (N= 38), 
there is a risk that this effect is random. Despite that,  genetic variants in the MMP9 gene 
(including the rs17576 polymorphism) may be promising new biomarkers in asthma 
pharmacogenetics and deserve further research attention. 
5.3.3. Association of genetic variants with treatment outcomes in patients using 
combination treatment 
106 patients were treated with combination treatment (ICS+LABA and/or LTRA) 
continuously over the period of 2 years. When success of treatment with ICS+LABA/LTRA 
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was assessed by changes in lung function parameters, the rs37973 polymorphism in the 
GLCCI1 gene was significantly associated with  the level of response to treatment according 
to % change in MEF50 predicted for certain age, gender and posture after 6 months. 
Additionally, rs37973 was associated with treatment outcomes according to changes in 
FENO levels and asthma control after 6 and 12 months of medication use. The rs9910408 
polymorphism (TBX21) was significantly associated with the level of response to 
combination treatment according to changes in lung function after 6 months and 1.5 years (% 
change in FEV1- after 6 months and 1.5 years and MEF50- after 6 months), as well as with 
treatment outcomes assessed by changes in FENO after 6 months of medication use. 
rs242941 in the CRHR1 gene was significantly associated with treatment success assessed by 
changes in lung function parameters after 6 months and 2 years (% change in MEF50- after 6 
months and FEV1- after 6 months and 2 years) of ICS+LABA/LTRA use. Additionally, 
rs242941 was associated with treatment outcomes according to changes in FENO levels after 
6 months, 1.5 years and 2 years of medication use, as well as with the level of response to 
treatment assessed by changes in asthma control after 2 years of medication use (see Table 
19). After adjustment for confounding variables, only treatment outcomes assessed by 
changes in FENO and asthma control were significantly associated with rs9910408 in TBX21 
(according to changes in FENO after 6 months) and rs242941 in the CRHR1 gene (according 
to changes in FENO level after 2 years of treatment use), see Table 19. No significant 
associations of treatment outcomes were identified in the adjusted model for rs37973. 
Although the afore mentioned associations have not been reported for combination treatment 
use so far, they are likely associated with the ICS component in combination regimes, and 
certain studies have shown an association of all of these genetic variants with response to 
treatment with inhaled corticosteroids, although mainly according to changes in FEV1 and 
airway hyperresponsiveness but not with changes in FENO or asthma control (see Section 
5.3.1). 
The rs1042713 polymorphism in the ADRB2 gene was significantly associated with treatment 
outcomes assessed by changes in FENO after 6 and 12 months as well as with response to 
treatment according to changes in asthma control after 6 months and 1.5 years of 
ICS+LABA/LTRA use (see Table 19). After adjustment for confounders, rs1042713 was 
only associated with treatment success assessed by changes in FENO levels after 6 months of 
medication use (see Table 19). This association has not been previously reported. 
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When treament success was assessed by changes in FENO levels after 6 months of 
ICS+LABA/LTRA use, the frequency of the AA genotype in rs9910408 (TBX21) was 
significantly higher in good responders compared to the GG genotype (p= 0.000), see Table 
21. Moreover, the frequency of the A allele was significantly higher in good responders 
compared to patients with moderate and bad response to treatment (p< 0.0001), see Table 24. 
Although this association with response to treatment according to changes in FENO was not 
previously reported for ICS+LABA/LTRA use, a study involving pediatric patients with 
asthma on ICS demonstrated a similar allelic effect on the level of response to treatment with 
assessed by changes in AHR (Raby et al. 2006), which is why this association is probably due 
to the ICS component of combination treatment. 
For rs242941 in the CRHR1 gene, when the level of response to treatment was assessed by 
changes in FENO after 2 years of treatment, the frequency of the CC genotype was 
significantly higher in good and moderate responders compared to the AA genotype (p= 
0.007), see Table 21. Additionally, the frequency of the C allele was significantly higher in 
good and moderate responders compared to children with poor (bad) response to treatment 
(p= 0.0013), see Table 24. Although this association of response to treatment according to 
changes in FENO has not been previously reported for rs242941 and the C allele with 
combination treatment, a study involving adult patients with asthma using ICS reported 
similar results (allelic effect) and an association of positive treatment outcomes (improved 
lung function) with the C allele (Kim et al. 2009). Additionally, a study involving pediatric 
patients with asthma on treatment regimes with ICS reported an association of poor treatment 
response (according to changes in FEV1 reversibility after bronchodilatator administration) 
with the A allele (Rogers et al.). This indicates that this association of rs242941 and treatment 
success is likely due to the ICS component in combination treatment. 
When treatment outcomes were assessed by changes in FENO levels after 6 months of 
ICS+LABA/LTRA use, the frequency of the AA genotype in the rs1042713 polymorphism 
(ADRB2) was significantly higher in good responders compared to the GG genotype (p= 
0.001). Moreover, the frequency of the A allele was significantly higher in good responders 
compared to patients with moderate and bad response to treatment (p= 0.0139). This 
association of FENO- related treatment outcomes with rs1042713 has not been reported so 
far. Conversly, the A allele (encoding the Arg16 residue) has been associated with 
diminished response to treatment with -agonists (both SABA and LABA)- reduced PEF 
compared to baseline and higher asthma exacerbation rates (Cho 2010).  
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There was no significant association of response to treatment with ICS+LABA/LTRA with 
rs17576 (MMP9), neither prior nor post adjustment for confounding variables. 
 
5.4.  Identifying clusters in response to treatment 
The results of this study indicate that there might be specific patterns in the level of response 
to treatment with ICS, LTRA or combination therapy (ICS+LABA/LTRA) assessed by 
changes in lung function parameters (% change in FEV1 and MEF50), FENO levels and 
asthma control, see Figure 14 and Table 25. By employing the Ward`s HCA on original 
response data (not PCA transformed, as using PCA did not affect cluster stability), 4 distinct 
response clusters were identified. Since the method itself is always prone to forming 2 
separate classes by splitting the decision tree until it reaches a perfect fit, by employing a 
limit of the Gini index of 0.2 and based on cluster stability (Average proportion of non-
overlap, APN= 0.4;  APN is a measure of the average number of observations not placed in 
the same cluster by clustering based on the full data and clustering based on the data with a 
single variable removed iteratively, Brock et al. 2008) as well as empirical clinical and 
biological knowledge we have successfully identified 4 specific response clusters: 
 Cluster 1- patients with overall good response to treatment according to level of 
asthma control, moderate response to treatment according to lung function parameters 
(relative changes in FEV1 and MEF50) and moderate or bad response to treatment 
according to changes in FENO (N= 58); 
 Cluster 2- patients with overall good response to treatment according to level of 
asthma control, good or moderate levels of response to treatment according to 
changes in FENO, moderate response to treatment according % change in FEV1 and 
bad or moderate levels of response to treatment according to changes in MEF50 (N= 
87); 
 Cluster 3- patients with overall good response to treatment according to changes in 
disease control, good levels of response to treatment according to changes in both 
FEV1 and MEF50, as well as good response to treatment according to changes in 
FENO levels (N= 138); 
 Cluster 4- patients with overall poor (moderate and bad) response to treatment 
according to changes in lung function, moderate levels of response according to 
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FENO changes and long-term poor (bad) response to treatment according to level of 
asthma control (N= 64). 
The main discriminant variable in the response clustering according to the decision tree 
algorhytm was the level of response to treatment according to changes in asthma control after 
1.5 years of treatment (long-term control), followed by response to treatment according to 
changes in FENO, FEV1 and MEF50 in shorter assessment periods (6 and 12 months), see 
Figure 15. 
To date, only one study has focused on long-term treatment outcomes in 3 independent 
cohorts (including pediatric patients) and have successfully replicated SARP (Severe Asthma 
Research Program) clusters identified by Moore and colleagues (Moore et al. 2010) in 
distinguishing each cluster according to age of onset of asthma (early onset vs late onset 
disease), lung function (normal vs impaired lung function) and comorbidity, such as obesity 
and eczema (Chang et al. 2014). However, certain clusters had small sample size, especially 
those refering to more severe disease forms which may affect cluster stability and 
reproducibility of these results in other cohorts. In general, very few studies have focused on 
disease control and severity as outcomes. A study involving a cohort of almost 2000 adult 
asthmatics has successfully replicated 4 clusters in female participants and 3 clusters in men 
of variable severity (mild to severe persistent asthma) and symptom control (controlled, 
partly controlled, uncontrolled), although these findings were based on questionnaire data 
(use of medication, other healthcare use and self-assessment) and there were no objective 
parameters (such as lung function) measured (Mäkikyrö et al. 2017). Additionally, these were 
adult patients with asthma and these results may not be applicable in children. 
5.4.1. Identifying phenotypes underlying specific response to treatment 
outcomes 
The results of our study suggest specific patterns in the response to treatment assessed by 
changes in different parameters, including lung function, airway infammation (FENO) and 
asthma control. In order to identify possible disease features and phenotypes underlying such 
response patterns/outcomes, we have employed the same clustering method (Ward`s HCA on 
original data, not PCA transformed) on all relevant data from baseline (diagnosis, recruitment 
point), including:  baseline demographics (gender, age, duration of disease), atopy status, 
lung function (FEV1 and MEF50 predicted), FENO, sensitization and allergy data (distributed 
in categories, as discussed in Section 4.4), hematologic and biochemical blood test results, 
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comorbidity- GERD, OSAS, obesity/overweightness, AR, AD; treatment use and genetic data 
(rs37973, rs9910408, rs242941, rs1876828, rs1042713 and rs17576). These phenotyping 
results have identified 4 clusters (according to response ot treatment patterns): 
 Cluster 1- the smallest cluster (N= 58), older children (mean age ca. 12 years), with 
age of onset at about 6 years of age, lung function still in physiologic range (mean 
FEV1= 89% predicted and mean MEF50= 92% predicted for age, gender and posture), 
predominantly sensitized to house dust mite (strong sensitization, 68.97%) and with a 
dominant genotype (AA) and allelic effect (A allele) for rs37973 in the GLCCI1 gene; 
 Cluster 2 (N=87)- mean age ca. 10 years, with age of onset at about 5 years of age, 
normal lung function (mean FEV1= 96 % predicted and mean MEF50= 103% 
predicted), with ca 54% of participants exhibiting strong sensitization to house dust 
mite and predominantly heterozygotic for rs37973; 
 Cluster 3- the largest cluster (N= 138), mean age ca. 10 years with age of onset at 
about 6 years of age, impaired lung function (mean FEV1= 82% and mean MEF50= 
79% predicted), no significant association with strong sensitization to house dust mite 
(53% with strong sensitization, 47% negative) and predominantly heterozygotic for 
rs37973; 
 Cluster 4 (N= 64)- mostly younger children (mean age ca. 9.6 years) with age of onset 
at about 6 years of age, relatively normal FEV1 (mean= 88% predicted) but lower 
MEF50 (mean= 84% predicted), no significant association with strong sensitization to 
house dust mite (51.5% with strong sensitization, 48.5% negative) and predominantly 
heterozygotic for rs37973, see Table 26. 
The main discriminant variables in the phenotype clustering according to the decision tree 
algorhytm were MEF50 predicted at baseline, followed by use of reliever medication (SABA) 
which a parameter incorporated in asthma control assessment, use of combination treatment, 
hsCRP and neutrophil blood count (see Figure 16) which reflect type and level of 
inflammation, although some of these variables (ie. neutrophil count) were not significantly 
different between clusters in the cluster statistics. This may very well be an effect of different 
types of statistics applied in the decision tree algorhytm and cluster statistics (Kruskal- Wallis 
and 2 tests)- these two cannot be compared on the same scale of linearity. 
Our results indicate that clusters 1-3 have overall good long-term treatment outcomes 
assessed by changes in asthma control. Cluster 1 had  moderate levels of response to 
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treatment according to lung function parameters (both FEV1 and MEF50), which may 
explained by the fact that these patients didn`t have significantly impaired lung function at 
baseline. These patients also had relatively poor FENO-related response to treatment, which 
may be a consequence of strong sensitization to house dust mite, as the majority of these 
patients (almost 70%) had strong sensitization to house dust mite (class 4, sIgE > 17.51 
kU/L), see Table 25 and 26. A study involving a pediatic cohort in Korea has demonstrated 
that the levels of sIgE to house dust mite correlate with increases in FENO (Lee et al. 2015) 
and, moreover, a study involving asthmatic children from the Southern Mediterranean region 
suggests that in atopic children, sensitization to indoor inhaled allergens, including house dust 
mite, may increase airway inflammation levels (FENO) which leads to worsening of the 
pulmonary function (Ruggieri et al. 2017). Also, these patients were older and and had later 
onset of the disease (at about 6 years of age), which may also contribute to poorer response to 
treatment according to FENO and lung function parameters, as most studies indicate that late-
onset disease phenotypes imply more severe outcomes (Haldar et al. 2008, Siroux et al. 2011, 
Wu et al. 2014, Moore et al. 2010, Kim et al. 2013). House dust mite is an allergen with high 
allergenic potential (Calderon et al. 2016, D`Amato et al. 2007) and, moreover, sensitization 
to dust mite has been associated with poorer disease outcomes in children possibly indicating 
early remodeling as a consequence of  inflammation secondary to exposure to these allergens 
(Gaffin and Phipatanakul 2009). Cluster 1 also had the highest eosinophil count and the 
highest serum total IgE levels (see Table 26), although these associations were not 
statistically significant, but were major discriminants in the decision tree (see Figure 16). 
This may indicate a higher level of Th2 inflammation, but not significantly increased FENO 
levels which may be the reason for their poor FENO-related treatment effectiveness 
(Robinson et al. 2016). 
Cluster 2 was similar to cluster 1 in terms of response to treatment according to disease 
control and FEV1 parameters (moderate levels of response according to FEV1 and good 
according to asthma control), but they differed in FENO-related treatment outcomes. Cluster 
2 patients had good or moderate levels of response to treatment according to changes in 
FENO which is probably due to the fact that this cluster was not significantly associated with 
sensitization to house dust mite. These children had relatively earlier age of onset of disease 
(ca. 5 years of age). Additionally, cluster 2 differed from cluster 1 in the level of response to 
treatment according to changes in MEF50- these patients had poor (bad and moderate) MEF50- 
related response, although their baseline MEF50 measurements were not impaired, see Tables 
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25 and 26. This suggests that lung function in the distal airways deterriorates with time in 
these patients despite regular medication use which contributes to the importance of the small 
(distal airways) in children with asthma (Torrego Fernandez and Munoz Cano 2011). The 
peripheral (distal) airways are the predominant site of airway inflammation (Corren 2008) 
and may very well be a predominant site of airflow obstruction in asthmatics (Hamid and 
Tulic 2007). Additionally, there is evidence that the obstruction in the small (distal) airways 
may be involved in the pathophysiology and resistance to treatment with ICS in children, 
especially those with increased BMI (Ye et al. 2013) and that the impairment of the small 
airways disease may be present despite rare and mild asthma symptoms and normal 
spirometry in children (Singer et al. 2014). Also, cluster 2 had the highest levels of serum 
hsCRP (see Table 26), although this association was not statistically significant, but was a 
major discriminant in the decision tree algorythm (see Figure 16). This may indicate that 
these patients have higher levels of systemic inflammation and hence, poorer disease and 
treatment outcomes. Several studies have demonstrated that increased levels of hsCRP are 
associated with more severe asthma outcomes and may be an interesting novel biomarker in 
predicting asthma control and treatment response (Kilic et al. 2012, Monadi et al. 2016). 
Moreover, cluster 2 patients had a higher proportion of overweight and obese patients (36.78 
%) compared to other clusters, which is in concordance with other findings indicating that 
obesity in asthma is associated with poorer disease outcomes and poorer response to 
treatment with ICS according to changes in lung function parametres (Monahan et al. 2014) 
and moreover, that obese asthma could be a distinct and more severe asthma phenotype 
(Dixon et al. 2010, Teodorescu et al. 2013, Samson and Garber 2014). Additionally, since 
these patients had higher levels of serum hsCRP, this suggests that obesity in asthma 
promotes systemic inflammation which may reflect in the airways as well, which is in 
concordance with previous findings (Monahan et al. 2014). These patients also have higher 
levels of eosinophilic inflammation (eosinophil count) than clusters 3 and 4 but also higher 
neutrophil counts than clusters 1 and 3- although this was not statistically significant but 
major discriminants in the decision tree algorythm (see Table 26 and Figure 16), which 
supports recent findings that obesity in mice is associated with a mixed granulocytic 
inflammation and may contribute to a refractory therapeutic response as well as exacerbation 
of disease severity (Silva et al. 2017). 
Cluster 1 was also different from cluster 2 in exhibiting a dominant genotype (AA) and allelic 
(A allele) affect for the rs37973 polymorphism in the GLCCI1 gene, which has been 
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associated with positive treatment outcomes according to % change in lung function in 
patients using ICS  (Tantisira et al. 2011) and according to similar findings in this study. 
Cluster 3 was the largest of the four clusters and had overall good response to treatment 
according to all analyzed parameters (% change in FEV1, MEF50, FENO and asthma control). 
These patients were somewhat younger than patients in clusters 1 and 2 (mean age just under 
10 years) but still had a relatively later onset of disease (at about 6 years of age). 
Interestingly, these patients had the lowest values of FEV1 and MEF50 at baseline measured 
(see Tables 25 and 26), which indicates that they had the highest improvement in lung 
function in response to treatment. These patients also had a higher frequency of the A allele 
for rs37973, which may contribute to better responsiveness to the ICS component of their 
treatment regimes (Tantisira et al 2011) and is also in concordance with the findings of this 
study. Cluster 3 was also characterized by higher serum total IgE levels (as well as cluster 1), 
but not with significantly higher eosinophil or neutrophil count, which may indicate lower 
levels of airway inflammation in these patients contributing to positive treatment outcomes. 
Additionally, these patients also has the highest levels of FENO, although this association 
was not statistically significant but a major discriminant in the decision tree algorythm (see 
Table 26 and Figure 16), which may explain their better responsiveness to treatment with the 
ICS component (Price et al. 2018). 
Cluster 4 was the only one characterized by poor long-term control-related response. 
Additionally, these patients had poor (moderate and bad) levels of response to treatment 
according to lung function parameters (both FEV1 and MEF50), but positive treatment 
outcomes assessed by FENO changes. These patients were the youngest (mean age 9.6 years) 
but also had later onset of disease (ca. 6 years of age). They had somewhat lower FEV1 and 
MEF50 measurements at baseline, but still within acceptable physiologic range (see Tables 25 
and 26). Cluster 4 patients had a significantly higher proportion of patients with atopic 
dermatitis (AD), see Table 26, which is more common in severe asthma (Lee and Han 2018). 
This may be associated with an impairment of the epithelial barrier (skin) causing immune 
dysregulation, and lead to the atopic march- progression from AD to allergic rhinitis and 
asthma. Asthma and AD are known to aggravate each other (Celakovská and Bukac 2016). 
Additionally, cluster 4 patients had a higher proportion of more severe asthma forms 
(moderate and severe asthma) compared to other clusters, which contributes to their poorer 
responsiveness to treatment (GINA 2018), see Table 26. Although this association was not 
statistically significant, but a major discriminant in the decision tree algorythm, cluster 4 
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patients had the highest neutrophil count, which has been associated with more severe asthma 
outcomes and, moreover, with non-responsiveness to corticosteroids (Ray and Kolls 2017). 
Additionally, although this association was also not statistically significant, but a trend may 
be present, cluster 4 had lower platelet counts compared to other clusters (see Table 26). 
Platelets may actively be involved in the pathogenesis of allergic asthma via the regulation of  
Th2 inflammation mediated by active platelet-derived IL-33 protein activation and lower 
platelet count due to systemic inflammation is more prominent in children (Kowal et al. 2006, 
Ellaurie and Wang 2004). Platelets may also be involved in more extensive airway 
remodeling, as well as in the development of steroid-refractory asthma, since ICS do not 
affect platelet function (Takeda et al. 2017). 
Although this association was not statistically significant, clusters 2 and 4 had higher 
proportions of patients with food allergy, which is also likely why these patients had poorer 
response patterns since food allergy and asthma are known to aggravate each other and 
increase the risk for morbidity in each condition. Children with food allergy and asthma are 
more likely to have near-fatal or fatal allergic reactions to food allergens and are also more 
likely to have more severe forms of asthma (Wang and Liu 2011). 
In the past few years a number of studies have attempted to perform asthma phenotyping by 
employing novel bioinformatic tools (eg. cluster analysis and various techniques). Most of 
them have identified age of onset- early onset vs late onset disease presentation, usually in 
adults (Haldar et al. 2008, Siroux et al. 2011, Wu et al. 2014, Moore et al. 2010, Kim et al. 
2013); gender (Moore et al. 2010, Qiu et al. 2018); atopy status (Siroux et al. 2011, Howrylak 
et al. 2014), obesity (Haldar et al. 2008, Moore et al. 2010) and type of inflammation- 
eosinophil, neutrophil, mixed type, Th2 high/low (Wu et al. 2014, Loza et al. 2016, Qiu et al. 
2018, Su et al. 2018) as main discriminants distinguishing specific clusters (phenotypes)- 
usually 3 to 5 clusters. Certain studies have focused on disease control and severity 
(Mäkikyrö et al. 2017), airway obstruction and exacerbations (Howrylak et al. 2014), 
recurrent chest infections (Belgrave et al. 2017) and type and level of sensitization (Schoos et 
al. 2017). A literature overview of clustering studies focusing on identifying distinct asthma 
phenotypes and their main findings as well as limitations is presented in Supplement 5. 
Although phenotyping studies such as this one have performed unbiased statistically based 
analyses on larger cohorts of patients involving a wide range of clinical variables, they have 
been limited in the terms of clinical characteristics they have used to identify different 
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phenotypes in asthma and still do not provide much insight into the underlying disease 
mechanisms (Gauthier et al. 2015, Ray et al 2015). Additionally, different methods employed 
in these studies have been shown to yield different results in cluster assignments, especially 
in different populations (Prosperi et al. 2013). Our population, however, was very 
homogenous (all children, mostly milder disease forms, mostly atopic, ethnically 
homogenous), which was an advantage in identifying genetic traits associated with treatment 
response patterns, but a disadvantage in identifying clear disease phenotpyes. From all of this 
is is evident that further research and further classification involving larger numbers of 
patients, multi-centric, longitudinal and prospective studies and even more clinically relevant 
parameters are needed to adequately address the issues of the high levels of inter-patient 
variability in the level of response to treatment with common asthma medication.
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6. CONCLUSIONS AND FUTURE PROSPECTS 
 
The results of this study have confirmed that almost all of the selected genes and 
polymorphisms are likely candidate genes (genetic variants) in the pharmacogenetics of 
asthma. Although associations of treatment outcomes assessed by changes in FENO levels 
and asthma control have not been  reported so far for the genetic variants analyzed in this 
study, all of the polymorphisms with the exception of rs1876828 in the CRHR1 gene have 
been associated with either ICS, LTRA or combination treatment regimes, but this is most 
likely due to the fact that the frequency of the T allele and the TT genotype was very low 
(NTT= 7 in total, see Figure 13). The rs37973 polymorphism (GLCCI1) was significantly 
associated with positive treatment outcomes in children using inhaled corticosteroids (ICS) 
alone (the A alelle), while the rs9910408 genetic variant in the TBX21 gene (the A allele) as 
well as the rs242941 polymorphism in the CRHR1 gene (the C allele) were  associated with 
positive treatment outcomes in patients using both ICS alone and combination treatment 
regimes, which is in concordance with previous studies. This association of rs9910408 and 
rs242941 with good response to treatment with ICS+LABA/LTRA is most likely related to 
the ICS component of combination treatment regimes, since no such association with-
agonists or LTRA has been reported previously.  
The rs17576 polymorphism (MMP9) was associated with positive treatment outcomes in 
patients using leukotriene receptor antagonists alone (A allele). This is the first such 
association of rs17576 and treatment success in pediatric patients with asthma (and 
asthmatics in general) ever reported, but similar effects have been shown in a recent study 
focusing on other genetic variants in the MMP9 gene (Dragicevic et al. 2018). However, 
since the association with the level of response to treatment with LTRA and rs17576 was 
rather weak and identified only post adjustment for confounders and, moreover, due to the 
small sample size (N= 38), there is a risk that this effect is random. Despite that, genetic 
variants in the MMP9 gene (including the rs17576 polymorphism) may be promising new 
biomarkers in asthma pharmacogenetics and definitely deserve further research attention. 
The rs1042713 polymorphism in the ADRB2 gene was significantly associated with positive 
treatment outcomes in children using ICS+LABA/LTRA (A allele, encoding the Arg16 
residue). Although this association of FENO- related success of treatment with -agonists 
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with rs1042713 has not been reported so far, several studies have demonstrated an association 
of the A allele with poor response to treatment with SABA and LABA- reduced PEF 
compared to baseline and higher asthma exacerbation rates (Cho 2010, Basu et al. 2009). 
This may indicate that our results are random and the sample size is too small (N= 106) or the 
assessment period is too short (6 months in this study and in Basu et al. 2009), although 
candidate gene studies are not rare to give contradictory studies. For example, an association 
of the A allele in rs37973 in the GLCCI1 gene with good response to treatment with ICS has 
been reported by Tantisira and colleagues (Tantisira et al. 2011), while a recent study 
involving a Slovenian cohort of patients with asthma showed an association of positive 
treatment outcomes assessed by % change in FEV1 with the GG genotype (Rijavec et al. 
2018).  
In general, the results of this study have replicated genotype and allelic effects reported in  
other studies (larger and those involving adult and pediatric patients with asthma), with the 
exception of rs1042713 (ADRB2), although the sample size in specific treatment regime 
subsets (ICS alone, LTRA alone and ICS+LABA/LTRA) may be small (N= 158, N= 38 and 
N= 106, respectively). Although the assessment period was 2 years in total, the majority of 
genotype and allele-related effects were associated with shorter periods of time (6 months). 
This may reflect an actual and relatively immediate biological effect- genes being involved in 
the inflammatory response and asthma pathogenesis and their role in corticosteroid and -
agonist responsiveness, although there is a risk of the effect being confounded by other 
unrelated events such as poor response to treatment (impaired lung function and diminished 
disease control) due to a current respiratory infection or recent exposure to an allergen or 
elevated FENO levels due to poor adherence to treatment (Price et al. 2013). 
Additionally, the results of this study have failed to replicate the association of treatment 
outcomes assessed by changes in lung function (except for rs9910408 and ICS use) as most 
studies focused on % change in FEV1 as a primary endpoint. Instead, the majority of the 
associations in this study with specific genetic variants are related to treatment success 
according to changes in disease control and FENO levels. These results suggest that lung 
function may not be a preferred tool to be used to guide treatment in pediatric (as well as 
adult) patients with asthma, which is in absolute concordance with the latest GINA guidelines 
and the control-based management approach which focuses on achieving adequate control of 
symptoms and maintaining normal activity levels, as well as minimizing future risks of 
exacerbations (GINA 2018), see Supplement 2. Additionally, no previous studies have 
106 
 
investigated FENO as an outcome in pharmacogenetic research, although evidence suggests 
that FENO can also be used as a predictor of steroid responsiveness even more consistently 
than other parameters (Smith et al. 2005). FENO is a good biomarker of Th2- related allergic 
inflammatory response, as IL-13 promotes NO-synthase activity and NO production 
(Bagnasco et al. 2016). Hence, FENO may reflect corticosteroid effectiveness in reducing 
inflammation (which is the primary effect of ICS use) much better than other parameters such 
as lung function that encompasses a number of pathophysiologic mechanisms as well as 
structural changes in the airways. Moreover, the latest GINA guidelines suggest that 
treatment guided by FENO in children and young adults, is associated with a significant 
reduction in exacerbation rates and that it may be a good complementary approach 
compatible with control-based asthma management (GINA 2018).  
In conclusion, the results of this study indicate that all of the selected genes (GLCCI1, 
TBX21, CRHR1, ADRB2 and MMP9) are most likely candidate genetic variants in 
pharmacogenetics of asthma and may significantly contribute to the inter-individual 
variability  in the level of response to all classes of common asthma treatment. The results of 
this study also indicate that other biomarkers and approaches (other than lung function 
parameters and  airway hyperresponsiveness) may be more suitable in assessing treatment 
outcomes in pediatric patients and pharmacogenetic research, such as FENO and asthma 
control (symptom control and risk for exacerbations as well as exacerbation severity). Surely 
additional studies involving a larger number of patients, several (shorter and longer) 
treatment success assessment periods as well as functional studies to underpin possible 
pathophysiologic mechanisms underlying this treatment outcome heterogeneity are needed to 
confirm any of these results. 
We have also successfully identified 4 distinct response clusters varying in the level of 
response to treatment according to the afore mentioned parameters and duration of treatment 
(short-term vs long-term). Clusters 1 and 3 seemed to have a more positive pattern of 
treatment outcomes and were characterized by more prominent atopic markers (higher 
sensitization levels and strong sensitization to house dust mite for cluster 1, higher total IgE 
levels, higher eosinophilia for cluster 1, higher FENO, low neutrophilia) and a predominant 
allelic (A allele) effect for rs37973 in the GLCCI1 gene. Conversly, they had a relatively later 
onset of disease (6 years of age or more). Clusters 2 and 4 had poorer treatment success 
patterns and were characterized by higher levels of airway and systemic inflammation (higher 
hsCRP for cluster 4), multiple comorbidities (food allergy, atopic dermatitis for cluster 4 and 
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obesity for cluster 2, which is in concordance with the obese asthma phenotype), but varied in 
the type of inflammation (predominantly neutrophilic for cluster 4 and mixed-type for cluster 
2). Cluster 2 was the only one with relatively earlier onset of asthma (5 years of age), while 
cluster 4 had more severe forms of asthma and lower platelet counts associated with more 
extensive airway remodeling and poorer treatment effectiveness. 
The results of this study emphasize the issues in asthma treatment and management due to the 
overgeneralized approach to the disease, not taking into account specific disease phenotypes. 
This is the first study to identify treatment resposne patterns in children with asthma and 
plausible pathophysiologic and molecular mechanisms underlying such treatment outcomes. 
From the results of this study it is more than evident that in order to optimize medication 
selection and maximize treatment response in patients with asthma, especially children (since 
prevention and acting in a timely manner early in the disease presentation may prevent 
asthma progression later in life), further characterization of specific disease phenotypes is 
more than necessary. This may aid in developing complex prediction models which will 
stratify patients according to their specific disease traits and risk for treatment failure which 
will help in revisiting and recategorizing current treatment selection guidelines, aiming at 
establishing novel and better therapeutic options but surely further research and clinically 
based evidence is needed. A better understanding of individual variations in response to 
treatment, especially in children, will help clinicians in optimising asthma treatment and 
enable each patient to have full quality of life with minimal or no impediment from their 
asthma. 
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9. SUPPLEMENTS 
9.1. Supplement 1. Asthma Control Test for children between the age of 4 
and 11 years 
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Figure 17. Asthma Control Test (ACT) for children (ages 4 to 11 years). 
 
9.2. Supplement 2. Summary of the current guidelines in the management 
and treatment of asthma 
The long-term goals of asthma management are: 
 To achieve good control of symptoms and maintain normal activity levels, 
 To minimize future risks of exacerbations, fixed airflow limitation and side-effects. 
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In control-based asthma management, pharmacological and non-pharmacological treatment is 
adjusted in a continuous cycle that involves assessment, treatment and review (Figure 5). For 
many patients, symptom control is a good guide to a reduced risk of exacerbations. However, 
with add-on asthma therapies (including ICS/LABA) or different treatment regimes (eg. 
ICS/LABA maintenance and reliever therapy) and in patients with severe asthma or difficult-
to-treat or brittle asthma, they may be a discordance in responses for symptom control and 
exacerbations. In these cases, stepping up ICS doses may raise issues on side-effects of long-
term use. 
 
Figure 5. The control-based asthma management cycle and its main components. In children, especially those 
under the age of 5 years, parents or caregivers have a very important role in asthma management, which is wy 
their preferences and satisfaction is cruicial in the management process. Modified from (source): GINA 2018, 
GINA Pediatric 2015. 
Some alternative strategies have been evaluated for adjusting asthma treatment, such as: 
 Treatment guided by sputum eosinophil count: this approach is associated with a 
reduced risk of exacerbations and similar levels of symptom control and lung 
function; 
 Treatment guided by fractional concentration of exhaled nitric oxide (FENO): in 
children anad young adults, this approach is associated with a significant reduction in 
the number of patients with 1 or more exacerbations and in exacerbation rate, there 
are no differences in symptom control or ICS medication use in this approach in 
comparison with others. 
For each treatment step, a „preferred“ controller medication is recommended with the optimal 
benefit to risk ratio for both symptom control and exacerbation risk reduction, based on 
efficacy studies, safety dana and cost-effectiveness, on a population level. Any patient 
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characteristics that may predict a clinically important difference in their response to treatment 
compared to the „generalized model“, should be taken into account. 
As there is still no real cure to asthma (due to the overwhelming complexity of this disease), 
today, common asthma treatment is actually symptomatic treatment, with short-term 
medications that are mostly used to relieve current symptoms (reliever medication) and 
long-term medication is used in case of persistent symptoms to control the underlying 
inflammation and prevent exacerbations (controller medication). 
In general, the goal of asthma management is establishing good disease control with a 
tendency to stepping down treatment regimes if adequate control is achieved. 
At present, Step 1 is no controller medication and as-needed SABA (reliever medication). 
However, there is more and more evidence that chronic inflammation is present even in 
patients infrequetn and recent-onset symptoms and that regulat daily low dose ICS is highly 
effective in reducing symptoms, risk of exacerbations, hospitalization and asthma-related 
death. 
In case of persistent symptoms and/or exacerbations despite low dose ICS, consider stepping 
up but first check for common problems (inhaler technique, adherence, comorbidity etc.). 
Consider stepping down once good asthma control has been achieved and maintained for 
about 3 months, to find the patient`s lowest treatment that controls both symptoms and 
exacerbations (Figure 6). 
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Figure 6. A schematic representation of the stepwise approach in asthma management. *For children aged 4 to 
11 years, the use of theophyline is not recommended as controller treatment and the preferred option in Step 3 is 
medium dose ICS, whereas for adults and adolescents the preferred option in step 3 is ICS/LABA. In step 5, 
some patients may benefit from low dose OCS, but long-term systemic side-effects may occur. For children 
under the age of 5 years, step 1 treatment is as needed SABA, step 2 is daily or intermittent low dose ICS 
or LTRA, step 3 is „double low dose ICS“ and add-on option is LTRA, while step 4 is increasing the dose 
of ICS and add-on regular LTRA, with further expert advice, investigation and reconsidering diagnosis 
highly recommended. Source: GINA 2018, GINA Pediatric 2015. 
Recommended options  for INITIAL controller treatment in adults and adolescents are 
presented in Table 27. 
Table 27. Recommended options for initial controlled treamtent according to presenting symptoms, with levels 
of evidence. 
Presenting symptoms Preferred initial controller 
Asthma symptoms or need for bronchodilatator 
(SABA) < 2 times a month; no nighttime waking 
during the past month and no risk for 
exacerbations (including no exacerbations in the last 
year) 
No controller (Evidence D) 
Infrequent symptoms, but the patient has one or 
more risk factors for exacerbations- low lung 
function, history of exacerbations requiring OCS (oral 
corticosteroids) in the last year, or lifetime history of 
Low dose ICS (Evidence D) 
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hospitalization in intensive care for asthma 
Symptoms or need for SABA ≥ 2 times a  month 
and ≤ 2 times a week or nighttime awakening due 
to asthma ≥ 1 time a month 
Low dose ICS (Evidence B) 
Symptoms or need for SABA > 2 times a week Low dose ICS (Evidence A); other (but less effective) 
options include LTRA and theophyline  
Troublesome symptoms most days or nighttime 
awakenings ≥ 1 time a week, especially if risk factors 
for exacerbations exist 
Medium/high dose ICS (Evidence A) or low dose 
ICS/LABA (Evidence A) 
Initial asthma presentation with severly 
uncontrolled asthma or with an acute exacerbation 
Short course of oral corticosteroids (OCS) AND 
regular controller medication (high dose ICS- 
Evidence A or moderate dose iCS/LABA- Evidence 
D) 
Review patient`s response after 2-3 months, or earlier depending on clinical urgency  
Step down treatment once good control has been achieved and maintained for 3 months 
 
The stepwise approach to control symptoms and minimize future risk for exacerbations is 
presented in Table 28. 
Table 28. Stepwise approach to asthma management with levels of evidence. 
 Medication Symptoms/exacerbations 
Step 
1 
As-needed reliever inhaler (SABA) Occasional daytime symptoms (< 2 times 
a month) of short duration (few hours), 
NO nighttime awakening, normal lung 
function (≥ 80% of predicted or personal 
best) 
Other options- low dose ICS (recommended- Evidence B) 
or inhaled anticholinergics, oral SABA or short-acting 
theophyline- only in adults, slower onset of action and 
higher risk for side-effects (Evidence A) 
Presence of any risk for exacerbation, 
such as FEV1 < 80% predicted or 
personal best, a history of exacerbation in 
the past 12 months (Evidence B) 
Step 
2 
Low dose controller plus as-needed reliever (preferred 
option- low dose ICS plus as-needed SABA- Evidence A) 
Step up if symptoms are not controlled 
well, if there is a history of exacerbations 
or risk for exacerbation (including lung 
function) 
Other options- LTRA (less effective than ICS), appropriate 
for patients with AR (Evidence B)¸for adults and 
adolescents, low dose ICS/LABA may be more effective in 
reducing symptoms and improving lung function, but does 
not further reduce risk for exacerbation compared to ICS 
alone (Evidence A) 
Step One or two controller medications plus as-needed reliever 
Table 27. continued 
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3 (preferred option for adults and adolescents- low dose 
ICS/LABA plus as-needed SABA or low dose ICS/LABA 
as both maintenance and reliever; preferred option for 
children 6-11 yrs is moderate dose ICS plus as-needed 
SABA; for children ≤5 yrs preferred option is double low 
dose ICS and consider LTRA as add-on)- Evidence A 
Other options- medium dose ICS, low dose ICS plus LTRA 
or sustained-release theophyline (less effective)- Evidence 
A/B 
Step 
4 
Two or more controllers plus as-needed reliever- preferred 
option for adults and adolescnets is low dose ICS/LABA as 
both maintenance and reliever or medium ICS/LABA plus 
asneeded SABA; for children 6-11 yrs if moderate dose 
ICS plus as-needed SABA does not achieve adequate 
control, refer to expert advice; for children ≤5 yrs, increase 
iCS dose and add-on LTRA- Evidence A 
Other options- tiotropium or  theophyline or high dose 
ICS/LABA-only in adults and in case good control is not 
achieved with medium dose ICS/LABA plus a third 
controller (LTRA, theophyline) on a trial basis- Evidence 
A/B 
Step 
5 
High level care and add-on treatment, such as tiotropium, 
anti-IgE (omalizumab), anti-IL5 (reslizumab), sputum-
guided treatment approach, low dose oral corticosteroids 
(OCS) 
Refer to expert advice 
 
Categories of ICS treatment according to ICS dose are presented in Table 29. 
Table 29. Low, medium and high doses of inhaled corticosteroids. 
Adults and adolescents (12 yrs and older) 
Drug Low daily dose (mcg) Medium daily dose 
(mcg) 
High daily dose (mcg) 
Budesonide (dry powder 
inhaler, DPI) 
200-400 >400-800 >800 
Ciclesonide 
(hydrofluoroalkane 
propellant, HFA) 
80-160 >160-320 >320 
Fluticasone propionate 100-250 >250-500 >500 
Table 28. continued 
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(DPI)   
Children 6-11 yrs 
Drug Low daily dose (mcg) Medium daily dose 
(mcg) 
High daily dose (mcg) 
Budesonide (dry powder 
inhaler, DPI) 
100-200 >200-400 >400 
Ciclesonide 
(hydrofluoroalkane 
propellant, HFA) 
80 >80-160 >160 
Fluticasone propionate 
(DPI) 
100-200 >200-400 >400 
 
 
9.3. Supplement 3. List of all inahled, food and other allergens used in 
standard SPT in participants. 
Table 30. List of all inahled, food and other allergens used in standard SPT in participants. 
Type of allergen Allergen species Binomial nomenclature 
 
 
House dust 
 
House dust mite 
Dermatophagoides farinae 
Dermatophagoides pteronyssinus 
House dust mix- mite, cockroach and animal dander 
 
Animal dander 
Cat dander Felis domesticus 
Dog dander Canis familiaris 
Rabbit epithelium Oryctolagus cuniculus 
 
 
 
Grass pollen 
Cocksfoot Dactylis glomerata 
Timothy grass Phleum pratense 
Cultivated rye Secale cereale 
5 grasses mix- cocksfoot, sweet 
vernal-grass, rye-grass, meadow 
grass, and timothy 
Dactylis glomerata, Anthoxanthum 
odoratum, Lolium perenne, Poa 
pratensis and Phleum pratense 
 
Weed pollen 
Common ragweed Ambrosia elatior 
Mugwort Artemisia vulgaris 
 
 
 
Tree pollen 
Common silver birch Betula verrucosa 
Hazel Corylus avellana 
Olive Olea europaea 
Pine Pinus radiata 
Trees mix- maple, horse-chestnut, Acer pseudoplatanus, Aesculus 
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plane tree and lime tree hippocastanum, Platanus acerifolia 
and Tilia x europaea 
Shrub pollen Mimosa Mimosa pudica 
 
Molds 
Alternaria Alternaria alternata 
Cladosporium Cladosporium herbarum or spp. 
 
 
 
 
 
 
 
 
 
 
Food allergens 
Egg white Gallus spp. 
Egg yolk Gallus spp. 
Cow`s milk Boss spp. 
Wheat Triticum aestivum 
Corn/maize Zea mays 
Soy Glycine max (Soja hispida) 
Rye Secale cereale 
Peanut Arachis hypogaea 
Sesame Sesamum indicum 
Tuna (yellowfin) Thunnus albacares 
Hake Merluccius merluccius 
Trout Oncorhynchus mykiss 
Kiwi Actinidia deliciosa 
Hazelnut Corylus avellana 
Walnut Juglans spp. 
Almond Amygdalus communis 
Rice Oryza sativa 
Strawberry Fragaria vesca 
Apple Malus x domestica 
Orange Citrus sinensis 
Peach Prunus persica 
Potato Solanum tuberosum 
Tomato Lycopersicon esculatum 
Parsley Petroselinum crispum 
Drugs 
 
Penicilloyl G 
Amoxicilloyl 
 
Insect venom 
Common wasp (Yellow jacket) Vespula spp. 
European hornet Vespa crabro 
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9.4. Supplement 4. Definition of response to treatment abbreviations 
Resp_FEV1_diagn to 1
st
 control- response to treatment according to changes in FEV1 after 
6 months (recruitment to 1
st
 control) 
Resp_FENO_diagn to 1
st
 control- response to treatment according to changes in FENO 
after 6 months (recruitment to 1
st
 control) 
Resp_CTRL_diagn to 1
st
 control- response to treatment according to changes in asthma 
control after 6 months (recruitment to 1
st
 control) 
Resp_MEF50_diagn to 1
st
 control- response to treatment according to changes in MEF50 
after 6 months (recruitment to 1
st 
control) 
Resp_FEV1_1
st
  to 2
nd
 control- response to treatment according to changes in FEV1 after 6 
months (1
st
 to 2
nd
 control) 
Resp_FENO_1
st
  to 2
nd
 control- response to treatment according to changes in FENO after 6 
months (1
st
 to 2
nd
 control) 
Resp_CTRL_ 1
st
  to 2
nd
 control- response to treatment according to changes in asthma 
control after 6 months (1
st
 to 2
nd
 control) 
Resp_MEF50_1
st 
to 2
nd
 control- response to treatment according to changes in MEF50 after 6 
months (1
st
 to 2
nd
 control) 
Resp_FEV1_2
nd
 to 3
rd
 control- response to treatment according to changes in FEV1 after 6 
months (2
nd
 to 3
rd
 control) 
Resp_FENO_2
nd
  to 3
rd
 control- response to treatment according to changes in FENO after 
6 months (2
nd
 to 3
rd
 control) 
Resp_CTRL_ 2
nd 
to 3
rd
 control- response to treatment according to changes in asthma 
control after 6 months (2
nd
 to 3
rd
 control) 
Resp_MEF50_2
nd
 to 3
rd
 control- response to treatment according to changes in MEF50 after 
6 months (2
nd
 to 3
rd
 control) 
Resp_FEV1_3
rd
 to 4
th
 control- response to treatment according to changes in FEV1 after 6 
months (3
rd
 to 4
th
 control) 
143 
 
Resp_FENO_3
rd
  to 4
th
 control- response to treatment according to changes in FENO after 6 
months (3
rd
 to 4
th
 control) 
Resp_CTRL_ 3
rd
 to 4
th
 control- response to treatment according to changes in asthma 
control after 6 months (3
rd
 to 4
th
 control) 
Resp_MEF50_3
rd 
to 4
th
 control- response to treatment according to changes in MEF50 after 6 
months (3
rd
 to 4
th
 control) 
Resp_FEV1_diagn to 2
nd
 control- response to treatment according to changes in FEV1 after 
12 months (recruitment to 2
nd
 control) 
Resp_FENO_diagn to 2
nd
 control- response to treatment according to changes in FENO 
after 12 months (recruitment to 2
nd
 control) 
Resp_CTRL_diagn to 2
nd
 control- response to treatment according to changes in asthma 
control after 12 months (recruitment to 2
nd
 control) 
Resp_MEF50_diagn to 2
nd
 control- response to treatment according to changes in MEF50 
after 12 months (recruitment to 2
nd 
control) 
Resp_FEV1_diagn to 3
rd
 control- response to treatment according to changes in FEV1 after 
18 months (recruitment to 3
rd
 control) 
Resp_FENO_diagn to 3
rd
 control- response to treatment according to changes in FENO 
after 18 months (recruitment to 3
rd
 control) 
Resp_CTRL_diagn to 3
rd
 control- response to treatment according to changes in asthma 
control after 18 months (recruitment to 3
rd
 control) 
Resp_MEF50_diagn to 3
rd
 control- response to treatment according to changes in MEF50 
after 18 months (recruitment to 3
rd 
control) 
Resp_FEV1_diagn to 4
th
 control- response to treatment according to changes in FEV1 after 
24 months (recruitment to 4
th
 control) 
Resp_FENO_diagn to 4
th
 control- response to treatment according to changes in FENO 
after 24 months (recruitment to 4
th
 control) 
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Resp_CTRL_diagn to 4
th
 control- response to treatment according to changes in asthma 
control after 24 months (recruitment to 4
th
 control) 
Resp_MEF50_diagn to 4
th
 control- response to treatment according to changes in MEF50 
after 24 months (recruitment to 4
th 
control) 
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9.5. Supplement 5. An overview of clustering studies attempting to identify specific asthma phenotypes 
Table 31. A summary of clustering studies focusing on asthma phenotyping so far. 
Study method Major findings Limitations of the study 
k-means clustering in 3 independent asthma cohorts: 
N=184, N=187 and N=68 (Haldar et al. 2008) 
Identified 5 distinct asthma clusters: (i) early onset 
atopic, (ii) obese non-eosinphilic, (iii) benign, (iv) early 
symptom predominant and (v) inflammation predominant 
Did not include physiological measures of airway 
obstruction (eg. FEV1) in the analysis 
Latent class analysis (LCA) on 2 large study cohorts: 
N=641 and N=1895 (Siroux et al. 2011) 
Identified 4 distinct asthma phenotypes: (i) active treated 
allergic childhood-onset asthma, (ii) active treated adult-
onset asthma, (iii) and (iv) inactive or mild asthma, with 
differences in atopy status and age of onset 
Included more limited clinical information in the analysis 
than the previously described study 
Machine learning and k-means clustering analysis on a 
large number of clinical variables (N=112) in a large 
cohort of patients (N=378), including healthy controls 
(Wu et al. 2014) 
Identified 6 distinct asthma clusters: (i) to (ii) primarily 
healthy and mild asthmatics, (iii) to (vi) patients with 
severe asthma: (iv) early-onset allergic with low lung 
function and eosinophilia, (v) later-onset, mostly severe 
asthma with nasal polyps and eosinophilia, and (vi) 
persistent inflammation and exacerbations despite high 
systemic corticosteroid use. 
Used a large number of clinical variables (N=112), which 
may not always be feasible in a clinical setting. Findings 
need to be replicated and confirmed in larger independent 
cohorts. 
Ward’s minimum-variance hierarchical clustering 
method- bottom-up and Ward`s linkage approach (Moore 
et al. 2010) in the SARP cohort (severe asthma, mostly 
adults, N=726) 
Identified 5 distinct clusters: (i) early onset atopic asthma 
with normal lung function treated with two or fewer 
controller medications and minimal health care utilization 
(HCU), (ii) early-onset atopic asthma and preserved lung 
function but increased medication requirements and 
HCU, (iii) mostly older obese women with late-onset 
nonatopic asthma, moderate reductions in FEV1, and 
frequent oral corticosteroid use to manage exacerbations, 
Biomarkers such as bronchial challenge test (PC20 
metacholine), FeNO, total IgE, blood eosinophils and 
sputum eosinophils and neutrophils were collected in a 
smaller subset of participants (100 or less) does not give 
much insight into the pathophysiological mechanisms of 
specific phenotypes 
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(iv) and (v) severe airflow obstruction with 
bronchodilator responsiveness but differ in to their ability 
to attain normal lung function, age of asthma onset, 
atopic status, and use of oral corticosteroids 
Hierarchical cluster analysis by Ward's method, followed 
by κ-means cluster analysis on 2 independent adult 
cohorts- COREA, N=724 and SCH, N=1843 (Kim et al. 
2013) 
Indicated 4 asthma subtypes: (i) smoking asthma, (ii) 
severe obstructive asthma, (iii) early-onset atopic asthma, 
(iv) late-onset mild asthma 
Appropriateness of the variables used needs to be 
verified, did not use patterns of airway inflammatory 
cells as variables for cluster analysis, did not consider 
quality of life as a variable 
Fuzzy partition-around-medoid for initial clustering of 
the ADEPT and U-BIOPRED data, for validation of 
identified phenotypes, the GLMnet-classification model 
of ADEPT-asthma baseline clinical clusters was applied 
to classify the ADEPT-asthma subjects using data from 
baseline and 3, 6, and 12 month follow-up visits and 
baseline data of U-BIOPRED participants (Loza et al. 
2016)- both cohorts were adults (N=156, N=82, 
longitudinal data N=397) 
Identified 4 independent clusters: (i) mild, good lung 
function, early onset, low-inflammatory, predominantly 
Type-2, phenotype, (ii) moderate, hyper-responsive, 
eosinophilic phenotype, moderate asthma control, mild 
airflow obstruction and predominant Type-2 
inflammation, (iii) mixed severity, predominantly fixed 
obstructive, non-eosinophilic and neutrophilic” 
phenotype, moderate asthma control and low Type-2 
inflammation, (iv) severe uncontrolled, severe reversible 
obstruction, mixed granulocytic phenotype, moderate 
Type-2 inflammation.  
May not represent actual real-life situtation since 
participants were not randomly recruited from the general 
asthma population. Did not include smokers and 
obese/morbidly obese participants. 
 
Hierarchical clustering and PCA in a pediatric cohort- 
N=613 (Deliu et al. 2018) 
Identified 5 clusters: (i) difficult asthma,  (ii) early-onset 
mild atopic, (iii) early-onset mild non-atopic, (iv) late-
onset,  and (v) exacerbation-prone asthma 
Reproducibility and stability of certain models was poor 
Ward`s hierarchical clustering on an adults cohort 
recovering from an exacerbation- N=320 (Qiu et al. 
2018) 
Identified 4 clusters: (i) predominnatly female with 
sputum neutrophilia and a small degree of airflow 
obstruction and early-onset asthma, (ii) predominantly 
female, nonsmoking, high sputum eosinophilia, poor lung 
Reflects differences in recovery from exacerbations, not 
in pathophysiological or clinical features of the 
underlying disease. Still, it is very informative when it 
comes to predicting exacerbations 
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function and pO2 in arterial blood on admission, (iii) 
predominnatly female with sputum neutrophilia and a 
reduction in FEV1, (iv) exclusively male smoking 
subjects, high sputum eosinophilia and severe airflow 
obstruction. 
k-means clustering in a pediatric asthma cohort 
(Taiwanese Consortium of Childhood Asthma Study- 
TCCAS), N=351 (Su et al. 2018) 
Identified five distinct phenotypes of childhood asthma 
characterized by either eosinophil‐predominant or 
neutrophil‐predominant inflammatory characteristics. The 
gene expression profile analysis, noted significant 
differences for neutrophil‐predominant asthma. 
Additionally, in an independent inhaled corticosteroid 
(ICS) response cohort, neutrophil‐predominant asthma 
may be associated with corticosteroid nonresponsiveness. 
Clustering was performed only on 12 objective laboratory 
tests, possibly omitting relevant clinical data 
Unsupervised statistical learning techniques- exploratory 
factor analysis (EFA) and hierarchical clustering (HC) in 
a cohort of 383 children with asthma (Prosperi et al. 
2013) 
Different methods yielded different results in cluster 
assignments (particularly daa encoding and 
transformation), slightly favouring EFA 
Aggregation bias caused by the discretization of skewed 
variables, the use of mixed data types, didn`t perform a 
discrimination analysis of the original variables with 
respect to each clustering 
LCA on a cohort of adult asthmatics- Northern Finnish 
Asthma Study- NoFAS, N=1995 (Makikyro et al. 2017) 
Identified 4 clusters according to severity in women: 
controlled, mild asthma; partly controlled, moderate 
asthma; uncontrolled asthma, unknown severity, and 
uncontrolled, severe asthma, as well as 3 clusters in men: 
controlled, mild asthma; poorly controlled asthma, 
unknown severity, and partly controlled, severe asthma. 
Used questionnaire data only, no objective measurements 
Supervised learning algorithms including feed-forward 
neural networks (NN), support vector machines (SVM), 
andrandom forests (RF) on a cohort of pre-school 
Identified 3 different classes (Wheeze, Wheeze +, Other), 
with recurrent chest infections as the strongest feature in 
the models with dependent outcome 
A large proprtion of missing data (25% per patient on 
average) 
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children with wheezing- PSW cohort, N=150, mean 
age=33,66 months (Belgrave et al. 2017) 
Linear discriminant analysis (LDA) and quadratic 
discriminant analysis (QDA) on 3 cohort in the CARE 
Network trial- Pediatric Asthma Controller Trial (PACT), 
N=285; Characterizing Response to Leukotriene 
Receptor Antagonist and Inhaled Corticosteroid (CLIC), 
N=144; Best ADd-on Therapy Giving Effective 
Response (BADGER), N=182 replicating SARP clusters 
refering to treatment response (Chang et al. 2014) 
For all 3 cohorts 4 SARP clusters were replicated: (i) 
late- onset, normal lung, (ii) early- onset, normal lung, 
(iii) early onset/comorbidity and (iv) early- onset, severe 
lung.  
Smaller number of participants assigned to the early-
onset/comorbidity and early-onset/severe-lung clusters; 
the retrospective nature of the study limited the 
analyzable characteristics 
Spectral clustering in the pediatric Childhood Asthma 
Management Program (CAMP), N=1041, longitudinal 
follow-up for 48 months (Howrylak et al. 2014) 
Identified 5 reproducible clusters on the basis of 3 groups 
of features: atopic burden, degree of airway obstruction, 
and history of exacerbation. Cluster grouping predicted 
long-term asthma control (measured by the need for oral 
corticosteroids, OCS) or additional controller 
medications, as well as longitudinal differences in 
pulmonary function 
Evaluated only children and since pediatric and adult 
asthma might represent 2 different disease states with 
different pathogenic mechanisms and natural histories, 
clusters may not apply to adult asthmatics; didn`t inlcude 
children with severe asthma; clinical outcomes in the 
clusters are somewhat limited because of their small 
sample size and modest differences; retrospective nature 
of the study 
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Unsupervised cluster analysis for 3-dimensional data 
(nonnegative sparse parallel factor analysis) in a birth 
cohort Copenhagen Prospective Studies on Asthma in 
Childhood 2000 (COPSAC 2000), N=398 (Schoos et al. 
2017) 
Identified 7 snesitization trajectories: age- and allergen-
specific patterns in the COPSAC 2000 birth cohort data: 
(i) dog/cat/horse, (ii) timothy grass/birch, (iii) molds, (iv) 
house dust mites, (v) peanut/wheat flour/mugwort, (vi) 
peanut/soybean, and (vii) egg/milk/wheat flour. Asthma 
was solely associated with pattern 1. All 7 patterns were 
verified in an independent birth cohort BAMSE 
(Scandinavian birth cohort, Children, Allergy, Milieu, 
Stockholm, Epidemiology, N=3051) 
The at-risk nature of the COPSAC 2000 participants 
(children born to mothers with asthma) because this 
population can differ from unselected populations with 
regard to allergen exposures; differences in study design 
between BAMSE and COPSAC 2000 , including age of 
assessment of and age of assessment and diagnosis of 
clinical outcomes 
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